{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/contentassets/1b4b603c4ecf410588d584d5062cc9b8/legemiddelforbruket-i-norge-20172021.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Reseptregisteret Drug Consumpti in Norway 2017-2021 Data from Norwegian Drug Wh olesal es Statistics and the Norwegian Prescription DatabaseLEGEMIDDELSTATISTIKKLegemiddelforbruket i Norge 2017-2021 Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Con sumption in Norway 2017-2021 Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database L ive Storehagen Dansie Gry ata fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Consumption in Norway 2017- 2021 - D ata from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Databas e Forfattere/Authors: Live Storehagen Folkehelseinstituttets nettsider: www.fhi.no The report is only design omslag: Fete Sk\u00f8yen N-0213 Oslo Tel: +47 Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret / Drug Consumption in Norway 2017- 2021 - Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database 1981: Legemiddelforbruket Legemiddelforbruket 1985: Legemiddelforbruket 1987: Legemiddelforbruket 1988: Legemiddelforbruket Legemiddelforbruket i 1990: Legemiddelforbruket Legemiddelforbruket 1992: Legemiddelforbruket Legemiddelforbruket Legemiddelforbruket -2018 20 20: 201 5-2019 Grossistbasert og Reseptregisteret 20 21: i editions : 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004- drugs 2011: Legemiddelstatistikk elderly 2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008- 2012 2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009- 2015:2: Reseptregisteret L egemiddelstatistik k 2016:2: Reseptregisteret 2017: Legemiddelstatistikk 2017:2: Reseptregisteret 2012- the elderl y 2019: Legemiddelstatistikk Reseptregisteret 2014- 2018 2014- 2018. 2 Innhold INNHOLD 2 SAMMENDRAG 4 SUMMARY 6 1 INNLEDNING 8 2 MATERIALE OG METODE 10 2.1 Datakilder 10 2.2 Vareregisteret 10 2.3 ATC og DDD 11 2.4 M\u00e5leenheter og indikatorer 11 2.5 Vurderinger og forbehold 13 3 14 3.1 Totalt legemiddelsalg 14 3.2 Sammenstilling av datakildene 16 3.3 Utleveringsgrupper (A, B, C og F) og reseptkategorier (normalresept, refusjonsresepter) 17 3.4 3.6 Veterin\u00e6re legemidler (ATC gruppe Q) 29 4 STATISTIKK FOR ATC HOVEDGRUPPER 30 4.1 Forklaringer til hovedtabellene 30 4.2 A Ford\u00f8yelsesorganer og stoffskifte 31 4.3 B Blod og bloddannende organer 44 4.4 C Hjerte og kretsl\u00f8p 50 4.5 D Dermatologiske midler 59 4.6 G Urogenitalsystem og kj\u00f8nnshormoner 66 Hormoner til 80 4.9 L Antineoplastiske og M Muskler og skjelett 4.11 Nervesystemet 108 4.12 P Antiparasit\u00e6re midler, insekticider og insektmidler 123 4.13 R Respirasjonsorganer 127 4.14 S Sanseorganer 136 4. 15 V Varia 141 5 HISTORIKK OG BAKGRUNNSINFORMASJON 143 FOLKEMENGDE I NORGE salget 200 1 til 20 21, angitt i kroner (AIP) og DDD. Kostnadsveksten har over tid h\u00f8yere i i kroner , og utgjorde 25 % av kostnadene til humane Reseptregisteret (m\u00e5lt i DDD) ble utlevert til enkeltpersoner i 20 21. De resterende 2 % ble i hovedsak utlevert til institusjon er. Av den norske % utlevert minst ett legemiddel p\u00e5 resept i 20 21, 7 8 % av kvinnene og 6 5 % av mennene (ATC gruppe N) og legemidler Reseptregisteret fremg\u00e5 med antall og andel brukere. 6 Summary This year's report Drug consumption in Norway includes data and information from two sources, Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database (NorPD), for the period 2017- 202 1. Together, these sources provide a complementary picture of drug sales and consumption in Norway. Closer analys is of drug consumption in relation to the corona pandemic has not been conducted , but in some instances, it has been commented upon in the report. Norwegian Drug Wholesale s Statistics In 2021, drugs for human use were sold worth a total of NOK 22.8 billion (pharmacy purchase price (AIP)), an increase of 8.1 % from the previous year (Table 3.1). Over time, there has been a steady increase in sales measured in defined daily doses (DDD). In 2021, the number of DDDs was 4% higher than the previous year. The sale includes medicines with and without marketing authori sation in Norway. Non- prescription drugs accounted for around 9% of total sales measured in DDD. The sales of veterinary medicines were NOK 1.7 billion . Figure 3.1 shows the development in total sales of drugs for human use in the period 2001 to 2021 in NOK (AIP) and DDD. Over time, the increase in cost has been higher than the increase in volume, measured in DDD. Many antineoplasti c and immunomodulating agents do not have DDD. Increased prices as well as the introduction of new and more expensive drugs have affected the increase in cost. Costs will also be affected by exchange rates. Population growth and an increased proportion of older people also contribute to increased drug consumption. Antineoplastic and immunomodulatory agents (ATC group L) had the highest turnover in NOK and accounted for 25% of costs for human medicines in 2021 (Table 3.1). The group i ncludes expensive drugs for the treatment of cancer as well as biological drugs for the treatment of, for example, arthritis and multiple sclerosis. Norwegian Prescription Database (NorPD) Since the Norwegian Prescription Register was established in 2004, just over 6 million individuals have been included. The number of drugs dispensed according to prescription s during this period is about 785 million. 98% of the medicines in the NorPD (measured in DDD) were dispensed to individuals in 2021. The remaining 2% was mainly dispensed to institutions. Of the Norwegian population, 71% were dispensed at least one drug in 2021 with 78% of the m being women and 65% men (Table 3.4.1). The proportion (prevalence) was lowest in the age group 5 -9 years for both genders and increases with age. In people over the age of 70, around 90% of the individuals were given a prescription drug (figure 3.4.1). The two drug groups most commonly used by both genders in 2021 are agents acting on the nervous system (ATC group N) and agents acting on the respiratory system (ATC group R). Table 3.4.2 shows prevalence for each of the 14 ATC main groups; including total and distribution between women and men. The total sale of antibiotics has been declin ing steadily for several years with a considerable reduction during the past two years. This is probably a consequence of fewer infections due to infection control measures during the corona pandemic. 7 The main tables in Part 4 contain data from both data sources. Data from NorPD include medicines on prescription to individuals indicated as number and proportion of users. The Norwegian Drug Wholesale s Statistics also include s sales to hospitals , other health institutions and non- pharmacy outlets , mainly listed as DDD/1000 inhabitants/day. Not all medicines have an assigned DDD, here only data from NorPD is included with number and proportion of users. 8 1 Innledning \u00c5rets rapport, Legemiddelforbruket i (Norwegian Prescription Database; NorPD). Fra med 2020 er data fra disse to kildene samlet i en rapport, D Dermatologiske vil data i Del 2 Materiale og metoder. WHO Collaborating Centre for Drug Statistics Methodology er lokalisert ved Avdeling for legemiddelstatistikk, Folkehelseinstituttet, Data gruppe midler. I disse vil data 2010 v\u00e6rt under 1 % (0,07 % i 2021). Apotekforeningen de tre store legemiddelgrossistene (Alliance Healthcare Norge AS, Apotek 1 ordnet etter og ATC grupper i Del 4. Se nettsiden til WHO Collaborating Centre for Drug Statistics Methodology for mer informasjon om ATC/DDD innbyggere/d\u00f8gn at 10 av tilfeller for i l\u00f8pet av et \u00e5r, enten ved angitt DDD. har h\u00f8yere hadde omsetning i kroner, og utgjorde 25 % omsetning av antiinfektiver til systemisk br uk (ATC smitteverntiltak under koronapandemien. Figure 3.1 Total sales of medicines for human use in 200 1 to 20 21, NOK in 1000 million (AIP, left axis) and number of DDD s in 1000 million (right axis). Source: Norwegian Drug Wholesales Statistics. 0123456 05101520252001 2003 2005 2007 2009 2011 2013 2015 2021 1000 million 1000 mill NOK (AIP) Sales in 1000 mill DDD 15 Table 3.1: Sales of drugs per ATC main group in 20 21 and changes (%) from 20 20. Drugs with and without marketing authorisation are included. Sales in NOK in pharmacy purchase price (AIP). Source: Norwegian Drug Wholesales Statistics ATC main group Sales in mill DDD % change in DDDs Sales in mill NOK (AIP) % change in NOK (AIP) % share of total cost human medicines A - Alimentary tract and metabolism 557 5.2 2 933 20.6 12.8 B - Blood and blood forming organs 307 2.6 2 172 4.5 9.5 C - Cardiovascular system 936 3.6 1 214 1.6 5.3 D - Dermatologicals 7 7.9 557 8.4 2.4 G - Genito urinary system and sex hormones 243 2.0 893 0.5 3.9 H - Systemic hormonal preparations, excl. sex hormones and insulins 95 0.2 456 - 0.7 2.0 J - Antiinfectives for systemic use 35 - 1.2 1 662 - 0.4 7.3 L - Antineoplastic and immunomodulating agents 52 3.7 5 669 8.8 24.8 M - Musculo -skeletal system 133 4.3 849 10.6 3.7 N - Nervous system 527 4.5 3 428 8.0 15.0 P - Antipar asitic products, insecticides and repellents 2 - 7.4 64 2.2 0.3 R - Respiratory system 485 6.2 1 838 8.4 8.0 S - Sensory organs 38 0.3 613 7.6 2.7 V - Various 1 12.2 500 20.2 2.2 Total human medicines 3 419 4.0 22 849 8.1 100 16 Reseptregisteret Reseptregisteret ble opprettet 1. januar 2004, og har millioner. I ble rundt 98 % av Reseptregisterets antall DDD, og rundt 0 det 87 %. 17 Table 3.2 Comparison of drug sale based on data from the Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database in 20 21. Source: Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database ATC group Norwegian Drug Wholesales Statistics NorPD Total sale (millon DDD) OTC sale in percent (%) of total sales in DDD Sale to individuals in percent (%) of total sales in DDD A - Alimentary tract and metabolism 557 18 80 B - Blood and blood forming organs 307 4 92 C - Cardiovascular system1) 936 NA 97 D - Dermatologicals2) 7 NA 99 G - Genito urinary system and sex hormones 243 3 94 H - Systemic hormonal preparations, excl. sex hormones and insulins3) 95 NA 87 J - Antiinfectives for systemic use 35 0 86 L - Antineoplastic and immunomodulating agents2,3) 52 NA 83 M - Musculo -skeletal system 1 33 17 81 N - Nervous system 5 27 10 82 P - Antiparasitic products, insecticides and repellents 2 19 76 R - Respiratory system 485 25 73 S - Sensory organs2) 38 NA 95 V - Various 1 1 74 Total 3 419 9 87 1) In the ATC -group C the OTC preparations have not been assigned DDDs 2) In the ATC -groups D, L and S a major prop ortion of the substances have not been assigned DDDs 3) In the ATC -groups H and L there are no OTC preparations 3.3 Utleveringsgrupper (A, B, C og F) og i kroner (AIP). Reseptfrie legemidler hadde totalt salg i DDD, gikk salget av reseptfrie legemidler op p cirka 3 % fra 2020 til 202 1. I tabellene og Sales according to prescription groups 201 7-2021 , (narcotics (A), addictive medicines (B), other prescription medicines (C), Over the Counter (OTC) (F) in million DDD and million NOK (AIP). D rugs with and without marketing authorisation are included. Source: Norwegian Drug Wholesales Statistics Year Narcotics (A) Addictive medicines (B) Other prescription medicines (C) OTC medicines (F) Total sales (AIP) Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK 2017 40 575 120 247 2 549 16 094 383 1 475 3 091 18 392 2018 41 574 120 284 2 61 5 16 682 343 1 523 3 119 19 063 2019 44 585 123 313 2 71 8 17 152 314 1 632 3 199 19 683 2020 46 677 120 313 2 813 18 385 308 1 759 3 287 21 135 2021 51 740 120 326 2 931 19 871 316 1 912 3 419 22 849 Table 3.3.2 Human sales to individuals according to prescription groups 2017 -2021, (narcotics (A), addictive medicines (B), other prescription medicines (C), Over the Counter (OTC) (F) in million DDD. Drugs with and without marketing authorisation in Norway are included. Source: Norwegian Prescription Database Year Narcotics (A) Addictive medicines (B) Other prescription medicines (C) OTC medicines (F) Mill DDD Number of prescriptions Mill DDD Number of prescriptions Mill DDD Number of prescriptions Mill DDD Number of prescriptions 2017 35 1 225 098 111 4 927 120 2404 43 410 010 20 1 613 943 2018 37 1 273 171 112 4 952 017 2474 44 557 946 18 1 596 912 2019 39 1 341 519 114 5 033 589 2562 45 853 182 16 1 663 318 2020 41 1 407 525 112 4 851 286 2665 47 183 239 17 1 766 890 2021 45 1 524 593 112 4 938 110 2789 48 587 485 18 1 898 075 Table 3.3.3 Number of individuals and proportion of the population by prescription category 2017-2021. Source: Norwegian Prescription Database Year Non -reimbursable prescriptions Reimbursement prescriptions Health trust financed prescriptions Number of individuals Proportion (%) of the population Sales in mill NOK Number of individuals Proportion (%) of the population Sales in mill NOK Number of individuals Proportion (%) of the population Sales in mill NOK 2017 3 144 537 59.8 3294 2 526 893 48.1 12 174 46 020 0.9 4169 2018 3 152 124 59.5 3265 2 592020 48.9 12 073 57 871 2019 3 199 306 60.0 3412 2 689152 50.5 11 740 65 695 1.2 5548 2020 3 093 350 57.6 3517 2 750 610 51.1 12 761 81 305 1.5 5888 2021 3 165 721 58.7 3629 2 854 utlevert ett legemiddel p\u00e5 resept, 7 8 % av mennene Table 3.4.1 Number of individuals and one -year prevalence (%) of the population who had at least one drug dispensed in Norway 201 7-2021. Source: Norwegian Prescription Database Year 2017 2018 2019 2020 2021 Women n (%) 2 007 231 (76.9) 2 022 967 (77.0) 2 054 423 (76.5) 2 082 821 (77.9) Men n (%) 1 680 866 (63.4) 1 701 431 (63.8) 1 741 580 (64.9) 1 709 971 (63.2) 779 (65.0) Both genders (%) 3 688 097 (70.1) 3 724 411 (70.3) 3 795 679 (71.2) 3 746 214 (69.8) 3 849 600 (71.4) Figure 3.4.1 One -year prevalence (%) of the population who had at least one drug dispensed in 2021 in Norway according to age and gender. The grey line shows the one -year prevalence (%) for women excluding contraceptives for topical use (ATC code G02B) and hormonal contraceptives for systemic use (ATC code G03A). Source: Norwegian Prescription Database 0102030405060708090100 0 - 4 5 - 9 10 - 14 15 - 19 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 - 49 50 - 54 55 - 59 60 - 64 65 - 69 70 - 74 75+Prevalence (%) Women Men Women (excl. legemidler brukes i luftveiene (ATC gruppe R ). Table 3.4.2 One-year prevalence (%) of the population who had at least one drug dispensed in Norway in 2021 according to the main ATC groups. Source: Norwegian Prescription Database ATC Number of individuals per age group Total number of individuals Women % Men % Both genders % <15 15-44 45-69 70 A Alimentary tract and metabolism 53 035 306 968 519 800 374 209 1 254 012 27 % 20 % 23 % B Blood and blood forming organs 6889 98 498 288 240 374 852 768 479 14 % 14 % 14 % C Cardiovascular system 10 903 108 772 576 724 517 866 1 214 265 22 % 23 % 23 % D Dermatologicals 136 990 320 724 263 839 149 678 871 231 18 % 14 % 16 % G Genito urinary system and sex hormones 4551 427 107 305 066 178 214 914 938 26 % 9 % 17 % H Systemic hormonal preparations, excl. sex hormones and insulins 17 568 113 003 196 476 148 039 475 086 12 % 6 % 9 % J Antiinfectives for systemic use 80 606 434 671 404 063 225 289 1 144 629 26 % 17 % 21 % L Antineoplastic and immunomodulating agents 2036 30 901 61 175 43 014 137 126 3 % 2 % 3 % M Musculo -skeletal system 14 087 330 669 467 519 198 683 1 010 958 22 % 16 % 19 % N Nervous system 37 819 508 970 663 009 385 176 1 594 974 35 % 24 % 30 % P Antiparasitic products, insecticides and repellents 3946 37 178 31 252 12 601 84 977 2 % 1 % 2 % R Respiratory system 162 068 539 028 507 885 232 799 1 441 780 30 % 23 % 27 % S Sensory organs 89 814 212 790 234 980 179 747 717 331 15 % 11 % 13 % V Various 6268 21 552 14 141 8773 50 734 1 % 1 % 1 % Tabell 3.4.3 viser en oversikt i 2021. -kode R05DA01 etylmorfin som benyttes som hostedempende var ute av i fjo r en reduksjon i antall individer som fikk utlevert legemiddelet fra 260 000 i 2019 til 130 000 i 2020 , men er tilbake p\u00e5 listen i 2021 3.4.3 Drugs with the highest number of users in Norway 202 1 (excluding vaccines). Source: Norwegian Prescription Database ATC code Active ingredient Use Number of individuals Proportion (%) of the population 1 N02BE01 paracetamol1) Analgesic 682 627 12.7 2 549 R06AX27 Analgesic 345 989 6.4 6 B01AC06 acid Antithrombotic 338 381 6.3 7 773 5.2 722 5.1 13 M01AE01 226 4.4 14 H03AA01 levothyroxine sodium Thyroxine supplement 225 029 4.2 15 N02AX02 214 inhibitor) 207 869 3.9 199 929 3.7 19 R01AD09 mometasone1) nasal spray 197 592 717 3.6 21 22 corticosteroid 183 226 3.4 23 179 888 3.3 24 C08CA01 amlodipine Antihypertensive/cardiac disease 173 708 3.2 25 S01AA01 chloramphenicol eye drops 169 018 3.1 26 C09CA06 candesartan Antihypertensive/cardiac disease 163 966 3.0 27 G03CA03 estradiol Hormonal replacement and postmenopausal osteoporosis 162 909 3.0 28 G03AA07 levonorgestrel and ethinylestradiol Hormonal contraception 149 993 2.8 29 simvastatin Lipid modifying 149 172 2.8 30 N05CH01 melatonin Hypnotic 148 064 2.7 1) The ATC -level comprises OTC -medicinal products. The number of individuals is registered for presctription sale only I vil ogs\u00e5 finne i kapittel 2021 tilgjengelig i Kommunehel sa og 1. Number of users per 1000 inhabitants (prevalence) by selected drug categories in 2017 -2021 and proportion of women (%) within each drug category in 2021. The table contains data for all the predefined drug categories available at www.reseptregisteret.no /www.norpd.no Selected drug categories Users per 1000 inhabitants Proportion of women (%) within the drug category 2017 2018 2019 2020 2021 -codes: G03A) 66.8 65.1 64.6 37.7 39.0 41.3 19.4 20.3 21.3 18.6 19.8 Hormons (ATC -codes: G03C and G03F) 109.9 112.0 114.4 120.1 excl. R03CA) 86.6 ATC levels M01A and N02B contain several OTC drugs. The actual, total number of users will thus be higher than the number of users in the database 2) This group contains many OTC drugs. The actual, total number of users will thus be higher than the number of users in the database 24 3.5 Reseptfrie legemidler I Norge ble det Top selling OTC medicines available in non -pharmacy outlets and in pharmacies 2017 -2021, total OTC sale given in DDD/1000 inhabitants/day. Source: Norwegian Drug Wholesales Database. ATC and Indication Total OTC sale given in DDD/1000 inhabitants/day active ingredient 2017 2018 2019 2020 2021 M01AE01 Pain 9.3 8.7 8.8 8.8 9.7 ibuprofen1) N02BE01 Pain 14.8 14.9 15.2 15.0 16.0 paracetamol1) N07BA01 cessation 7.9 8.0 8.2 Allergy 5.8 5.8 6.4 7.2 7.2 cetirizine1) 1) Includes sales of OTC packages only. 2) Includes oxymetazolin og xylometazolin (inclusive combinations with ipratropium), for sales per med 2020 Total sales paracetamol (OTC and prescription- only packages) in DDD/1000 inhabitants/day in pharmacy and non- pharmacy outlets 2012 Drug 2021 20 55 har med fra 2020. I tillegg ble det i 2021 solgt i underkant av .2 % av salget av 0102030405060 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021DDD/1000 inhabitants/day Year Prescription only OTC - in pharmacies OTC - non-pharmacy outlets 26 reseptfrie smertestillende 2020 \u00f8kning i forhold til salget i 2020 m\u00e5lt i doser (DDD). I forhold til 2019, var det bromheksin dette er en .9 % fra 2020, men en nedgang p\u00e5 37 % i forhold til 2019. 210 000 som Dette er nedgang p\u00e5 .4 % i forhold til 2019. Dette .7 % forhold til (sildenafil) solgt 180 000 % mer enn Reseptfritt var 217 000 pakninger i 2021, som er 5 % lavere enn i 2020. Midler mot underlivsplager i 2020, 2 % av salget i denne % i forhold til 2020, men ble redusert med 17 % sammenlignet med 2019. 29 legemidler i Norge. p\u00e5 1 4 % i forhold til 2020. St\u00f8rste del av \u00f8kningen er i legemidler kroner, lakselus, midler mot and -VET: Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance Norway. 2021. -norm 1. 4.2 A ing (GERD). Protonpumpehemmer til forebyggende er noen av de andre gruppene. viser at ATC gruppe .8 % av de totale legemiddelkostnadene (m\u00e5lt i AIP) og 1 7 % av 2020. Bupropion er en diabetes. Av disse beregnet at 23 har type 1 -diabetes. Salget av legemidler til 2 - diabetes kan en viss reguleres og behandles med kosthold, type 2 -diabetes med til 2021, en \u00f8kning p\u00e5 mer 2020 til 2021 \u00f8kte antall brukere brukere av de ulike legemidlene tidligere ukjente tilfeller diagnostiseres, og at de som har diabetes lever lengre og har et bedre behandlingstil av legemidlene n\u00e5 flere bruksomr\u00e5der en n diabetes. Figure 4.2 Proportion of the population (prevalence %) who had dispensed at least one drug for treatment of type 2 -diabetes (A10B Blood glucose lowering drugs, excl. insulins) 2017 - ATC 4 th levels A10BC, A10BF, A10BG and A10BX are deleted due to low sales. Source: The Norwegian Prescription Database GLP -1-analogen liraglutid er glucose lowering (SGLT2) inhibitorsA10B - TotalPropotion (%) of the population2017 b pasienter med 2 -diabetes behandles Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 A ALIMENTARY TRACT AND METABOLISM 521 173 613 655 99.1 113.8 A02A ANTACIDS 1.50 1.44 1.44 1.54 1.56 6 369 6 512 6 888 7 562 7 686 1.2 1.4 A02AA Magnesium compounds 0.00 0.00 0.01 0.01 0.01 84 99 125 140 187 0.0 0.0 A02AA04 magnesium hydroxide (3 g) 0.00 0.00 0.01 0.01 0.01 84 99 125 140 187 0.0 0.0 A02AC Calcium A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 0.45 0.44 0.43 0.48 0.50 1 489 1 488 1 614 1 938 1 896 0.3 0.4 A02AD01 ordinary salt combinations 0.45 0.44 0.43 0.48 0.50 1 489 1 488 1 614 1 938 1 896 0.3 0.4 A02AH Antacids with sodium bicarbonate 0.25 0.26 0.27 0.29 0.29 4 267 4 468 4 680 5 006 5 152 0.8 1.0 A02B DRUGS FOR PEPTIC ULCER AND H2-receptor antagonists 3.67 3.56 2.56 5 683 8.7 1.2 A02BA01 cimetidine (0.8 g) 0.00 0.00 0.00 0.01 0.01 18 18 64 129 106 0.0 0.0 A02BA02 ranitidine (0.3 g) 3.19 3.13 2.13 45 163 46 861 41 396 <5 0 8.6 0.0 A02BA03 famotidine (40 mg) 0.47 0.43 0.43 0.65 0.66 441 303 1 649 5 578 6 347 0.1 1.2 A02BB Prostaglandins 0.03 0.03 0.03 0.03 0.03 476 512 471 445 462 0.1 0.1 A02BB01 misoprostol (0.8 mg) 0.03 0.03 0.03 0.03 0.03 476 512 471 445 462 0.1 0.1 A02BC Proton pump 67.00 70.63 73.34 490 93.3 463 39 402 39 132 39 976 39 148 7.9 A02BC02 pantoprazole (40 mg) 25.74 27.87 30.38 887 50.2 66.4 A02BC03 lansoprazole (30 mg) 4.92 4.61 4.48 4.35 4.12 34 983 33 068 31 735 30 964 29 290 6.7 5.4 A02BC05 esomeprazole (30 mg) 24.43 24.94 26.37 27.74 28.70 176 064 181 117 191 338 202 381 207 869 33.5 38.6 A02BX Other drugs for peptic ulcer 0.66 0.73 0.79 5 367 5 382 6 110 7 020 7 330 1.0 1.4 A02BX02 sucralfate (4 g) 0.06 0.06 0.06 0.07 0.10 518 670 825 0.1 0.2 A02BX12 bismuth subnitrate - - - - - 58 11 12 0 0 0.0 0.0 A02BX13 alginic acid 0.59 0.59 0.60 0.65 0.69 4 824 4 894 5 612 6 394 6 562 0.9 1.2 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 2.83 2.75 2.79 2.78 2.30 70 684 72 780 75 450 77 732 83 670 13.4 15.5 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 1.53 1.47 1.49 1.49 0.96 5 738 5 628 6 099 8 005 7 951 1.1 1.5 A03AA Synthetic anticholinergics, esters with tertiary amino group 0.00 0.00 0.00 0.00 0.00 56 77 69 75 76 0.0 0.0 36 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 (0.6 g) 0.00 0.00 0.0 anticholinergics, quaternary ammonium compounds 0.05 0.05 0.05 0.06 0.05 1 382 1 411 1 731 2 371 2 465 0.3 0.5 A03AB02 glycopyrronium bromide (0.3 mg P) 0.05 0.05 0.05 0.06 0.05 1 373 1 401 1 722 2 362 2 459 0.3 0.5 A03AB05 propantheline 0.00 0.00 0.00 0.00 0.00 0.00 (0.1 g) 0.00 0.00 0.00 0.00 0.00 45 28 40 42 13 0.0 0.0 A03AX Other drugs for functional gastrointestinal disorders 1.47 1.42 1.43 1.43 0.91 4 284 4 134 4 294 5 564 5 435 0.8 1.0 A03AX13 silicones (0.5 g) 1.47 1.42 1.43 1.43 0.91 4 284 4 134 4 294 4 206 3 263 0.8 0.6 A03AX15 menthae piperitae aetheroleum 0.00 0.00 0 0 0 1 396 2 221 0.0 0.4 A03B BELLADONNA AND DERIVATIVES, PLAIN 0.15 0.15 0.15 0.15 0.13 3 108 3 398 3 788 3 913 4 017 0.6 0.8 A03BA Belladonna alkaloids, tertiary amines 0.12 0.12 0.12 0.11 0.09 1 919 2 096 2 206 2 027 1 866 0.4 0.4 A03BA01 atropine (1.5 mg) 0.05 0.04 0.04 0.04 0.04 8 13 13 10 9 0.0 0.0 A03BA03 hyoscyamine (1.2 mg) 0.07 0.07 0.08 0.07 0.05 1 911 2 083 2 193 2 017 1 857 0.4 0.3 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 0.03 0.03 0.04 0.04 0.04 1 202 1 318 1 602 1 912 2 184 0.2 0.4 A03BB01 butylscopolamine (60 mg) 0.03 0.03 0.04 0.04 0.04 1 202 1 318 1 602 1 912 2 184 0.2 0.4 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 0.00 0.00 0.00 19 19 16 25 0.0 0.0 A03CA Synthetic anticholinergic agents in combination with psycholeptics 0.00 0.00 0.00 0.00 22 psycholeptics 0.00 0.00 0.00 16 0.0 0.0 A03F PROPULSIVES 1.15 1.13 1.15 1.14 1.21 63 378 65 341 67 370 68 181 73 960 12.1 13.7 A03FA Propulsives 1.15 1.13 1.15 1.14 1.21 63 378 65 341 67 370 68 181 73 960 12.1 13.7 A03FA01 metoclopramide (30 mg) 1.14 1.12 1.15 1.13 1.20 63 262 65 211 67 268 68 051 73 843 12.0 13.7 A03FA03 domperidone (30 mg O,P/0.12 g R) 0.01 0.01 0.01 0.01 0.01 133 141 110 141 125 0.0 0.0 A03FA05 alizapride 0.38 0.37 0.38 20 854 22 099 23 852 23 976 26 060 4.0 4.8 A04A ANTIEMETICS AND ANTINAUSEANTS 0.36 0.35 0.38 0.37 0.38 20 854 22 099 23 852 23 976 26 060 4.0 4.8 A04AA Serotonin (5HT3) antagonists 0.33 0.33 0.35 0.35 0.36 18 169 19 412 21 022 22 115 23 890 3.5 4.4 A04AA01 ondansetron (16 mg) 0.32 0.31 0.34 0.33 0.34 15 811 16 482 17 610 18 518 19 965 3.0 3.7 37 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 0.00 0.00 0.00 0.00 85 113 134 108 mg O/0.25 P mg) 0.00 0.00 0.00 52 16 12 15 14 0.0 0.0 A04AA55 palonosetron, combinations 0.01 0.01 0.01 0.02 0.02 3 760 4 678 5 146 5 621 5 927 0.7 1.1 A04AD Other antiemetics 0.03 0.03 0.03 0.02 0.02 3 785 3 257 3 269 2 202 2 507 0.7 0.5 A04AD01 scopolamine (1 plaster) 0.03 0.02 0.02 0.02 0.02 2 572 2 710 2 904 1 954 2 250 0.5 0.4 A04AD12 aprepitant (150 mg P/165 mg O) 0.01 0.00 0.00 0.00 0.00 1 223 551 369 254 258 0.2 0.1 A05 BILE AND LIVER THERAPY 0.45 0.47 0.50 0.54 0.59 3 210 3 373 3 599 3 766 3 835 0.6 0.7 A05 BILE AND LIVER THERAPY 0.47 0.50 0.54 0.59 0.62 3 373 3 599 3 766 3 835 4 034 0.6 0.8 A05A BILE THERAPY 0.47 0.50 0.54 0.59 0.62 3 373 3 599 3 766 3 835 4 034 0.6 0.8 A05AA Bile acids and derivatives 0.47 0.50 0.54 0.59 0.62 3 373 3 599 3 766 3 835 4 034 0.6 0.8 A05AA02 ursodeoxycholic acid (0.75 g) 0.47 0.50 0.53 0.58 0.61 3 373 3 595 3 758 3 826 4 019 0.6 0.8 A05AA04 obeticholic acid (10 mg) 0.00 0.00 0.00 0.01 0.01 7 30 43 68 82 0.0 0.0 A06 DRUGS FOR CONSTIPATION 22.85 22.76 22.46 25.31 26.38 94 189 102 443 109 059 122 820 137 987 17.9 25.6 A06A DRUGS FOR CONSTIPATION 22.85 22.76 22.46 25.31 26.38 94 189 102 443 109 059 122 820 137 987 17.9 25.6 A06AA Softeners, emollients 0.10 0.12 0.00 0.20 0.34 1 344 1 521 1 421 1 743 1 896 0.3 0.4 A06AA01 liquid paraffin 0.10 0.12 0.20 0.34 1 344 1 521 1 421 1 743 1 896 0.3 0.4 A06AB Contact laxatives 8.76 8.48 8.25 8.55 8.66 30 836 30 018 29 853 30 487 31 527 5.9 5.9 A06AB02 bisacodyl (10 mg) 2.97 2.84 2.66 2.75 2.77 5 533 5 642 5 430 5 743 5 918 1.1 1.1 A06AB06 senna glycosides 1.41 1.30 1.19 1.16 1.10 1 329 1 270 1 162 1 148 1 110 0.3 0.2 A06AB08 sodium picosulfate (5 mg) 4.33 4.29 4.35 4.59 4.75 16 766 17 244 17 864 19 463 20 391 3.2 3.8 A06AB20 contact laxatives in combination - - - - - 16 0 0 0 0 0.0 0.0 A06AC Bulk -forming laxatives 1.56 1.61 1.60 2.12 2.52 4 717 6 120 7 542 9 420 12 026 0.9 2.2 A06AC01 ispaghula (psylla seeds) (7 g) 1.56 1.61 1.60 2.12 2.52 4 717 6 120 7 542 9 420 12 026 0.9 A06AD Osmotically acting 13.12 64 136 72 531 91 395 104 628 12.2 19.4 A06AD11 lactulose (6.7 g) 8.87 8.59 8.52 9.12 9.13 18 482 18 532 19 491 21 621 23 210 3.5 4.3 A06AD12 lactitol (10 g) 0.00 0.00 0.00 0.00 (10 g) 0.00 0.00 0.00 0.00 0.00 28 17 17 22 42 phosphate (50 g) 0.00 0.00 0.00 0.00 combinations 2.10 2.49 2.64 3.64 3.98 47 73 447 85 674 9.0 15.9 A06AG Enemas 1.18 1.16 1.15 1.19 1.25 6 790 6 748 6 920 7 361 7 414 1.3 1.4 A06AG02 bisacodyl 0.13 0.12 0.12 0.12 0.12 1 452 1 263 1 159 1 149 1 023 0.3 0.2 A06AG04 glycerol - - - - 0.00 1 024 1 069 1 027 1 079 1 137 0.2 0.2 A06AG06 oil - - - - 0.00 114 106 183 212 212 0.0 0.0 A06AG10 docusate sodium, incl. combinations 0.10 0.10 0.10 0.09 0.10 1 900 2 023 2 131 2 318 2 281 0.4 0.4 38 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2 779 2 773 2 892 3 187 3 325 0.5 0.6 A06AH Peripheral opioid receptor antagonists 0.07 0.08 0.10 0.12 0.13 801 903 1 078 1 224 1 252 0.2 0.2 A06AH01 methylnaltrexone bromide (6 mg) 0.01 0.01 0.01 0.01 0.01 132 82 103 116 103 0.0 0.0 A06AH03 naloxegol (25 mg) 0.06 0.08 0.09 0.11 0.12 693 1 005 1 137 1 175 0.1 0.2 A06AX Other drugs for constipation 0.20 0.22 0.20 0.36 0.37 2 676 2 984 3 226 3 995 4 691 0.5 0.9 A06AX01 glycerol - - - - 0 134 128 204 206 265 0.0 0.1 A06AX04 linaclotide (0.29 mg) 0.16 0.18 0.15 0.31 0.31 2 160 2 478 2 592 3 261 3 849 0.4 0.7 A06AX05 prucalopride (2 mg) 0.04 0.04 0.04 0.05 0.06 480 464 549 722 747 0.1 0.1 A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/A NTIINFECTIVE AGENTS 7.85 8.21 8.57 8.82 9.12 88 852 92 385 94 433 94 940 96 474 16.9 17.9 A07A INTESTINAL ANTIINFECTIVES 0.30 0.31 0.32 0.33 0.34 36 965 37 504 37 756 37 107 36 034 7.0 6.7 A07AA Antibiotics 0.30 0.31 0.32 0.33 0.34 36 965 37 504 37 756 37 107 36 034 7.0 6.7 A07AA01 neomycin 0 - 0.0 A07AA02 nystatin (1.5 MU) 0.24 0.23 0.23 0.23 0.22 36 290 36 738 36 929 36 228 35 044 6.9 6.5 A07AA06 paromomycin (3 g) 0.00 0.00 0.00 0.00 0.00 42 76 31 31 (2 g) 0.00 0.00 0.00 0.00 g) 0.06 0.08 0.09 0.10 A07B INTESTINAL ADSORBENTS 0.04 0.04 0.04 0.03 0.03 196 261 290 274 324 0.0 0.1 A07BA Charcoal preparations 0.04 0.04 0.04 0.03 0.03 65 95 74 67 55 0.0 0.0 A07BA01 medicinal charcoal (5 g) 0.04 0.04 0.04 0.03 0.03 65 95 74 67 55 0.0 0.0 A07BB Bismuth preparations - - - - - 131 166 216 207 269 0.0 0.1 A07C ELECTROLYTES WITH CARBOHYDRATES 0.04 0.04 0.04 0.04 0.04 426 420 424 250 307 0.1 0.1 A07CA Oral rehydration salt formulations 0.04 0.04 0.04 0.04 0.04 426 420 424 250 307 0.1 0.1 A07D ANTIPROPULSIVES 1.60 1.68 1.74 1.64 1.66 23 288 25 560 26 595 26 885 28 310 4.4 5.3 A07DA Antipropulsives 1.60 1.68 1.74 1.64 1.66 23 288 25 560 26 595 26 885 28 310 4.4 5.3 A07DA02 opium (0.1 g) 0.02 0.03 0.04 0.05 0.05 306 400 486 575 591 0.1 0.1 A07DA03 loperamide (10 mg) 1.50 1.55 1.62 1.54 1.55 22 778 24 846 26 083 26 443 27 874 4.3 5.2 A07DA06 eluxadoline (0.2 g) 0.00 0.02 0.00 119 432 57 0 0 0.0 0.0 A07DA53 loperamide, combinations 0.07 0.09 0.08 0.05 0.06 437 423 438 368 388 INTESTINAL ANTIINFLAMMATORY AGENTS 5.86 6.14 6.42 6.77 7.05 30 654 31 533 32 418 33 586 34 788 5.8 6.5 A07EA Corticosteroids acting locally 0.44 0.44 0.45 0.47 0.49 7 507 7 712 7 977 8 545 9 238 1.4 1.7 A07EA01 prednisolone (1 enema) 0.00 0.00 0.00 0.0 0.1 A07EA02 hydrocortisone 0.02 0.01 0.00 322 198 67 <5 <5 0.1 - 39 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 0.49 7 230 7 543 7 902 8 536 046 1.4 0.01 0.00 47 51 0.0 0.0 cromoglicic acid (0.8 g) 0.00 0.01 0.00 0.00 0.00 47 53 47 40 51 0.0 0.0 A07EC Aminosalicylic acid and similar agents 5.41 5.69 5.97 6.30 6.55 25 797 26 488 27 071 27 753 28 434 4.9 5.3 A07EC01 sulfasalazine (2 g) 0.68 0.66 0.59 0.56 0.63 5 457 5 410 5 240 4 872 4 654 1.0 0.9 A07EC02 mesalazine (1.5 g) 4.66 4.96 5.32 5.68 5.87 20 045 20 861 21 617 22 927 23 645 3.8 4.4 A07EC03 olsalazine (1 g) 0.04 0.04 0.04 0.03 0.03 273 254 230 216 197 0.1 0.0 A07EC04 balsalazide (6.75 g) 0.03 0.03 0.03 0.03 0.03 471 388 374 369 368 0.1 0.1 A07F ANTIDIARRHEAL MICROORGANISMS 0.01 0.00 0.00 0.01 0.01 559 422 418 500 541 0.1 0.1 A07FA Antidiarrheal microorganisms 0.01 0.00 0.00 0.01 0.01 559 422 418 500 541 0.1 0.1 A07FA01 lactic acid producing organisms - - - - 0.00 294 215 153 132 127 0.1 0.0 A07FA02 saccharomyces boulardii (1 g) 0.01 0.00 0.00 0.01 0.01 287 217 268 371 423 0.1 0.1 A07FA51 lactic acid producing organisms, combinations - - - - - <5 <5 <5 <5 0 0.40 0.52 0.71 1.48 6 256 8 052 10 415 14 222 28 221 1.2 5.2 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 0.31 0.40 0.52 0.71 1.48 6 256 8 052 10 415 14 222 28 221 1.2 5.2 A08AA Centrally acting antiobesity products 0.01 0.13 0.28 0.49 1.29 265 3 072 6 090 10 328 24 554 0.1 4.6 A08AA62 bupropion and naltrexone 0.01 0.13 0.28 0.49 1.29 265 3 072 6 090 10 328 24 554 0.1 4.6 A08AB Peripherally acting antiobesity products 0.31 0.27 0.24 0.23 0.18 6 019 5 187 4 625 4 232 4 184 1.1 0.8 A08AB01 orlistat (0.36 g) 0.31 0.27 0.24 0.23 0.18 6 019 5 187 4 625 4 232 4 184 1.1 0.8 A09 DIGESTIVES, INCL. ENZYMES 0.86 0.90 1.00 1.05 1.08 6 597 6 919 7 356 7 774 7 837 1.3 1.5 A09A DIGESTIVES, INCL. ENZYMES 0.86 0.90 1.00 1.05 1.08 6 597 6 919 7 356 7 774 7 837 1.3 1.5 A09AA Enzyme preparations 0.79 0.81 0.91 0.93 0.96 6 364 6 657 7 013 7 320 7 575 1.2 1.4 A09AA02 multienzymes 6 648 6 999 7 280 7 523 1.2 1.4 A09AB Acid preparations 0.08 0.09 0.09 0.13 0.12 65 63 73 146 84 0.0 0.0 A09AB01 glutamic acid hydrochloride (1.5 g) 0.07 0.08 0.09 0.11 0.11 51 53 52 53 42 A09AB02 betaine hydrochloride (1 g) 0.00 0.00 0.00 0.02 0.01 9 10 18 90 42 0.0 0.0 A09AB03 hydrochloric acid - - - - - 5 0 <5 <5 0 0.0 0.0 A09AC Enzyme and acid preparations, combinations - - - - - 195 217 289 343 199 0.0 0.0 A09AC01 pepsin and acid preparations - - - - - 194 217 289 336 161 0.0 0.0 A10 DRUGS USED IN DIABETES 55.42 56.23 58.50 60.26 65.95 192 542 199 563 208 034 221 619 255 508 36.6 47.4 A10A INSULINS AND ANALOGUES 20.25 20.49 20.71 20.49 20.59 65 733 68 137 70 320 72 759 75 493 12.5 14.0 40 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2021 8.71 8.87 8.92 9.15 43 534 45 172 46 167 47 414 48 762 8.3 9.0 A10AB01 insulin (human) (40 U) 0.11 0.09 0.07 0.07 0.06 742 640 541 484 446 0.1 0.1 A10AB04 insulin lispro (40 U) 2.35 2.06 1.95 1.89 1.85 11 202 10 699 10 017 9 755 9 640 2.1 1.8 A10AB05 insulin aspart (40 U) 5.82 6.50 6.79 6.91 7.20 32 700 35 590 36 819 38 243 39 631 6.2 7.4 A10AB06 insulin glulisine (40 U) 0.09 0.06 0.06 0.06 0.05 459 385 332 313 286 0.1 0.1 A10AC Insulins and analogues for intermediate -acting 6.35 5.86 5.45 4.86 4.43 33 804 32 247 30 443 28 508 27 706 6.4 5.1 A10AC01 insulin (human) (40 U) 6.35 5.86 5.45 4.86 4.43 33 804 32 247 30 443 28 508 27 706 6.4 5.1 A10AD Insulins and analogues for injection, intermediate - or long - acting combined with fast-acting 1.13 0.94 0.79 0.64 0.53 4 678 4 081 3 474 2 918 2 466 0.9 0.5 A10AD04 insulin lispro (40 U) 0.09 0.07 0.06 0.05 0.04 405 342 296 237 217 0.1 0.0 A10AD05 insulin aspart (40 U) 1.05 0.87 0.73 0.59 0.50 4 278 3 741 3 182 2 685 2 250 0.8 0.4 A10AE Insulins and analogues for injection, long -acting 4.41 4.99 5.60 6.06 6.48 25 315 29 213 33 165 36 318 38 824 4.8 7.2 A10AE02 insulin (beef) (40 U) 0.00 0.00 0.00 0.00 glargine (40 2.86 2.88 2.86 16 352 16 677 16 950 17 159 17 121 3.1 3.2 A10AE05 insulin detemir (40 U) 0.99 0.82 0.72 0.59 0.51 5 721 4 957 4 536 3 920 3 534 1.1 0.7 A10AE06 insulin degludec (40 U) 0.51 0.97 1.34 1.78 2.21 3 386 5 938 8 349 10 874 13 132 0.6 2.4 A10AE54 insulin glargine and lixisenatide (40 U) 0.00 0.02 0.02 0.02 0 32 129 134 132 0.0 0.0 A10AE56 insulin degludec and liraglutide (40 U) 0.16 0.40 0.66 0.79 0.87 1 642 3 459 5 152 6 134 6 792 0.3 1.3 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 35.17 35.74 37.79 39.77 45.36 154 588 160 29.4 40.0 A10BA Biguanides 15.12 588 132 455 140 651 22.8 26.1 A10BA02 metformin (2 g) 15.12 15.08 15.69 15.75 16.64 120 061 122 463 126 455 140 651 22.8 26.1 A10BB Sulfonylureas 6.77 5.82 5.20 4.52 3.86 29 721 26 538 23 787 21 131 18 793 5.7 3.5 A10BB01 glibenclamide (7 mg) 0.09 0.07 0.06 0.05 0.04 615 530 471 406 369 0.1 A10BB07 glipizide (10 mg) 0.31 0.27 0.23 0.18 0.05 2 109 1 785 1 552 1 297 977 0.4 0.2 A10BB12 glimepiride (2 mg) 6.37 5.48 4.91 4.29 3.76 27 064 24 274 21 820 19 464 17 884 5.2 3.3 A10BD Combinations of oral blood glucose lowering drugs 4.21 4.54 4.94 4.93 5.11 26 294 28 781 31 085 31 811 32 607 5.0 and pioglitazone (2 UD) 0.00 0.00 0.00 0.01 23 27 30 37 39 0.0 0.0 A10BD07 metformin and sitagliptin (2 UD) 2.05 2.36 2.63 2.59 2.64 13 391 15 199 16 627 16 932 16 987 2.6 3.2 A10BD08 metformin and vildagliptin (2 UD) 1.76 1.62 1.54 1.39 1.32 10 655 10 162 9 710 9 048 8 395 2.0 1.6 A10BD10 metformin and saxagliptin (2 UD) 0.02 0.02 0.01 0.01 0.01 110 112 101 67 65 0.0 0.0 A10BD11 metformin A10BD15 metformin and dapagliflozin (2 UD) 0.13 0.16 0.22 0.28 0.36 852 1 166 1 519 1 927 2 421 0.2 0.5 41 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 empagliflozin (2 UD) 0.01 0.03 0.04 0.05 0 122 227 268 314 0.0 0.1 A10BD20 metformin and empagliflozin (2 UD) 0.12 0.22 0.33 0.45 0.56 881 1 527 2 278 2 954 3 777 0.2 0.7 A10BD21 saxagliptin and dapagliflozin (1 UD) 0.01 0.03 0.04 0.04 0.05 91 201 243 255 289 0.0 0.1 A10BD23 metformin and ertugliflozin (2 UD) 0.00 0.00 0.01 12 0.0 A10BD24 sitagliptin and ertugliflozin (1 UD) 0.00 0.01 0.01 0.02 0 17 67 91 102 0.0 0.0 A10BF Alpha glucosidase inhibitors 0.04 0.03 0.02 0.03 0.02 442 416 369 275 256 0.1 0.1 A10BF01 acarbose (0.3 g) 0.04 0.03 0.02 0.03 0.02 442 416 369 275 256 0.1 0.1 A10BG Thiazolidinediones 0.20 0.23 0.20 0.17 0.16 1 415 1 373 1 327 1 153 1 093 0.3 0.2 A10BG03 pioglitazone (30 mg) 0.20 0.23 0.20 0.17 0.16 1 415 1 373 1 327 1 153 1 093 0.3 0.2 A10BH 25 212 27 093 28 211 28 314 28 004 4.8 5.2 A10BH01 sitagliptin (0.1 g) 2.14 2.40 2.60 2.55 2.50 14 903 16 770 18 144 18 199 18 021 2.8 3.3 A10BH02 vildagliptin (0.1 g) 0.33 0.30 0.28 0.25 0.24 2 374 2 163 2 035 2 079 1 900 0.5 0.4 A10BH03 saxagliptin (5 mg) 0.21 0.19 0.17 0.14 0.13 1 233 1 087 968 844 793 0.2 0.2 A10BH05 linagliptin (5 mg) 1.18 1.22 1.23 1.22 1.22 7 066 7 333 7 379 7 461 7 490 861 14 626 20 448 31 650 64 218 2.5 11.9 A10BJ01 exenatide (15 mcg/0.286 mg) 0.18 0.16 0.14 0.12 0.10 1 251 1 112 1 004 844 700 0.2 0.1 A10BJ02 liraglutide (1.5 mg) 1.39 1.52 1.63 1.90 3.59 9 083 10 119 11 206 13 080 24 073 1.7 4.5 A10BJ03 lixisenatide (20 mcg) 0.07 0.06 0.05 0.36 0.03 525 398 347 248 185 0.1 0.0 A10BJ05 dulaglutide (0.16 mg) 0.40 0.56 0.70 0.81 0.95 2 314 3 277 4 135 4 764 370 0.4 1.0 A10BJ06 semaglutide (0.11 mg) 0.00 0.41 1.55 3.99 0 18 5 267 14 483 36 984 0.0 6.9 A10BK Sodium -glucose co - transporter 2 (SGLT2) inhibitors 2.90 3.62 4.52 5.45 6.80 20 330 25 613 31 293 37 723 48 165 3.9 8.9 A10BK01 dapagliflozin (10 mg) 1.68 1.79 1.96 2.20 2.91 10 588 11 297 12 225 14 176 20 386 2.0 3.8 A10BK02 canagliflozin (0.2 g) 0.03 0.13 0.16 0 0 440 1 033 1 084 0.0 0.2 A10BK03 empagliflozin (17.5 mg) 1.21 3.71 10 105 14 625 18 907 22 755 26 940 1.9 5.0 A10BK04 ertugliflozin (10 mg) 0.00 0.02 0.03 0.03 0 49 189 213 223 0.0 0.0 A10BX Other blood glucose lowering drugs, excl. insulins 0.03 0.02 0.02 0.02 0.02 163 156 149 126 120 0.0 0.0 A10BX02 repaglinide (4 mg) 0.03 0.02 0.02 0.02 0.02 163 156 149 126 120 0.0 0.0 0.00 0.00 0.01 5 6 9 5 <5 - A12AA04 calcium carbonate (3 g) 0.00 0.00 0.00 0 0 173 218 44 0.0 0.0 A12AA06 calcium lactate gluconate (3 g) 0.31 0.14 0.12 1228 1012 838 989 1119 0.2 0.2 A12AX Calcium, combinations with vitamin D and/or 20526 20556 20567 21115 3.9 3.9 42 Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2021 A12BA Potassium 1.48 1.39 1.42 1.40 1.41 20 365 20 526 20 556 20567 21 115 3.9 3.9 A12BA01 potassium chloride (3 g) 1.25 1.16 1.18 1.15 1.14 18 209 18 118 17 922 17 753 18 155 3.5 3.4 A12BA02 potassium citrate (4 g) 0.23 0.23 0.24 0.25 0.27 2 647 2 898 3 104 3 315 3 507 0.5 0.7 A12C OTHER MINERAL SUPPLEMENTS 1.22 1.16 1.31 1.45 1.61 8 996 9 500 9 419 10 889 11 645 1.7 2.2 A12CA Sodium 0.48 0.60 0.67 0.77 0.92 2 554 3 114 3 292 3 919 4 463 0.5 0.8 A12CA01 sodium chloride (1 g) 0.48 0.60 0.67 0.77 0.92 2 554 3 114 3 292 3 919 4 463 0.5 0.8 A12CB Zinc 0.03 0.03 0.03 0.03 0.02 566 456 405 394 411 0.1 0.1 A12CB01 zinc sulfate (0.6 g) 0.03 0.03 0.03 0.03 0.02 566 456 405 394 411 0.1 0.1 A12CC Magnesium 0.70 0.54 0.61 0.65 0.66 6 063 6 184 5 926 6 865 7 146 150 146 0.0 0.0 A12CC10 magnesium oxide - - - - - 289 399 412 405 377 0.1 0.1 A12CC30 magnesium (different salts in 6353 6547 1.1 1.2 A12CX Other mineral products - - - - - 17 15 21 22 20 0.0 0.0 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 0.00 0.00 0.00 0.00 0.00 1 017 998 987 STEROIDS 0.00 0.00 0.00 0.00 0.00 1 1 158 1 258 0.2 0.2 A14AA Androstan derivatives - - - - - 974 951 928 1 107 1 224 0.2 0.2 A14AA07 prasterone - - - - - 973 951 928 1105 1 222 0.2 0.2 A14AA08 oxandrolone - - - - - <5 0 2017 2018 2019 2020 2021 A16 123.62 127.97 144.23 137.14 229 205 212 (2 g) 73.06 84.12 91.41 101.25 174 183 176 0.0 0.0 A16AA04 mercaptamine (2 g) 6.50 6.90 6.36 7.22 6.50 10 10 10 9 10 0.0 0.0 A16AA05 carglumic acid (0.2 g) 21.30 22.30 26.23 26.71 24 24 26 27 0.0 A16AB Enzymes 70.63 69.63 71.68 75.49 82.43 86 90 imiglucerase (300 U) 6.43 6.13 6.34 5.96 5.47 8 9 7 6 6 0.0 0.0 A16AB03 agalsidase alfa (1 mg) 15.50 14.30 14.30 20.63 29.86 16 16 16 27 29 beta (5 mg) 38.70 38.40 38.70 36.79 43 43 41 37 0.0 0.0 A16AB05 laronidase (1 TU) 1.30 1.20 1.33 1.24 1.24 - - - - - - - A16AB07 alglucosidase alfa (0.1 <5 <5 <5 - - Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 alfa (20 mg) 4.40 5.20 5.3 3.84 3.85 10 12 12 11 9 0.0 0.0 A16AX Various alimentary tract and metabolism products 81.18 103.2 2 acid (0.6 g) 7.48 6.08 5.93 14.24 27.42 42 35 32 86 107 0.0 0.0 A16AX03 sodium phenylbutyrate (20 45.03 16 17 18 21 21 0.0 0.0 A16AX05 zinc acetate (0.15 g) 8.00 9.40 9.25 11.27 7.31 14 15 17 15 16 0.0 0.0 A16AX06 miglustat (0.3 g) 7.40 8.40 9.21 7.73 8.52 8 10 8 7 7 0.0 0.0 A16AX07 sapropterin - - - - - 33 36 39 44 49 0.0 0.0 A16AX08 teduglutide (5 mg) 15.80 28.80 29.59 28.99 44 A16AX09 glycerol phenylbutyrate (15 g) 1.14 1.83 3.11 5 7 0.0 0.0 - - 14.75 17.62 14 14 16 17 21 0.0 0.0 A16AX14 migalastat (61.5 mg) 0.80 3.60 6.75 7.80 1.92 <5 5 9 10 <5 - g) 1.73 6.99 12.13 8.96 0 <5 21 17 15 0.0 44 Blod m\u00e5lt i kostnad (9.0 % av total AIP), og i DDD (9 .5 % av total DDD), se tabell 3.1. Antitrombotiske midler (B01) utgj\u00f8r 64 % av forbruket av gruppe B m\u00e5lt i DDD, etterfulgt av midler anemi av all DDD i gruppe B01AC, etterfulgt av klopidogrel 12 %. Reseptregisteret % av kvinner og 17 % av menn over 65 \u00e5r et andel 50-\u00e5rsalder, figur 4.3.2. 2011 2012 2013 2014 2015 2016 2017 2018 2019 05101520253035 50 - 59 years 60 - 69 years 70 - 79 years 80 years aboveProportion (%) of population WomenB01AC06 - Acetylsalicylic Figure 4.3.2. Prevalence (%) of use of the most used antithrombotic agents in 2021; acetylsalisylic 50-59 years, 60 -69 years, 70 -79 years and 80 years and above. Source: Norwegian Prescription Database Midler mot anemi Reseptregisteret viser \u00f8kt siste 05101520253035 50 - 59 years 60 - 69 years 70 - 79 years 80 years aboveProportion (%) of population MenB01AC06 - Acetylsalicylic B01AF03 Prescription Database DDD/1000 inhabitants/day Number of indiv iduals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 B Vitamin K antagonists 6.02 5.01 4.20 3.59 3.12 51 304 42 737 35 585 30 110 25 933 9.8 4.8 B01AA01 dicoumarol (0.1 g) 0.00 0.00 0.00 0.00 warfarin (7.5 mg) 6.02 5.01 4.20 3.59 3.12 51 268 42 704 35 558 30 078 25 905 9.8 4.8 B01AA07 acenocoumarol (5 mg) 0.00 0.00 0 0 0 5 - B01AB Heparin group 6.25 6.08 6.09 5.54 5.10 56 928 56 295 54 853 49 935 51 162 10.8 9.5 B01AB01 heparin (10 TU) 0.17 0.16 0.17 0.27 0.13 1 327 1 230 1 227 1 395 1 267 0.3 0.2 B01AB04 dalteparin 2.31 2.21 20 307 19 037 21 309 20 147 20 376 3.9 382 239 381 337 74.8 70.7 B01AC04 clopidogrel (75 mg) 4.55 5.18 6.05 6.90 7.63 30 764 34 742 40 351 45 069 49 030 5.9 9.1 B01AC05 ticlopidine (0.5 g) 0.02 0.01 0.01 0.01 0.01 104 81 72 69 62 0.0 0.0 B01AC06 381 69.3 62.8 B01AC07 dipyridamole (0.4 g O/0.2 g P) 2.83 2.49 2.11 1.25 1.11 17 789 16 485 14 447 8 713 7 186 3.4 1.3 B01AC09 epoprostenol (0.2 g P) <5 <5 - treprostinil (4.3 mg) 0.00 0.00 0.00 0.01 0.00 24 18 20 23 22 0.0 0.0 B01AC22 prasugrel (10 mg) 0.20 0.20 0.20 0.20 0.23 1 625 1 645 1 599 1 693 1 916 0.3 0.4 B01AC23 cilostazol (0.2 g) g) 1.12 1.11 1.14 1.05 0.96 9 588 9 654 9 857 9 456 8 774 1.8 B01AC25 cangrelor (50 mg) 0.00 0.00 0.00 0.00 (1.8 mg) 0.00 0.00 0.00 0.00 21 19 0.0 B01AC30 acetylsalicylic acid and dipyridamole (2 caps) 2.70 2.61 2.72 2.69 2.46 16 809 16 207 17 199 16 667 15 009 3.2 2.78 number of DDDs/year 2017 2018 2019 2020 2021 B01AD Enzymes 4 715 5 378 4 714 4 331 <5 <5 <5 0 0 - 0.0 B01AD02 alteplase (0.1 g) 2 846 2 946 3 053 3 046 3 018 <5 <5 <5 0 0 - 0.0 B01AD11 tenecteplase (40 mg) 1 869 1 795 2 325 1 668 1 313 0 0 <5 0 0 0.0 0.0 DDD/1000 inhabitants/day 2017 2018 2019 2021 B01AE Direct thrombin inhibitors 1.88 1.87 1.84 1.73 1.65 13 118 12 918 12 373 11 684 11 087 2.5 2.1 B01AE07 dabigatran etexilate (0.3 g) 1.88 1.87 1.84 1.73 1.65 13 118 12 918 12 373 11 684 11 087 2.5 2.1 B01AF Direct inhibitors 11.87 14.47 16.96 18.82 20.66 83 783 101 147 117 170 131 248 145 969 15.9 27.1 B01AF01 rivaroxaban (20 mg) 4.80 5.02 5.08 5.04 4.92 30 795 31 823 32 160 32 457 32 755 5.9 6.1 48 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of indiv iduals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 7.03 9.27 11.53 13.29 15.13 54 002 69 381 84 053 96 830 110 490 10.3 20.5 B01AF03 edoxaban (60 mg) 0.05 0.18 0.35 0.50 0.61 448 1 479 2 589 3 630 4 390 0.1 0.8 B01AX Other antithrombotic agents 0.00 0.00 0.00 0.00 26 21 0.0 0.0 B01AX01 defibrotide (1.75 g P) 0.00 - - - - - - - B01AX05 fondaparinux (2.5 mg) 0.00 0.00 0.00 0.00 26 25 21 0.0 0.0 B01AX07 caplacizumab (10 mg P) 0.00 - - - - - - - B02 ANTIHEMORRHAGICS 0.25 0.24 0.25 0.26 0.28 14 447 14 724 13 968 14 741 15 929 2.8 3.0 B02A ANTIFIBRINOLYTICS 0.20 0.20 0.20 0.21 0.22 13 819 14 075 13 247 14 025 15 151 2.6 2.8 B02AA Amino acids 0.20 0.20 0.20 0.21 0.22 13 817 14 074 13 246 14 024 15 149 2.6 2.8 B02AA02 tranexamic acid (2 g) 0.20 0.20 0.20 0.21 0.22 13 817 14 074 13 246 14 024 15 149 2.6 2.8 B02B VITAMIN K AND OTHER HEMOSTATICS 0.04 0.05 0.05 0.05 0.06 740 771 827 843 908 0.1 0.2 B02BA Vitamin K 0.02 0.01 0.01 0.01 0.01 269 283 272 242 231 0.1 0.0 B02BA01 phytomenadione (20 mg) 0.02 0.01 0.01 0.01 0.01 269 283 272 242 231 0.1 0.0 B02BD Blood coagulation factors - - - - - 287 295 313 308 324 0.1 0.1 B02BD02 coagulation factor VIII - - - - - 198 200 212 214 217 0.0 0.0 B02BD03 factor VIII inhibitor bypassing activity - - - - - 8 6 5 <5 <5 0.0 - B02BD04 coagulation factor IX - - - - - 51 58 53 56 58 0.0 0.0 B02BD06 von Willebrand factor and coagulation factor VIII in combination - - - - - 14 12 23 16 22 0.0 0.0 B02BD08 coagulation factor VIIa - - - - - 15 19 21 14 19 0.0 0.0 B02BX Other systemic hemostatics 0.03 0.03 0.04 0.04 0.05 182 192 248 298 359 0.0 0.1 B02BX04 romiplostim (30 mcg) 0.01 0.01 0.01 0.01 0.01 41 45 45 53 64 0.0 0.0 B02BX05 eltrombopag (50 mg) 0.02 0.02 0.02 0.03 0.03 150 154 206 250 291 0.0 0.1 B02BX06 emicizumab (15 mg) 0.00 0.00 0.00 0 0 6 9 11 0.0 0.0 B02BX08 avatrombopag (20 mg O) 0.00 0 0 0 0 257 905 37.4 47.8 B03A IRON PREPARATIONS 6.65 6.40 6.51 6.63 6.63 41 525 44 375 48 560 50 350 55 720 7.9 10.3 B03AA Iron bivalent, oral preparations 6.55 6.29 6.39 6.51 6.48 712 42 479 46 48 391 53 538 7.6 9.9 B03AA01 ferrous glycine sulfate (0.2 g) 1.22 1.33 1.51 1.58 1.61 10 275 12 755 15 799 16 126 17 966 2.0 3.3 B03AA02 ferrous fumarate (0.2 g) 0.16 0.08 1 959 1 380 7 0 0 0.4 0.0 B03AA07 ferrous sulfate (0.2 g) 5.34 4.96 4.88 4.93 4.87 28 907 29 019 31 408 32 791 36 185 5.5 6.7 B03AB Iron trivalent, oral preparations - - - - 0.01 0 10 45 50 137 0.0 0.0 B03AB10 ferric maltol (60 mg O) - - - - 0.01 0 10 45 50 137 0.0 0.0 B03AC Iron, parenteral preparations 0.09 0.10 0.12 0.12 0.14 1 968 2 065 2 028 2 170 2 322 0.4 0.4 B03B VITAMIN B 12 AND FOLIC ACID 37.81 39.55 42.28 44.76 48.48 160 606 171 522 182 574 193 598 212 198 30.5 39.4 B03BA Vitamin B 12 (cyanocobalamin and analogues) 18.75 19.04 20.15 20.07 20.35 104 146 111 353 118 472 119 106 127 741 19.8 23.7 49 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of indiv iduals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 O/20 mcg P) 3.09 5.79 7.97 9.90 10.14 20 180 39 218 53 135 63 874 73 583 3.8 13.7 B03BA03 hydroxocobalamin (20 mcg) 15.64 13.25 12.17 10.16 10.21 87 855 76 290 69 701 59 107 57 819 16.7 10.7 B03BA05 mecobalamin (1.5 mg O/0.2 mg P) 0.02 0.01 0.01 0.01 0.01 179 64 45 47 43 0.0 0.0 B03BB Folic acid and derivatives 19.06 20.51 22.13 24.69 28.13 62 657 67 279 72 327 84 256 95 893 11.9 17.8 B03BB01 0.07 0.08 0.09 0.07 237 254 332 335 0.23 731 1180 1712 0.0 2020 2021 B06 OTHER HEMATOLOGICAL AGENTS 5 024 5 579 5 943 6 511 7 717 135 141 143 156 162 0.0 0.0 B06A OTHER HEMATOLOGICAL AGENTS 5 024 5 579 5 943 6 511 7 717 135 141 143 156 162 0.0 0.0 B06AA Enzymes - - - - - 8 10 11 12 12 0.0 0.0 B06AA03 hyaluronidase - - - - - 8 10 11 12 12 0.0 0.0 B06AC Drugs used in hereditary angioedema 5 024 5 579 5 943 6 511 7 717 126 130 132 144 150 0.0 0.0 B06AC01 c1-inhibitor, plasma derived (1.4 TU) 3 448 4 042 4 310 4 778 5 265 88 90 93 106 108 0.0 0.0 B06AC02 icatibant (30 mg) 1 576 1 537 1 601 1 634 2 032 87 90 99 108 115 0.0 0.0 B06AC04 conestat alfa (3.5 TU) 32 1 0 0 <5 <5 0 0.0 0.0 B06AC05 lanadelumab (21.4 mg) 0 <5 <5 <5 0.0 - B06AC06 berotralstat (0.15 g O) 56 0 0 0 0 <5 0.0 - 50 4.4 C m\u00e5lt i DDD (936 i forekomst etter nervesystemet (ATC gruppe N), respirasjonsorganer (ATC gruppe R) ford\u00f8yelsesorganer og stoffskifte (ATC befolkningen gruppe C , og blant de over 70 \u00e5r fikk 70 % et legemiddel i ATC gruppe C. antihypertensives angiotensin II receptor (ARBs, C09C and C09D), and renin inhibitors (C09XA) in Norway between 2002 and 2021. Source: Norwegian Drug Wholesales Statistics, Norwegian Institute of Public Health Lipidmodifiserende midler Data fra Grossistbasert legemiddelstatistikk viser at bruk midler (C10) har siste 20 \u00e5rene (se figur 4.4. 2). Reseptregisteret at prevalens av lipidmodifiserende midler i befolkningen var rundt 12 % i 2021 (11 % for kvinner, 13 % for menn). Cirka fire av ti \u00e5r % av totalt antall DDD for statiner og 68 % av alle legemidler i gruppe C10. Bruken av 050100150200250300 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021DDD/1000 inhabitants/dayantihypertensives (C02) agents (C07) ACE inhibitors plain and comb. (C09A and C09B) plain and comb. men har 52 %; bruk av antistoff har \u00f8kt 3 - 4 4. 4.2. of (incl. with statins, C10AX09 and C10BA), and other lipid modifying drugs in Norway between 2002 and 2021. Source: Norwegian Drug Wholesales Statistics 020406080100120140160180 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 other lipid-modifying agents Year 53 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 C CARDIAC THERAPY 10.03 9.62 9.46 9.00 9.09 109 552 109 094 107 577 105 015 105 653 20.8 19.6 C01A CARDIAC GLYCOSIDES 1.14 1.02 0.96 0.85 0.87 11 153 10 482 10 012 9 626 9 453 2.1 1.8 C01AA Digitalis glycosides 1.14 1.02 0.96 0.85 0.87 11 153 10 482 10 012 9 626 9 453 2.1 1.8 C01AA04 digitoxin (0.1 mg) 0.03 0.02 0.02 0.01 0.01 398 322 244 194 155 0.1 0.0 C01AA05 digoxin (0.25 mg) 1.11 1.00 0.94 0.84 0.85 10 769 10 167 9 778 9 441 9 303 2.1 1.7 C01B ANTIARRHYTHMICS, CLASS I AND III 2.33 2.38 2.51 2.48 2.63 16 810 17 401 18 265 18 795 19 406 3.2 3.6 C01BA Antiarrhythmics, class Ia 0.02 0.02 0.02 0.01 0.01 100 99 102 84 43 0.0 0.0 C01BA03 disopyramide (0.4 g) 0.02 0.02 0.02 0.01 0.01 96 94 98 81 39 0.0 0.0 C01BB Antiarrhythmics, class Ib 0.00 39 45 43 44 0.0 C01BB02 mexiletine ( 0.8 g O,P) 0.00 39 45 42 43 46 0.0 0.0 C01BC Antiarrhythmics, class Ic 1.18 1.17 1.19 1.13 1.18 8 152 8 194 8 353 8 420 8 554 1.6 1.6 C01BC03 propafenone (0.3 g O,P) 0.00 7 5 <5 10 10 0.0 0.0 C01BC04 flecainide (0.2 g) 1.18 1.17 1.19 1.13 1.18 8 145 8 190 8 349 8 410 8 544 1.6 1.6 C01BD Antiarrhythmics, class III 1.13 1.19 1.31 1.33 1.44 8 871 9 391 10 124 10 588 11 121 1.7 (0.2 g) 0.79 0.81 0.87 0.89 0.93 6 551 6 813 7 270 7 508 7 854 1.3 1.5 C01BD07 dronedarone (0.8 g) 0.34 0.38 0.43 0.45 0.51 2 520 2 792 3 128 3 343 3 561 0.5 0.7 29 484 342 28 817 30 605 5.3 5.7 0.39 0.39 586 29 484 29 342 28 817 30 605 5.3 5.7 C01CA03 norepinephrine 0.05 0.05 0.05 0.09 0.05 - - - - - - - C01CA17 midodrine (30 mg) 0.00 0.00 0.00 0.01 0.01 69 72 115 163 197 0.0 0.0 C01CA24 epinephrine (0.5 mg) 0.22 0.23 0.23 0.30 0.22 27 455 29 352 29 177 28 603 30 370 5.2 5.6 C01CA26 VASODILATORS USED IN CARDIAC DISEASES 6.14 5.79 5.55 5.11 5.16 57 317 54 878 52 919 50 546 48 874 10.9 9.1 C01DA Organic nitrates 6.14 5.79 5.55 5.11 5.16 57 316 54 877 52 919 50 545 48 873 10.9 9.1 C01DA02 glyceryl trinitrate (2.5 mg SL/5mg O/TD) 1.17 1.11 1.05 0.91 0.96 44 297 42 415 40 747 38 397 36 778 8.4 6.8 C01DA08 isosorbide dinitrate (60 mg) - - - - - 231 0 0 0 0 0.0 0.0 C01DA14 isosorbide mononitrate (40 mg) 4.97 4.68 4.50 4.20 4.20 23 752 22 774 22 006 21 306 20 744 4.5 3.9 C01E OTHER CARDIAC PREPARATIONS 0.04 0.04 0.05 0.05 0.05 286 289 373 430 501 0.05 0.09 C01EB Other cardiac preparations 0.04 0.04 0.05 0.05 0.05 286 289 373 430 501 0.1 0.1 C01EB09 ubidecarenone - - - - - 0 10 22 24 30 0.0 0.0 C01EB10 adenosine (15 mg) 0.02 0.02 0.01 0.01 (40 mg) 0.00 0.00 0.00 0.00 11 9 13 0.0 0.0 C01EB17 ivabradine (10 mg) 0.02 0.02 0.03 0.03 0.04 249 241 305 357 407 0.1 0.1 C01EB18 ranolazine (1.5 g) 0.00 0.00 0.00 0.00 0.01 28 32 35 43 53 0.0 0.0 54 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 3.75 3.52 3.65 17 723 17 686 16 774 18 006 18 424 3.4 3.4 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 1.29 1.25 1.40 1.37 1.38 7 025 7 169 7 787 9 148 9 132 1.3 1.7 C02AB Methyldopa 0.00 0.00 0.00 0.00 (1 g) 0.00 0.00 0.00 30 0.0 C02AC Imidazoline receptor agonists 1.29 1.24 1.39 1.37 1.38 6 982 7 132 7 749 9 121 9 106 1.3 1.7 C02AC01 clonidine (0.45 mg) 0.02 0.03 0.04 0.09 0.09 200 282 514 1 866 1 657 0.0 0.3 C02AC02 guanfacine (3 mg) 0.04 0.05 0.07 0.09 0.10 417 477 638 734 852 0.1 0.2 C02AC05 moxonidine (0.3 mg) 1.23 1.16 1.29 1.19 1.18 6 367 6 377 6 600 6 528 6 604 1.2 1.2 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 2.67 2.37 2.26 2.06 2.17 10 818 10 630 9 064 8 930 9 289 2.1 1.7 C02CA Alpha -adrenoreceptor antagonists 2.67 2.37 2.26 2.06 2.17 10 818 10 630 9 064 8 930 9 289 2.1 1.7 C02CA01 prazosin (5 mg) 0.01 0.02 0.02 0.02 0.01 140 145 122 145 130 0.0 0.0 C02CA04 doxazosin (4 mg) 2.66 2.35 2.24 2.04 2.16 10 681 10 488 8 943 8 790 9 164 2.0 1.7 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 0.03 0.04 0.04 0.03 0.03 383 411 427 439 570 0.1 0.1 C02DB Hydrazinophthalazine derivatives 0.03 0.04 0.04 0.03 0.03 322 363 370 366 396 0.1 0.1 C02DB02 hydralazine (0.1 g) 0.03 0.04 0.04 0.03 0.03 322 363 370 366 396 0.1 0.1 C02DC Pyrimidine derivatives 0.00 0.00 0.00 0.01 0.01 62 50 63 76 177 0.0 0.0 C02DC01 minoxidil (20 mg) 0.00 0.00 0.00 0.01 0.01 62 50 63 76 177 0.0 0.0 C02K OTHER ANTIHYPERTENSIVES 0.05 0.05 0.06 0.06 0.06 326 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 0.0 C02KX Antihypertensives for pulmonary arterial hypertension 0.05 0.05 0.06 0.06 317 328 354 350 361 0.1 0.1 C02KX01 bosentan (0.25 g) 0.02 0.01 0.01 0.01 0.01 106 103 112 109 101 0.0 0.0 C02KX02 ambrisentan (7.5 mg) 0.01 0.01 0.01 0.01 0.01 58 47 53 51 55 0.0 0.0 C03 DIURETICS 32.01 31.70 30.80 29.77 28.43 170 540 169 412 163 999 162 119 160 984 32.4 29.9 C03A LOW -CEILING DIURETICS, THIAZIDES 5.13 893 31 977 28 447 27 595 24 889 6.3 4.6 C03AA Thiazides, plain 1.84 1.79 1.65 1.64 1.87 12 495 13 253 11 874 12 499 15 929 2.4 mg) 1.84 1.79 1.65 1.64 1.87 12 492 13 250 11 870 12 498 15 917 2.4 3.0 C03AB Thiazides and potassium in combination 3.30 2.98 2.66 2.41 1.31 20 465 18 795 16 630 15 152 11 826 3.9 plain 0.00 0.00 0.00 0.00 (25 mg) 0.00 0.00 0.00 0.00 0.00 6 6 6 6 7 0.0 0.0 55 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 10.85 11.24 11.63 79 694 75 970 74 597 78 887 79 256 15.3 14.8 C03CA02 bumetanide (1 mg) 11.41 11.37 11.85 11.20 10.14 42 921 44 130 46 220 44 135 43 382 8.2 8.1 C03D POTASSIUM -SPARING AGENTS 1.68 1.72 1.84 2.00 2.18 21 421 22 492 24 209 26 290 28 147 4.1 5.2 C03DA Aldosterone antagonists 1.68 1.72 1.84 2.00 2.18 21 406 22 476 24 196 26 275 28 128 4.1 5.2 C03DA01 spironolactone (75 mg) 1.51 1.54 1.60 1.67 1.79 20 091 20 980 22 160 23 591 24 835 3.9 4.6 C03DA04 eplerenone (50 mg) 0.17 0.18 0.24 0.33 0.39 1 489 1 671 2 236 2 918 3 551 0.3 0.7 C03DB Other potassium - sparing agents 0.00 0.00 0.00 0.00 0.00 18 16 21 (10 mg) 0.00 0.00 0.00 0.00 25 23 0.0 0.0 C03E DIURETICS AND POTASSIUM -SPARING AGENTS IN COMBINATION 2.61 2.36 1.99 1.71 1.57 15 279 13 339 11 099 9 768 9 224 2.9 1.7 C03EA Low -ceiling diuretics and potassium -sparing agents 2.61 2.36 1.99 1.71 1.57 15 279 13 339 11 099 9 768 9 224 2.9 1.7 C03EA01 hydrochlorothiazide and potassium -sparing agents (1 UD) 2.61 2.36 1.99 1.71 1.57 15 279 13 339 11 099 9 768 9 224 2.9 1.7 C03X OTHER DIURETICS 0.02 0.04 0.05 0.07 0.08 160 187 224 275 298 0.0 0.1 C03XA Vasopressin antagonists 0.02 0.04 0.05 0.07 0.08 160 187 224 275 298 0.0 0.1 C03XA01 tolvaptan (30 mg) 0.02 0.04 0.05 0.07 0.08 160 187 224 275 298 0.0 0.1 C04 PERIPHERAL VASODILATORS 0.07 0.06 0.06 0.06 0.06 0.07 0.06 0.06 0.06 0.07 0.06 0.06 0.06 ) 0.07 0.06 0.06 507 501 BLOCKING AGENTS 34.76 34.06 33.84 32.97 32.39 378 400 379 381 904 384 506 72.0 32.48 31.92 375 321 376 704 379 602 379 443 382 146 71.4 70.9 C07AA Beta blocking agents, non-selective 1.51 1.40 1.36 1.31 1.26 20 491 21 170 22 064 21 680 20 669 3.9 3.8 C07AA03 pindolol (15 0.83 17 116 (0.16 g) 0.64 0.57 0.51 0.48 0.41 4 346 3 872 3 484 3 165 2 953 0.8 0.6 C07AA12 nadolol (0.16 g) 0.01 0.02 0.02 0.02 0.02 163 189 206 245 266 0.0 0.1 C07AB Beta blocking agents, selective 30.01 29.52 29.39 28.64 28.15 336 587 337 155 339 095 342 701 64.0 63.6 C07AB02 metoprolol (0.15 g) 23.86 23.42 23.10 22.76 283 411 285 655 288 054 288 235 291 670 53.9 54.1 C07AB03 atenolol (75 mg) 3.14 2.74 2.74 2.29 2.13 23 277 21 435 18 868 17 517 17 007 4.4 3.2 C07AB07 bisoprolol (10 mg) 3.01 3.10 3.21 3.24 3.24 33 069 34 311 35 632 36 314 36 925 6.3 6.9 C07AB12 nebivolol (5 mg) 0.01 0.01 0.02 0.02 0.02 79 98 127 143 140 0.0 0.0 C07AG Alpha and beta blocking agents 2.62 2.56 2.56 2.53 2.51 22 064 22 019 22 439 22 391 22 757 4.2 4.2 56 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2 819 2 963 3 134 3 164 3 351 0.5 0.6 C07AG02 carvedilol (37.5 mg) 2.44 2.38 2.38 2.35 2.33 19 267 19 077 19 335 19 258 19 440 3.7 3.6 C07B BETA BLOCKING AGENTS AND THIAZIDES 0.62 0.58 0.53 0.49 0.47 3 342 3 113 2 883 2 738 2 564 0.6 0.5 C07BB Beta blocking agents, selective, and thiazides 0.62 0.58 0.53 0.49 0.47 3 342 3 113 883 2 738 2 564 0.6 0.5 0.53 0.49 0.47 3 336 3 105 2 875 2 735 2 564 0.6 0.5 CHANNEL BLOCKERS 57.95 58.78 61.57 62.21 63.68 256 269 500 278 668 48.7 51.7 C08C SELECTIVE 59.43 60.06 61.67 241 764 246 256 090 265 567 46.0 C08CA01 amlodipine (5 mg) 31.37 33.78 37.12 137 090 155 136 163 575 167 038 173 708 26.1 32.2 C08CA02 felodipine (5 mg) 3.36 3.40 3.58 3.45 3.31 12 982 14 561 14 804 14 194 13 856 2.5 2.6 C08CA03 isradipine (5 mg) 0.07 0.02 351 275 <5 0 0 0.1 0.0 C08CA05 nifedipine (30 mg) 9.98 7.72 5.77 5.64 5.84 50 280 47 653 25 203 24 057 25 637 9.6 4.8 C08CA06 nimodipine (0.3 g O/50 mg P) 0.00 0.00 0.00 45 35 (10 mg) 10.79 11.63 12.95 13.12 13.41 44 738 51 137 54 170 54 688 56 094 8.5 10.4 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 2.38 2.22 2.14 2.15 2.02 15 374 15 121 14 918 14 478 14 183 2.9 2.6 C08DA Phenylalkylamine derivatives 1.75 1.60 1.56 1.52 1.43 11 662 11 357 11 261 10 914 10 645 2.2 2.0 C08DA01 verapamil (0.24 g) 1.75 1.60 1.56 1.52 1.43 11 662 11 357 11 261 10 914 10 645 2.2 2.0 C08DB Benzothiazepine derivatives 0.63 0.62 0.58 641 3 581 0.7 0.7 C09 43.75 43.08 137 321 138 649 138 734 137 469 137 358 26.1 25.5 C09AA ACE inhibitors, plain 44.05 44.07 44.50 43.75 43.08 137 321 138 649 138 734 137 469 137 358 26.1 25.5 C09AA01 captopril (50 mg) 0.27 0.24 0.20 0.19 0.17 1 339 1 205 1 094 976 895 0.3 0.2 C09AA02 enalapril (10 mg) 9.97 9.77 9.87 9.73 9.59 46 333 46 453 46 507 46 173 46 284 8.8 8.6 C09AA03 lisinopril (10 mg) 4.46 4.29 4.19 4.04 3.92 20 709 20 334 19 418 18 721 18 125 3.9 3.4 C09AA04 perindopril (4 mg) 0.01 0.01 0.01 0.02 0.02 52 60 80 202 178 0.0 0.0 C09AA05 ramipril (2.5 mg) 29.34 29.76 30.22 29.77 29.39 69 406 71 099 72 069 71 858 72 374 13.2 13.4 COMBINATIONS 5.12 4.78 4.58 4.37 4.23 29 243 28 185 27 004 25 849 25 240 5.6 4.7 C09BA ACE inhibitors and diuretics 4.77 4.44 4.2 C09BA02 diuretics 2.97 2.69 17 149 15 15180 14 768 3.3 2.7 C09BA03 lisinopril and diuretics (1 UD) 1.80 1.64 1.50 1.38 1.29 10 189 9561 8 777 8036 7 595 1.9 1.4 57 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 calcium channel blockers 0.35 0.34 0.40 0.43 0.47 1 930 2 125 2 418 2684 2 923 0.4 0.5 C09BB02 enalapril and lercanidipine 0.35 0.34 0.40 0.43 0.47 1 930 2125 2 418 2 684 2 923 0.4 0.5 C09C 263 47.3 15.52 15.66 15.51 67 344 69 440 71 294 71 549 71 868 12.8 13.3 C09CA02 eprosartan (0.6 g) 0.17 0.15 0.12 0.11 0.09 988 902 830 686 507 mg) 9.51 9.73 10.34 10.85 11.89 38 060 40 080 40 005 42 958 47 126 7.2 8.7 C09CA04 irbesartan (0.15 g) 4.28 4.12 4.09 3.91 3.88 17 853 17 579 17 232 16 540 16 035 3.4 3.0 C09CA06 candesartan (8 mg) 30.63 33.14 37.10 39.43 42.55 118 609 129 744 141 509 151 381 163 966 22.6 30.4 C09CA07 telmisartan (40 mg) 1.34 1.40 1.40 1.41 1.35 5 680 5 794 5 840 5 920 5 855 1.1 1.1 1 644 1 695 1 703 0.3 0.3 C09D 119 33.6 30.4 C09DA01 and diuretics (1 UD) 11.04 10.63 10.14 9.77 9.55 63 337 61 870 58 886 57 080 55 890 12.1 10.4 C09DA02 eprosartan and diuretics (1 UD) 0.20 0.18 0.16 0.15 0.14 1 113 1 024 945 867 803 0.2 0.2 C09DA03 valsartan and 4.48 4.40 26 833 26 530 24 991 25 037 25 478 5.1 C09DA04 3.93 301 18 438 17448 UD) 10.21 10.25 10.18 10.12 10.14 59 488 60 366 59 966 60 139 61 311 11.3 11.4 C09DA07 telmisartan and diuretics (1 UD) 0.55 0.53 0.50 0.48 0.46 3 266 3 131 2 970 2 885 2 809 0.6 0.5 C09DA08 olmesartan medoxomil and diuretics (1 UD) 0.17 0.17 0.16 0.15 0.15 972 973 928 907 888 0.2 0.2 C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers 5.18 5.40 6.45 7.14 7.69 31 687 34 464 38 960 42 854 47 667 6.0 8.8 C09DB01 valsartan and amlodipine (1 375 34 097 42 390 47 170 6.0 8.8 C09DB02 amlodipine (1 372 0.1 receptor blockers combinations 4.44 5.87 6.61 26 922 29 700 32 36 183 40 686 4.55 4.86 5.14 5.56 26 003 28 023 29 852 31 796 34 452 5.0 6.4 C09X OTHER AGENTS ACTING ON THE RENIN - ANGIOTENSIN SYSTEM 0.01 0.00 0.00 0.00 0.00 -inhibitors 0.01 0.00 0.00 0.00 aliskiren (0.15 g) 0.01 0.00 0.00 0.00 0.00 32 10 8 9 9 0.0 0.0 58 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 195 647 256 108.0 212 312 192 106 174 850 160 085 149 172 40.4 27.7 C10AA02 lovastatin (45 C10AA03 pravastatin (30 mg) 2.99 2.88 2.76 2.57 2.45 17 903 17 497 16 597 15 917 15 222 3.4 2.8 C10AA04 fluvastatin (60 mg) 1.18 1.15 1.14 1.12 1.12 7 469 5 152 5 202 5 199 5 254 1.4 1.0 C10AA05 atorvastatin (20 mg) 82.29 59.46 94.98 107.73 117.70 29 329 577 382 459 416 549 56.2 77.3 C10AA07 rosuvastatin (10 mg) 6.24 7.35 8.90 10.71 12.50 25 959 30 921 36 645 43 736 50 111 4.9 9.3 C10AA08 pitavastatin (2 mg) 0.00 0.00 0.00 0.00 26 25 23 0.0 0.0 C10AB Fibrates 0.05 0.05 0.05 0.05 0.05 316 329 329 336 344 0.1 0.1 C10AB02 bezafibrate (0.6 g) 0.00 0.00 0.01 0.01 0.01 36 39 49 49 55 0.0 0.0 C10AB04 gemfibrozil (1.2 g) 0.01 0.01 0.01 0.01 0.01 67 61 57 53 49 0.0 0.0 C10AB05 fenofibrate (0.2 g) 0.04 0.04 0.03 0.04 0.04 215 230 223 235 241 0.0 0.0 C10AC Bile acid sequestrants 0.16 0.16 0.17 0.17 0.16 3 277 3 412 3 488 3 290 3 562 0.6 0.7 C10AC01 colestyramine (14 g) 0.09 0.09 0.10 0.10 0.10 2 610 2 763 2 858 2 712 3 050 0.5 0.6 C10AC02 colestipol (20 g) 0.01 0.01 0.01 0.00 0.00 216 196 189 205 12 - C10AD02 nicotinic acid - - - - - 10 7 <5 0 0 0.0 0.0 C10AX Other lipid modifying agents 5.58 7.65 8.06 11.85 13.70 38 964 53 421 56 626 75 845 85 108 7.4 15.8 C10AX06 omega -3-triglycerides incl. other esters and acids (4 tab) 0.56 0.56 0.56 0.58 0.59 4 725 4 813 4 716 4 766 4 910 0.9 0.9 C10AX09 ezetimibe (10 mg) 4.91 6.91 7.23 10.89 12.58 34 729 49 075 52 118 71 190 79 904 6.6 14.8 C10AX13 evolocumab (10 mg) 0.04 0.07 0.10 0.14 0.20 317 484 664 931 1 292 0.1 0.2 C10AX14 alirocumab (5.4 mg) 0.06 0.11 0.17 0.24 0.33 280 474 665 921 1 222 0.1 0.2 C10B LIPID MODIFYING AGENTS, COMBINATIONS 2.66 2.79 3.41 1.04 1.37 20 260 21 745 24 468 10 694 9 677 3.9 1.8 C10BA Combinations of various lipid modifying agents 2.66 2.79 3.41 1.04 1.37 20 260 21 745 24 468 10 694 9 677 3.9 555 4 629 652 4 206 3 968 0.9 and ezetimibe (1 UD) 1.94 2.11 2.62 0.24 15 847 17 293 20 021 4 766 141 3.0 0.0 C10BA06 rosuvastatin and ezetimibe (1 UD) 0.21 0.75 0 0 <5 2 007 5 637 0.0 1.1 59 4.5 D Dermatologiske midler D01 av de mest brukte legemiddel i ATC systemiske antibiotikapreparater i ATC gruppe J01. 61 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 D - - - - D01 ANTIFUNGALS FOR DERMATOLOGICAL USE - - - - - 150 144 153 603 161 220 162 666 166 246 28.6 30.8 D01A ANTIFUNGALS FOR TOPICAL USE - - - - - 132 033 134 334 142 726 144 114 146 508 25.1 27.2 D01AA Antibiotics - - - - - 27 41 33 30 54 0.0 0.0 D01AA01 nystatin - - - - - 27 41 33 30 54 0.0 0.0 D01AC Imidazole and triazole derivatives - - - - - 107 077 109 066 117 744 119 006 120 986 20.4 22.4 D01AC01 clotrimazole - - - - - 10 505 10 533 11 342 11 003 10 851 2.0 2.0 D01AC02 miconazole - - - - - 2 309 2 382 2 330 2 411 2 525 0.4 0.5 D01AC03 econazole - - - - - 1 016 1 035 1 177 1 231 1 375 0.2 0.3 D01AC08 ketoconazole - - - - - 20 378 21 874 24 981 24 796 24 375 3.9 4.5 D01AC20 imidazoles/triazoles in combination with corticosteroids - - - - - 78 325 78 597 84 038 85 641 87 874 14.9 16.3 D01AE Other antifungals for topical use - - - - - 28 823 29 126 29 029 29 355 29 751 5.5 5.5 D01AE02 methylrosaniline - - - - - 873 586 221 667 718 0.2 0.1 D01AE14 ciclopirox - - - - - 4 773 4 976 4 978 4 991 5 515 0.9 1.0 D01AE15 terbinafine - - - - - 19 520 19 823 20 306 20 216 20 780 3.7 3.9 D01AE16 amorolfine - - - - - 4 152 4 212 4 023 3 984 3 270 0.8 0.6 D01B ANTIFUNGALS FOR SYSTEMIC USE 1.24 1.28 1.22 1.24 1.31 22 760 24 057 23 256 23 476 24 891 4.3 4.6 D01BA Antifungals for systemic use 1.24 1.28 1.22 1.24 1.31 22 760 24 057 23 256 23 476 24 891 4.3 4.6 D01BA01 griseofulvin (0.5 g) 0.00 0.00 0.00 0.00 20 17 9 0.0 0.0 D01BA02 terbinafine (0.25 g) 1.24 1.28 1.22 1.24 1.31 22 733 24 038 23 243 23 463 24 883 4.3 4.6 D02 EMOLLIENTS AND PROTECTIVES - - - - - 75 655 111 677 141 006 162 641 188 235 14.4 34.9 D02A EMOLLIENTS AND PROTECTIVES - - - - - 75 646 111 665 140 988 162 628 188 218 14.4 34.9 D02AB Zinc products - - - - - 11 7 <5 <5 0 0.0 0.0 D02AC Soft paraffin and fat products - - - - - 7 16 39 37 33 0.0 0.0 D02AE Carbamide products - - - - - 73 598 109 620 139 113 161 191 186 582 14.0 34.6 D02AE01 carbamide - - - - - 73 598 109 620 139 113 161 191 186 582 14.0 34.6 D02AF Salicylic acid preparations - - - - - 1 651 1 709 1 482 963 1 197 0.3 0.2 D02AX Other emollients and protectives - - - - - 881 966 1 017 1 032 1 093 0.2 0.2 D02B PROTECTIVES AGAINST UV-RADIATION - - - - - 9 13 20 17 20 0.0 0.0 D02BA Protectives against UV - radiation for topical use - - - - - 9 13 20 17 20 0.0 0.0 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS - - - - - 67 147 226 236 344 0.0 0.1 D03A CICATRIZANTS - - - - - 67 147 226 236 344 0.0 0.1 D03AX Other cicatrizants - - - - - 67 147 226 236 344 0.0 0.1 D03AX03 dexpanthenol - - - - - 67 147 226 236 344 0.0 0.1 62 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 ANTIHISTAMINES, ANESTHETICS, ETC. - - - - - 8 761 8 573 8 872 8 919 9 125 1.7 1.7 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. - - - - - 8 761 8 573 8 872 8 919 9 125 1.7 1.7 D04AA Antihistamines for topical use - - - - - 6 5 14 21 21 0.0 0.0 D04AA13 dimetindene - - - - - 6 5 14 21 21 0.0 0.0 D04AB Anesthetics for topical use - - - - - 6 949 6 599 6 850 7 087 7 117 1.3 1.3 D04AB01 lidocaine - - - - - 6 949 6 599 6 850 7 087 7 117 1.3 1.3 D04AX Other antipruritics - - - - - 1 838 2 000 2 040 1 848 2 021 0.4 0.4 D05 ANTIPSORIATICS - - - - - 31 250 30 297 30 874 31 453 31 095 5.9 5.8 D05A ANTIPSORIATICS FOR TOPICAL USE - - - - - 29 303 28 441 29 061 29 680 29 262 5.6 5.4 D05AA Tars - - - - - 1 917 1 940 2 194 2 446 2 539 0.4 0.5 D05AC Antracen derivatives - - - - - 7 7 5 <5 <5 0.0 - D05AX Other antipsoriatics for topical use - - - - - 27 683 26 768 27 199 27 613 27 065 5.3 5.0 D05AX02 calcipotriol - - - - - 369 471 333 355 314 0.1 0.1 D05AX03 calcitriol - - - - - 1 162 1 022 956 828 832 0.2 0.2 D05AX52 calcipotriol, combinations - - - - - 26 676 25 818 26 336 26 819 26 264 5.1 4.9 D05B ANTIPSORIATICS FOR SYSTEMIC USE 0.18 0.18 0.18 0.18 0.16 2 519 2 463 2 464 2 446 2 445 0.5 0.5 D05BA Psoralens for systemic use 0.00 0.00 0.00 0.00 15 15 (10 mg) 0.00 0.00 0.00 0.00 15 7 Retinoids for treatment of psoriasis 0.18 0.18 0.18 0.17 0.16 2 442 2 412 2 443 2 436 2 436 0.5 0.5 D05BB02 acitretin (35 mg) 0.18 0.18 0.18 0.17 0.16 2 442 2 412 2 443 2 436 2 436 0.5 0.5 D05BX Other antipsoriatics for systemic use - - - - - 66 38 7 <5 <5 0.0 - D05BX51 fumaric acid derivatives, combinations - - - - - 66 38 7 <5 <5 0.0 - D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE - - - - - 108 688 106 034 106 769 100 859 96 631 20.7 17.9 D06A ANTIBIOTICS FOR TOPICAL USE - - - - - 54 255 53 258 54 360 51 502 50 326 10.3 9.3 D06AA Tetracycline and derivatives - - - - - 3 226 3 276 3 636 3 502 3 455 0.6 0.6 D06AA02 chlortetracycline - - - - - 29 28 17 20 26 0.0 0.0 D06AA03 oxytetracycline - - - - - 3 198 3 248 3 619 3 482 3 430 0.6 0.6 D06AX Other antibiotics for topical use - - - - - 51 217 50 165 50 923 48 170 47 047 9.7 8.7 D06AX01 fusidic acid - - - - - 47 857 47 492 49 608 46 224 44 504 9.1 8.3 D06AX05 bacitracin - - - - - 2 893 2 805 1 341 2 029 2 613 0.6 0.5 D06AX07 <5 5 <5 - - D06AX09 mupirocin - - - - - 43 39 49 64 55 0.0 0.0 D06AX13 retapamulin - - - - - 640 0 0 0 0 0.1 0.0 63 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE - - - - - 56 248 54 555 54 144 50 987 47 794 10.7 8.9 D06BA Sulfonamides - - - - - 2 866 2 893 2 603 2 609 2 482 0.6 0.5 D06BA01 silver sulfadiazine - - - - - 2 866 2 893 2 603 2 609 2 482 0.6 0.5 D06BB Antivirals - - - - - 35 270 34 585 32 831 33 432 31 811 6.7 5.9 D06BB03 aciclovir - - - - - 15 101 15 302 14 465 14 489 15 130 2.9 2.8 D06BB04 podophyllotoxin - - - - - 10 834 10 353 9 624 8 818 8 014 2.1 1.5 D06BB06 penciclovir - - - - - 871 691 560 457 413 0.2 0.1 D06BB10 imiquimod - - - - - 9 299 8 973 8 698 10 107 8 658 1.8 1.6 D06BB53 aciclovir, combinations - - - - - 0 32 133 178 181 0.0 0.0 D06BX Other chemotherapeutics - - - - - 18 720 17 665 19 305 15 270 13 767 3.6 2.6 D06BX01 metronidazole - - - - - 13 311 12 426 13 908 14 961 13 767 2.5 2.6 D06BX02 ingenol mebutate - - - - - 5 459 5 276 5 440 313 0 1.0 0.0 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS - - - - - 420 091 424 140 434 154 452 908 467 585 79.9 86.7 D07A CORTICOSTEROIDS, PLAIN - - - - - 360 719 361 931 369 300 384 962 399 707 68.6 74.1 D07AA Corticosteroids, weak (group I) - - - - - 36 466 36 147 39 765 40 077 41 594 6.9 7.7 D07AA02 hydrocortisone - - - - - 36 466 36 147 39 765 40 077 41 594 6.9 7.7 D07AB Corticosteroids, moderately potent (group II) - - - - - 124 714 125 572 128 189 134 780 137 775 23.7 25.6 D07AB02 hydrocortisone butyrate - - - - - 98 183 99 177 110 928 121 213 118 146 18.7 21.9 D07AB08 desonide - - - - - 28 161 27 855 19 569 15 290 21 114 5.4 3.9 D07AC Corticosteroids, potent (group III) - - - - - 176 748 173 575 182 629 184 840 192 486 33.6 35.7 D07AC01 betamethasone - - - - - 55 767 54 130 53 421 48 901 50 623 10.6 9.4 D07AC03 desoximetasone - - - - - 11 848 10 660 12 208 4 854 1 653 2.3 0.3 D07AC04 fluocinolone acetonide - - - - - 5 634 5 132 5 936 8 835 8 061 1.1 1.5 D07AC08 fluocinonide - - - - - 376 362 365 444 418 0.1 0.1 D07AC13 mometasone - - - - - 102 116 102 281 115 156 127 335 136 788 19.4 25.4 D07AC17 fluticasone - - - - - 8 661 7 759 3 622 2 718 2 284 1.7 0.4 D07AD Corticosteroids, very potent (group IV) - - - - - 74 810 76 790 69 790 79 874 84 097 14.2 15.6 D07AD01 clobetasol - - - - - 74 810 76 790 69 790 79 874 84 097 14.2 15.6 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS - - - - - 32 979 37 187 37 083 42 064 39 797 6.3 7.4 D07BB Corticosteroids, moderately potent, combinations with antiseptics - - - - - 4 673 6 995 9 <5 0 0.9 0.0 D07BB02 desonide and antiseptics - - - - - 4 673 6 995 9 <5 0 0.9 0.0 D07BC Corticosteroids, potent, combinations with antiseptics - - - - - 28 949 30 910 37 077 42 064 39 797 5.5 7.4 D07BC01 betamethasone and antiseptics - - - - - 26 980 28 898 34 338 39 213 35 129 5.1 6.5 64 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 and antiseptics - - - - - 2 260 2 135 2 960 3 067 5 239 0.4 1.0 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS - - - - - 26 831 25 976 27 865 26 938 27 967 5.1 5.2 D07CA Corticosteroids, weak, combinations with antibiotics - - - - - 26 181 25 439 27 828 26 897 27 936 5.0 5.2 D07CA01 hydrocortisone and antibiotics - - - - - 26 181 25 439 27 828 26 897 27 936 5.0 5.2 D07CC Corticosteroids, potent, combinations with antibiotics - - - - - 687 563 39 42 35 0.1 0.0 D07CC01 betamethasone and antibiotics - - - - - 684 562 37 41 35 0.1 0.0 D07X CORTICOSTEROIDS, OTHER COMBINATIONS - - - - - 31 931 32 027 33 261 35 306 36 923 6.1 6.9 D07XA Corticosteroids, weak, other combinations - - - - - 11 <5 0 0 0 0.0 0.0 D07XA01 hydrocortisone - - - - - 11 <5 0 0 0 0.0 0.0 D07XC Corticosteroids, potent, other combinations - - - - - 31 920 32 023 33 261 35 306 36 923 6.1 6.9 D07XC01 betamethasone - - - - - 31 920 32 023 33 261 35 306 36 923 6.1 6.9 D10 ANTI -ACNE PREPARATIONS 1.24 1.40 1.53 1.68 1.79 82 095 83 203 85 751 92 600 100 228 15.6 18.6 D10A ANTI -ACNE PREPARATIONS FOR TOPICAL USE - - - - - 71 573 70 961 72 251 77 874 84 593 13.6 15.7 D10AD Retinoids for topical use in acne - - - - - 46 115 47 702 50 432 54 251 57 286 8.8 10.6 D10AD01 tretinoin - - - - - 3 483 3 608 4 134 4 376 4 662 0.7 0.9 D10AD03 adapalene - - - - - 6 883 6 789 7 364 7 789 8 764 1.3 1.6 D10AD51 tretinoin, combinations - - - - - 10 042 10 111 10 663 11 441 12 594 1.9 2.3 D10AD53 adapalene, combinations - - - - - 28 445 29 909 31 280 34 052 34 936 5.4 6.5 D10AE Peroxides - - - - - 3 390 3 939 4 193 4 502 3 974 0.6 0.7 D10AE01 benzoyl peroxide - - - - - 3 390 3 939 4 193 4 502 3 974 0.6 0.7 D10AF Antiinfectives for treatment of acne - - - - - 14 791 11 271 8 527 9 342 10 735 2.8 2.0 D10AF01 clindamycin - - - - - 14 758 11 246 8 478 9 298 10 687 2.8 2.0 D10AF02 erythromycin - - - - - 35 26 51 45 48 0.0 0.0 D10AX Other anti -acne preparations for topical use - - - - - 14 562 15 006 15 613 17 002 20 468 2.8 3.8 D10AX03 azelaic acid - - - 14554 15003 <5 0 0.0 0.0 D10B ANTI -ACNE PREPARATIONS FOR SYSTEMIC USE 1.24 1.40 1.53 1.68 1.79 15 925 17 959 19 924 22 030 23 890 3.0 4.4 D10BA Retinoids for treatment of acne 1.24 1.40 1.53 1.68 1.79 15 925 17 959 19 924 22 030 23 890 3.0 4.4 D10BA01 isotretinoin (30 mg) 1.24 1.40 1.53 1.68 1.79 15 925 17 959 19 924 22 030 23 890 3.0 4.4 65 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 D11 OTHER DERMATOLOGICAL PREPARATIONS 0.16 0.15 0.16 0.20 0.27 38 672 41 048 43 883 48 733 52 598 7.4 9.8 D11A OTHER DERMATOLOGICAL PREPARATIONS - - - - - 38 672 41 048 43 883 48 733 52 598 7.4 9.8 D11AC Medicated shampoos - - - - 2585 2113 0.4 0.4 2113 0.4 0.4 D11AF Wart and anti -corn preparations - - - - - 3 214 3 010 333 312 628 0.6 0.1 D11AH Agents for dermatitis, excluding corticosteroids 0.09 0.08 0.09 0.14 0.21 19 667 20 505 23 057 26 380 28 762 3.7 5.3 D11AH01 tacrolimus - - - - - 11 229 11 511 12 090 12 955 14 027 2.1 2.6 D11AH02 pimecrolimus - - - - - 8 054 8 630 10 640 12 989 13 963 1.5 2.6 D11AH04 alitretinoin (20 mg) 0.09 0.08 0.09 0.10 0.12 967 973 1 041 1 104 1 184 0.2 0.2 D11AH05 dupilumab (21.4 mg) 0.00 0.00 0.04 0.10 0 6 19 389 703 0.0 0.1 D11AX Other - - - - 469 597 644 738 886 0.1 0.2 D11AX10 finasteride (1 mg) 0.07 0.06 0.07 0.06 0.06 519 511 560 530 610 0.1 0.1 D11AX16 eflornithine - - - - - 934 1 019 1 086 1 202 1 315 0.2 0.2 D11AX18 diclofenac - - - - - 406 304 261 345 284 0.1 0.1 D11AX21 brimonidine - - - - - 1 805 1 405 1 518 1 435 1 412 0.3 0.3 D11AX22 ivermectin - - - - - 8 311 10 395 13 068 14 099 15 277 1.6 2.8 66 4.6 G Urogenitalsystem og er den st\u00f8rste av undergruppene i av all 2021). Reseptregis teret viser siden 2015, en reduksjon p\u00e5 rundt 2 aldersgruppen b\u00e5de Grossistbasert legemiddelstatistikk og Reseptregisteret. 67 Figure 4.6.1 Sales of oral and transdermal hormonal contraceptives 201 2-2021. Source: Norwegian Drug Wholesales Statis tics Figure 4.6.2 Sales of hormone IUDs (G02BA03) and contraceptive implants (G03AC08) 2012-2021Source: Norwegian Drug Wholesales Statistics 020000400006000080000100000120000140000160000180000200000220000240000260000280000300000 2012 2013 2014 2015 2016 2017 2018 010000200003000040000500006000070000 2012 2013 2014 2015 2017 2019 2020 2021Number of IUDs/s.c. implants YearIntrauterine Gruppen med p -piller og Norwegian women in age groups 10 -49 years who had dispensed at least one hormonal contraceptive in 202 1 according to the following categories: Intrauterine contraceptives (G02BA), vaginal rings (G02BB), progestogens and estrogens, sequential preparations mini pills, and implants (G03AC). Source: Norwegian Prescription D atabase 020000400006000080000100000120000 10 - 19 20 - 29 30 - 39 40 - 49Number of usersIntrauterine contraceptives (IUDs) Intravaginal contraceptives (vaginal combinations Progestogens and estrogens, sequential preparations Progestogens (mini pills, injections and implants) 69 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 41 124 941 40 735 43 838 8.1 8.1 G01A 0.78 519 41 124 40 941 40 735 43 838 8.1 8.1 G01AA Antibiotics 0.06 0.05 0.05 0.03 0.04 23 450 22 820 21 954 16 277 20 436 4.5 3.8 G01AA10 clindamycin (0.1g) 0.06 0.05 0.05 0.03 0.04 23 450 22 820 21 954 16 277 20 436 4.5 3.8 G01AC Quinoline derivatives 0.01 0.02 0.02 0.02 0.02 6 558 7 965 8 153 11 039 11 391 1.3 2.1 G01AC05 dequalinium (20 mg) 0.01 0.02 0.02 0.02 0.02 6 558 7 965 8 153 11 039 11 391 1.3 2.1 G01AD Organic acids - - - - - 10 11 6 7 <5 0.0 - G01AD02 acetic acid - - - - - 10 11 6 7 <5 0.0 - G01AF Imidazole derivatives 0.76 0.77 0.77 17 047 15 814 2.9 2.9 G01AF01 metronidazole (0.5 g) 0.02 0.02 0.02 0.03 0.02 6 303 6 261 6 257 9 038 7 962 1.2 1.5 G01AF02 clotrimazole (0.1 g) 0.69 0.69 0.68 0.70 0.66 7 989 5 936 6 574 7 480 7 455 1.5 1.4 G01AF05 econazole (0.1 g) 0.05 0.06 0.07 0.04 0.03 1 127 1 034 1 122 924 760 0.2 0.00 (90 mg) 0.00 0.00 0.00 0.00 0.00 9 8 17 0.0 0.0 G02 OTHER GYNECOLOGICALS 52 144 55 341 54 026 53 259 54 857 9.9 10.2 G02A UTEROTONICS 0.01 0.01 0.01 0.01 0.01 11 <5 0.0 G02AD Prostaglandins 0.01 0.01 0.01 0.01 0.01 - - - - - - - number of packages 2017 2018 2019 2020 2021 G02B CONTRACEPTIVES FOR TOPICAL USE 49 912 53 117 51 838 51 048 52 550 9.5 9.8 G02BA Intrauterine contraceptives 34 139 38 444 38 191 38 253 40 941 6.5 7.6 G02BA03 plastic IUD with progestogen, numbers of IUD 54 975 60 423 59 914 59 191 64 637 34 139 38 444 38 191 38 253 40 941 6.5 7.6 G02BB Intravaginal contraceptives 16 170 15 083 13 982 13 127 11 943 3.1 2.2 G02BB01 vaginal ring with progestogen and estrogen, given in DDD/day 11 303 10 535 10 283 9 333 8 398 16 170 15 083 13 982 13 127 11 943 3.1 2.2 DDD/1000 inhabitants/day 2017 2 257 2 348 0.4 0.4 G02CB01 bromocriptine (5 mg) 0.05 0.04 0.04 0.03 0.03 654 595 473 367 329 0.1 0.1 G02CB03 cabergoline (0.5 mg) 0.04 0.04 0.05 0.05 0.05 1 503 1 579 1 684 1 788 1 918 0.3 0.4 70 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2021 G02CB04 quinagolide (65 mcg) 0.03 0.02 0.02 0.02 0.02 175 162 151 145 131 0.0 0.0 DDD/day 2017 2018 2019 2020 2021 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 594 870 594 131 602 681 600 553 600 351 113.1 111.4 G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 351 197 345 927 347 090 346 708 336 357 66.8 62.4 G03AA Progestogens and estrogens, fixed combinations 196 432 188 200 189 457 183 429 83 655 230 419 222 612 219 882 219 818 28 788 039 24 840 22 068 6.1 4.1 G03AA11 norgestimate and ethinylestradiol 20 0 0 0 0 and ethinylestradiol 34822 33762 33332 7 630 351 7 564 7 430 1.5 1.4 G03AA14 nomegestrol and estradiol 794 837 429 274 1 068 1 080 1 025 5 373 0.2 0.1 G03AA16 dienogest and ethinylestradiol 54 226 436 0 977 0.0 0.2 G03AB Progestogens estrogens, sequential preparations 7 737 6 829 6 373 4 107 2 399 9 293 8 116 7 635 6 842 2 902 1.8 0.5 G03AB04 norethisterone and ethinylestradiol 6 576 5 742 5 231 2 640 2 110 7 727 6 684 6 057 5 005 1 693 1.5 0.3 G03AB08 dienogest and estradiol 1 160 1 087 1 142 1 467 289 1 577 1 441 1 590 2 232 1 404 0.3 0.3 G03AC Progestogens 128 200 132 116 134 849 138 200 141 125 24.6 26.3 G03AC01 norethisterone (oral) 2 990 2 740 2 470 2 340 2 286 4 625 4 256 3 823 3 673 3 657 0.9 0.7 G03AC06 medroxyprogesterone (parenteral) 12 830 12 190 11 540 11 200 9 603 17 296 16 340 15 329 14 679 12 807 3.3 2.4 G03AC08 etonogestrel (number of s.c. implants) 23 030 25 510 29 820 30 191 30 200 19 677 23 778 27 216 27 999 28 363 3.8 5.3 G03AC09 desogestrel (oral) 59 250 60 880 62 010 64 730 68 174 90 935 92 421 92 913 95 886 101 888 17.4 19.0 G03AC10 drospirenone 151 0 0 0 0 498 0.0 0.1 G03AD Emergency contraceptives 340 330 310 311 319 141 115 102 101 71 0.0 0.0 G03AD01 levonorgestrel (1.5 mg) 90 110 100 130 149 56 56 45 52 29 0.0 0.0 G03AD02 ulipristal (30 mg) 250 220 210 181 170 85 60 58 50 43 0.0 0.0 G03B ANDROGENS 9 170 8 740 9 010 9 470 9 660 15 427 15 997 16 387 17 830 18 484 2.9 3.4 G03BA 3-oxoandrosten (4) derivatives 9 160 8 740 9 000 9 460 9 654 15422 15997 16386 17828 P/ 60 mg SL/50 mg TD gel/ 3 mg TD) 9 160 8 740 9 000 9 460 9 654 15 422 15 997 16 386 17 828 18 482 2.9 3.4 G03BB 5-androstanon (3) derivatives 10 0 10 10 6 9 6 7 9 11 0.0 0.0 G03BB01 mesterolone (50 mg) 10 0 10 10 6 9 6 7 9 11 0.0 0.0 71 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 G03C ESTROGENS 47 960 48 780 51 760 56 730 58 685 150 015 156 073 163 866 168 971 177 801 28.5 33.0 G03CA Natural and semisynthetic estrogens, plain 42 990 44 100 47 190 52 410 54 455 143 976 150 343 158 505 163 695 172 724 27.4 32.0 G03CA01 ethinylestradiol (0.025 mg) 40 30 30 20 15 17 12 9 8 6 0.0 0.0 G03CA03 estradiol (50 mcg TD/1 mg mg O/25 mcg V/ 7.5 mcg vaginal ring) 26 060 27 950 31 490 37 180 39 790 136 672 142 826 149 693 154 332 162 909 26.0 30.2 G03CA04 estriol (2 mg O/0.2 mg V) 16 890 16 120 15 670 15 210 14 650 8 853 9 411 11 176 12 043 12 789 1.7 2.4 G03CA57 conjugated estrogens (0.625 mg) 0 0 0 0 0 <5 <5 <5 0 0.0 0.0 G03CX Other estrogens 4 970 4 680 4 570 4 320 4 230 6 897 6 528 6 137 6 067 5 848 1.3 1.1 G03CX01 tibolone (2.5 mg) 4 970 4 680 4 570 4 320 4 230 6 897 6 528 6 137 6 067 5 848 1.3 1.1 G03D PROGESTOGENS 8 220 8 860 10 170 9 740 11 810 39 183 39 586 39 083 29 926 33 061 7.5 6.1 G03DA Pregnen (4) derivatives 5 380 6 070 7 430 8 250 10 180 16 568 17 737 18 184 20 215 22 856 3.2 4.2 G03DA02 medroxyprogesterone (5 mg O/7 mg P) 2 310 2 700 3 820 3 990 4 140 6 869 7 303 7 041 8 255 8 913 1.3 1.7 G03DA04 progesterone (30 mg O/5 mg P/90 mg V) 3 070 3 370 3 610 4 260 6 040 9 934 10 675 11 399 12 268 14 339 1.9 2.7 G03DB Pregnadien derivatives 130 180 220 330 420 241 388 561 843 1 093 0.1 0.2 G03DB01 dydrogesterone (10 mg) 30 90 130 210 280 64 221 379 626 845 0.0 0.2 G03DB08 dienogest (2 mg) 100 90 90 120 140 177 167 182 217 249 0.0 0.1 G03DC Estren derivatives 2 710 2 610 2 520 1 160 1 210 23274 22376 21400 9803 10193 4.4 1.9 G03DC02 norethisterone (5 mg) 2 710 2 610 2 520 1 160 1 210 23274 21400 9803 10193 4.4 1.9 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 29 650 30 770 31 610 33 280 34 000 41514 42210 43995 46098 47299 7.9 8.8 G03FA Progestogens and estrogens, fixed combinations 22 740 23 560 24 180 25 520 25 930 32 749 33 086 34 509 36 093 37 349 6.2 6.9 G03FA01 norethisterone and estrogen 21 970 22 760 23 490 24 530 24 690 31 823 32 146 33 772 35 122 35 784 6.1 6.6 G03FA12 medroxyprogesterone and estrogen 770 800 670 590 500 1 027 1 053 1 035 733 837 0.2 0.2 G03FA14 dydrogesterone and estrogen 20 400 740 0 0 64 710 1 121 0.0 0.2 G03FB Progestogens and estrogens, sequential preparations 6 910 7 210 7 430 7 760 8 070 9 801 10 129 10 571 11 155 11 373 1.9 2.1 G03FB05 norethisterone and estrogen 6 910 7 210 7 420 7 560 7 710 9 801 10 129 10 547 10 837 10 833 1.9 2.0 G03FB08 dydrogesterone and estrogen 10 200 360 0 0 31 380 609 0.0 0.1 72 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 AND OTHER OVULATION STIMULANTS 2 029 1 537 1 367 1 272 1 407 9 047 8 573 8 165 7 994 8 772 1.7 1.6 G03GA Gonadotropins 1 249 1 007 987 922 1 027 7 587 7 743 7 636 7 517 8 342 1.4 1.6 G03GA01 chorionic gonadotrophin (250 U) 390 110 60 70 60 736 91 46 42 64 0.1 0.0 G03GA02 human menopausal gonadotrophin (75 U) 330 320 350 300 2849 2782 2796 2503 2610 0.5 0.5 G03GA04 urofollitropin (75 U) 0 20 30 30 50 <5 225 357 353 495 - 0.1 G03GA05 follitropin alfa (75 U) 380 420 460 450 500 3 532 4 000 4 197 4 018 4 601 0.7 0.9 G03GA06 follitropin beta (75 U) 110 80 20 2 0 1 324 851 226 41 0 0.3 0.0 G03GA08 choriogonadotropin alfa (0.25 mg) 29 36 38 37 40 6 467 7 067 7 022 6 884 7 655 1.2 1.4 G03GA09 corifollitropin alfa (0.15 mg) 2 2 1 0 0 486 469 192 103 85 0.1 0.0 G03GA10 follitropin delta (12 mcg) 3 7 9 10 10 98 220 274 290 212 0.0 0.0 G03GA30 combinations 5 12 19 23 27 96 215 294 326 403 0.0 0.1 G03GB Ovulation stimulants, synthetic 780 530 380 350 380 1 935 1 031 707 651 575 0.4 0.1 G03GB02 clomifene (9 mg) 780 530 380 350 380 1 935 1 031 707 651 575 0.4 0.1 G03H ANTIANDROGENS 11 050 10 560 10 630 10 140 8 840 14 553 13 982 13 806 13 336 12 163 2.8 2.3 G03HA Antiandrogens, plain 80 90 110 130 130 255 312 364 482 580 0.1 0.1 G03HA01 cyproterone (0.1 g) 80 90 110 130 130 255 312 364 482 580 0.1 0.1 G03HB Antiandrogens and estrogens 10 970 10 470 10 010 8 14301 estrogen 10 970 10 470 10 010 8 710 14301 13672 13446 12855 11584 2.7 2.2 G03X AND MODULATORS OF THE GENITAL SYSTEM 816 468 578 505 550 2 062 1 155 1 608 1 921 1 970 0.4 0.4 G03XA Antigonadotropins and similar agents 10 10 10 10 10 46 44 39 37 35 0.0 0.0 G03XA01 danazol (0.6 g) 10 10 10 10 10 46 44 39 37 35 0.0 0.0 G03XB Progesterone receptor modulators 596 268 298 55 50 1 766 894 844 318 36 0.3 0.0 G03XB01 mifepristone (0.2 g) 36 38 38 40 <5 <5 <5 - - G03XB02 ulipristal (5 mg) 560 230 260 15 10 1 765 893 843 317 35 0.3 0.0 G03XC Selective estrogen receptor modulators 210 190 180 150 140 250 217 194 176 156 0.1 0.0 G03XC01 raloxifene (60 mg) 210 190 180 150 140 250 217 194 176 156 0.1 0.0 G03XX Other sex hormones and modulators of the genital system 90 290 350 0 0 533 1 391 1 743 0.0 0.3 G03XX01 prasterone (6.5 mg) 90 290 350 0 0 533 1 391 1 743 0.0 0.3 73 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 202 2017 6 7 0.0 0.0 0.22 0.24 2839 3499 0.3 G04BD11 7619 2021 G04BE Drugs used in erectile dysfunction 15 577 17 682 19 917 2615 2864 0.5 G04BE03 sildenafil 7 264 8 071 8 518 11 51730 10.2 6635 5266 5116 1.6 1.0 G04BE10 avanafil 98 107 121 286 1224 1606 1574 1775 0.1 0.3 G04BE30 fentolamin, combinations 31 41 42 636 727 796 1084 1165 0.1 0.2 G04BX Other urologicals 66 74 73 82 84 378 491 451 447 528 0.1 0.1 G04BX01 magnesium hydroxide (0.5 g) 18 17 15 14 16 17 20 19 20 17 0.0 0.0 G04BX14 dapoxetine (30 mg) 6 9 8 7 10 294 394 347 323 396 0.1 0.1 G04BX15 pentosan polysulfate sodium (0.3 g) 38 44 46 57 56 61 72 75 83 98 0.0 0.0 G04BX16 tiopronin (0.8 g) 4 4 4 4 2 5 5 <5 5 <5 0.0 - DDD/1000 inhabitants/day 2017 2018 21 21 0.0 0.0 G04CA02 tamsulosin (0.4 mg) 0.05 0.06 0.05 421 395 350 294 274 0.1 0.1 G04CA52 tamsulosin and 0.17 0.08 686 705 562 henholdsvis 39 % og 56 % av all DDD i gruppe H. Reseptregisteret viser at i 2021 fikk rundt 9 % ett legemiddel \u00abfalsk 75 Figure 4.7.1 Proportion of the population (prevalence ) who had dispensed at least one glucocorticosteroid (H02AB) according to age groups 20 17-2021. tid, salget er n\u00e6r doblet fra 2000 til 20 . 020406080100120 0 - 9 years 10 - 19 years 20 - 39 years 40 - 69 years 70 years and abovePropotion () of the popul\u00f8ation age groups2017 2018 2019 2020 2021 76 Figure. 4.7.2. Proportion of the population (prevalence ) who had dispensed a thyroid preparation (H03AA) according to age groups in selected years. Source: Norwegian Prescription Database 020406080100120140 Women Men Women Men Women Men 0 - 29 years 30 - 59 years 60 years and aboveProprtion () of the population2009 2013 2017 2021 77 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES INSULINS H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 1.92 1.86 1.90 1.76 1.79 27 881 27 530 26 181 25 468 27 417 5.3 5.1 H01A ANTERIOR ANALOGUES 0.52 0.52 0.53 0.49 0.48 2 133 2 178 2 203 2 242 2 246 0.4 087 2 133 2 148 2 189 2 184 0.4 0.4 H01AC01 somatropin (2 U) 0.51 0.51 0.52 0.48 0.46 2 083 2 130 2 148 2 189 2 184 0.4 0.4 H01AC03 mecasermin (2 Other anterior pituitary lobe hormones and analogues 0.01 0.01 0.01 0.01 0.01 42 41 50 50 61 0.0 0.0 H01AX01 pegvisomant (10 mg) 0.01 0.01 0.01 0.01 0.01 42 41 50 50 61 0.0 0.0 H01B POSTERIOR PITUITARY LOBE HORMONES 1.07 1.01 1.05 0.95 0.98 19 303 18 603 17 326 16 856 11 998 10 971 10 984 2.3 2.0 U) 0.00 0.00 0.00 0.18 0.16 0.19 7 320 6 607 5 302 5 889 6 996 1.4 1.3 H01BB02 oxytocin (15 U) 0.22 0.16 0.18 0.16 0.19 7 320 6 607 5 302 5 889 6 996 1.4 1.3 H01C HYPOTHALAMIC HORMONES 0.33 0.33 0.32 0.32 0.33 6 745 7 042 6 954 6 671 7 517 1.3 1.4 H01CA Gonadotropin -releasing 0.10 0.10 0.08 0.06 0.07 2 632 2 483 2 184 1 652 1 725 0.5 0.3 H01CB Somatostatin and analogues 0.21 0.21 0.22 0.23 0.24 944 987 997 1 119 1 147 0.2 0.2 H01CB02 octreotide (0.7 mg) 0.13 0.12 0.11 0.12 0.13 617 607 576 665 709 0.1 0.1 H01CB03 lanreotide (3 mg) 0.08 0.09 0.10 0.11 0.10 351 397 445 464 450 H01CB05 pasireotide (1.2 mg) 0.00 0.00 0.00 0.00 0.00 13 17 20 0.0 0.0 H01CC Anti -gonadotropin - releasing hormones 0.02 0.02 0.02 0.02 0.02 3 650 4 053 4 233 4 309 5 052 0.7 0.9 H01CC01 ganirelix (0.25 mg) 0.02 0.02 0.02 0.02 0.02 3 071 3 495 3 844 4 073 4 810 0.6 0.9 H01CC02 cetrorelix (0.25 mg) FOR SYSTEMIC USE 19.86 19.76 19.87 18.65 18.86 240 227 242 831 227 795 234 907 45.7 43.6 H02A FOR SYSTEMIC USE, PLAIN 19.86 19.76 19.87 18.65 18.86 240 195 242 827 256 114 227 612 1 632 1 665 0.3 0.3 H02AA02 fludrocortisone (0.1 mg) 0.42 0.42 0.42 0.44 0.42 1 546 1 563 1 0.3 0.3 H02AB Glucocorticoids 19.44 19.35 19.45 18.21 18.44 239 986 242 887 227 587 234 719 45.6 43.5 H02AB01 betamethasone (1.5 mg O,P/0.4 mg P (depot)) 1.23 1.20 1.17 1.07 1.09 3 476 3 984 4 301 3 008 4 101 0.7 0.8 78 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2.69 3.40 10 446 11 688 13 801 14 724 16 029 2.0 3.0 H02AB04 methylprednisolone (7.5 mg O/20 mg P) 1.06 0.93 0.81 0.77 0.65 7 919 6 941 6 095 5 043 4 433 1.5 0.8 H02AB06 prednisolone (10 13.26 13.19 13.17 11.97 12.11 187 348 183 226 35.6 34.0 H02AB07 prednisone (10 mg) 0.02 0.01 0.01 0.01 0.01 268 114 69 133 48 0.1 0.0 H02AB08 triamcinolone (7.5 mg) 0.45 0.43 0.45 0.41 0.41 34 710 32 421 35 504 29 624 29 767 6.6 5.5 H02AB09 hydrocortisone (30 mg) 0.24 0.25 0.26 0.25 0.24 948 989 1 090 1 148 1 211 0.2 0.2 H02AB10 cortisone (37.5 mg) 0.49 0.49 0.52 0.53 0.52 3 254 3 351 3 418 3 522 3 629 0.6 0.7 H02AB13 deflazacort (15 mg) 0.01 0.01 0.01 0.01 0.01 55 59 64 66 72 0.0 0.0 H02B CORTICOSTEROIDS FOR SYSTEMIC 0.00 0.00 0.00 0.00 (0.6 g) 0.00 0.00 0.00 0.00 0.00 8 13 H03 THYROID THERAPY 26.12 27.55 27.68 27.44 27.18 216 620 209 382 212 354 221 225 029 39.8 41.7 H03AA02 liothyronine sodium (0.06 mg) 0.40 0.41 0.56 0.50 0.53 8 412 9 883 10 348 10 764 11 228 1.6 2.1 H03AA05 thyroid gland preparations (0.1 g) 0.73 0.91 0.93 0.78 0.56 4 144 4 885 5 081 4 874 4 561 0.82 0.85 7 525 8 175 8 617 9 079 9 550 1.4 1.8 H03BA Thiouracils 0.10 0.11 0.12 0.11 0.10 559 552 570 601 558 0.1 0.1 H03BA02 propylthiouracil (0.1 g) 0.10 0.11 0.12 0.11 0.10 559 552 570 601 558 0.1 0.1 H03BB Sulfur -containing imidazole derivatives 0.63 0.70 0.73 0.77 0.76 7 157 7 814 8 246 8 687 9 197 1.4 1.7 H03BB01 carbimazole (15 mg) 0.63 0.70 0.73 0.77 0.76 7 157 7 814 8 246 8 687 9 197 1.4 1.7 H04 PANCREATIC HORMONES 0.01 0.01 0.02 0.01 0.02 5 427 5 353 5 693 4 945 5 745 1.0 1.1 H04A GLYCOGENOLYTIC HORMONES 0.01 0.01 0.02 0.01 0.02 5 427 5 353 5 693 4 945 5 745 1.0 1.1 H04AA Glycogenolytic hormones 0.01 0.01 0.02 0.01 0.02 5 427 5 353 5 693 4 945 5 745 1.0 1.1 H04AA01 glucagon (1 mg) 0.01 0.01 0.02 0.01 0.02 5 427 5 353 5 693 4 945 5 745 1.0 1.1 H05 CALCIUM HOMEOSTASIS 0.25 0.25 0.26 0.28 0.32 2 096 2 139 2 239 2 351 2 687 0.4 0.5 H05A PARATHYROID HORMONES AND ANALOGUES 0.14 0.14 0.14 0.14 0.17 1 151 1 133 1 179 1 201 1 421 0.2 0.3 0,14 0,17 1 421 0,2 0,3 H05AA02 teriparatide (20 mcg) 0.14 0.14 0.13 0.14 0.17 1 151 1 123 1 149 1 170 1 387 0.2 0.3 H05AA03 0.00 0.00 <5 22 31 32 36 - 0.0 79 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2021 H05B ANTI -PARATHYROID AGENTS 0.11 0.12 0.12 0.14 0.15 945 1 006 1 060 1 150 1 267 0.2 0.2 H05BA Calcitonin Other anti -parathyroid 0.12 0.14 1001 0.2 H05BX02 paricalcitol (2 mcg) 0.03 0.03 0.03 0.03 0.03 333 336 361 350 317 0.1 0.1 80 4.8 J Antiinfektiva bruk virussykdommer. B J utgj\u00f8r 7 .3 % av de totale med henholdsvis 5 .2 og 8. 9 % m\u00e5lt i doser (DDD). For an tivirale midler bruk Fra til utgangen av var salget redusert med 25. 8 % Figure 4.8.1 Sales of antibacterials for systemic use (J01) in 2001 -2021 The total of J01 includes shown specifically the figure. Source: Norwegian Drug Wholesales Statistics Reseptregisteret viser at mer enn 20 % av norske kvinner og 13 % handlingsplanen mot antibiotikaresistens i helsetjenesten 2. Fenoksymetylpenicillin sto for 22 % av antibiotikareseptene og i underkant og pivmecillinam var de tre mest solgte midlene m\u00e5lt i DDD 52 fra 2019 2020, men har \u00f8kt med 17 % i 2021. I aldersgruppen 5 ser akne 0510152025 2002 2004 forekomst av resistens i Norge (NORM/NORMvet- rapporten)3). Figure 4.8.2 Proportion of users (prevalence) of antibacterials for systemic use (ATC group J01, excl. methenamine) from 2019 to 2021 by age and gender. Source: Norwegian Prescription Database Antivirale midler til systemisk bruken m\u00e5lt i redusert med 75 % og m\u00e5lt i antall brukere med 7 0 % 2021 i Den nasjonale utbredt av 50 % 2018 til 2019, mens \u00f8kningen bare har v\u00e6rt p\u00e5 1 -2 % de siste to \u00e5rene. En rapport om bruk av antivirale resistens NORM and NORM -VET: Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance Antivirals and the Occurrence of Antiviral Resistance in Norway 2020, Folkehelseinstituttet : https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2021/ravn -rapport -2021.pdf 84 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 J ANTIINFECTIVES USE USE 16.58 15.34 15.16 1 063 315 1 026 347 1 046 173 891 945 899 988 202.2 166.9 J01A TETRACYCLINES 3.01 2.86 2.96 2.65 2.68 159 385 152 178 158 962 127 057 125 813 30.3 23.3 J01AA Tetracyclines 3.01 2.86 2.96 2.65 2.68 159 385 152 178 158 962 127 057 125 813 30.3 23.3 J01AA02 doxycycline (0.1 g) 1.69 1.61 1.67 1.38 1.30 122 266 115 437 121 112 89 307 86 401 23.3 16.0 J01AA04 lymecycline (0.6 g) 0.95 0.93 0.98 1.08 1.11 24 396 24 801 26 525 29 660 31 210 4.6 5.8 J01AA06 oxytetracycline (1 g) 0.00 0.00 0.00 0.00 26 J01AA07 tetracycline (1 g) 0.36 0.32 0.31 0.19 0.27 15 267 14 240 13 852 11 001 10 737 2.9 2.0 J01AA08 minocycline (0.2 g) 0.00 0.00 0.00 0.00 0.00 0.0 J01C BETA -LACTAM ANTIBACTERIALS, PENICILLINS 6.99 6.87 7.12 6.05 5.98 730 187 713 977 735 182 624 024 642 437 138.9 119.2 J01CA Penicillins with extended spectrum 2.47 2.46 2.53 2.22 2.19 298 397 299 136 303 783 265 361 267 399 56.8 49.6 J01CA01 ampicillin (6 g) 0.04 0.05 0.05 0.05 0.03 54 66 55 54 68 0.0 0.0 J01CA04 amoxicillin (1.5 g) 0.87 0.84 0.89 0.65 0.67 119 990 117 652 118 029 81 768 85 238 22.8 15.8 J01CA08 pivmecillinam (0.6 g) 1.56 1.57 1.58 1.52 1.49 190 781 194 102 199 160 194 072 192 717 36.3 J01CA11 mecillinam (1.2 g) 8 -lactamase sensitive penicillins 3.61 3.43 2.77 2.70 394 483 373 327 028 296 199 310 443 75.0 57.6 J01CE01 benzylpenicillin (3.6 g) 0.23 0.24 0.23 0.23 0.14 166 209 214 221 175 0.0 0.0 J01CE02 phenoxymethylpenicillin (2 g) 3.38 3.18 3.33 2.53 2.56 394 344 373 170 387 854 295 977 310 271 resistant penicillins 0.84 0.90 0.93 0.95 0.95 103 589 105 681 109 543 111 626 114 412 19.7 21.2 J01CF01 dicloxacillin (2 g) 0.70 0.74 0.76 0.78 0.79 103 272 105 557 109 423 111 476 114 243 19.6 21.2 J01CF02 cloxacillin (2 g) 0.13 0.16 0.17 0.16 0.16 379 105 123 164 203 0.1 0.0 J01CF05 flucloxacillin (2 g) 0.00 0.00 0.00 0.00 0.00 66 79 82 0.0 J01CR Combinations of penicillins, incl. beta - lactamase inhibitors 0.07 0.08 0.10 0.11 0.13 1 652 2 829 4 595 6 041 8 541 0.3 1.6 J01CR02 amoxicillin and beta - lactamase inhibitor (1.5 g) 0.02 0.03 0.04 0.05 0.07 1 588 2 762 4 519 5 972 8 472 0.3 1.6 J01CR05 piperacillin and beta - lactamase inhibitor (14 g) 0.05 0.05 0.05 0.06 0.06 66 70 83 78 79 0.0 0.0 J01D OTHER BETA -LACTAM ANTIBACTERIALS 0.38 0.39 0.37 0.37 0.34 13 449 12 545 12 151 11 048 10 766 2.6 2.0 J01DB First -generation cephalosporins 0.17 0.18 0.17 0.16 0.17 12 546 11 728 11 322 10 272 10 098 2.4 1.9 J01DB01 cefalexin (2 g) 0.09 0.09 0.07 0.07 0.06 12 529 11 708 11 311 10 252 10 080 2.4 1.9 J01DB03 cefalotin (4 g) 0.08 0.07 0.00 0.02 0.02 17 22 7 14 11 0.0 0.0 J01DB04 cefazolin (3 g) 0.01 0.03 0.09 0.08 0.09 0 0 5 8 7 0.0 0.0 J01DC Second -generation cephalosporins 0.03 0.03 0.03 0.02 0.01 72 75 68 69 42 0.0 0.0 J01DC02 cefuroxime (0.5 g O/3 g P) 0.03 0.03 0.03 0.02 0.01 72 75 68 69 42 0.0 0.0 85 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 J01DD Third -generation cephalosporins 0.15 0.16 0.15 0.14 0.13 785 717 711 636 543 0.2 0.1 J01DD01 cefotaxime (4 g) 0.12 0.12 0.12 0.11 0.11 305 169 191 167 186 0.1 0.0 J01DD02 ceftazidime (4 g) 0.01 0.01 0.01 0.01 0.00 75 55 34 53 39 0.0 0.0 J01DD04 ceftriaxone (2 g) 0.02 0.02 0.02 0.03 0.02 412 494 484 414 320 0.1 0.1 J01DF Monobactams 0.00 0.00 0.00 0.00 15 9 0.0 0.0 J01DH Carbapenems 0.03 0.03 0.03 0.03 0.03 86 71 67 101 110 0.0 0.0 J01DH02 meropenem (3 g) 0.02 0.02 0.02 0.03 0.02 63 53 49 74 75 0.0 0.0 J01DH03 ertapenem (1 g) 0.00 0.00 0.00 0.00 22 0.93 0.90 0.90 121 434 125 601 131 238 126 390 125 177 23.1 23.2 J01EA Trimethoprim and derivatives 0.35 0.34 0.36 0.33 0.31 68 123 66 834 68 121 64 614 61 467 13.0 11.4 J01EA01 trimethoprim (0.4 g) 0.35 0.34 0.36 0.33 0.31 68 123 66 834 68 121 derivatives 0.49 0.53 0.57 0.57 0.59 58 807 64 637 69 732 67 941 69 446 11.2 12.9 J01EE01 sulfamethoxazole and trimethoprim 0.49 0.53 0.57 0.57 0.59 58 807 64 637 69 732 67 941 69 446 11.2 12.9 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 1.18 1.05 1.04 0.80 0.67 187 736 163 672 158 725 J01FA Macrolides 0.93 0.80 0.80 0.57 0.45 145 999 123 073 118 620 74 487 62 905 27.8 11.7 J01FA01 erythromycin (2 g O/1 g O,P) 0.54 0.44 0.45 0.29 0.17 82 929 67 903 66 917 39 866 26 321 15.8 4.9 J01FA02 spiramycin (3 g) 0.00 0.00 0.00 0.00 0.13 0.11 0.11 0.09 0.10 15 730 13 281 12 498 9 481 10 276 3.0 1.9 J01FA10 azithromycin (0.3 g) 0.26 0.24 0.24 0.19 0.18 49 933 43 855 40 980 25 945 26 897 9.5 5.0 J01FF Lincosamides 0.25 0.25 0.25 0.23 0.22 46 587 44 857 44 181 40 809 40 245 8.9 7.5 J01FF01 clindamycin (1.2 g O/1.8 g P) 0.25 0.25 0.25 0.23 0.22 46 587 44 857 44 181 40 809 40 245 8.9 7.5 J01G AMINOGLYCOSIDE ANTIBACTERIALS 0.09 0.09 0.10 0.10 0.07 222 185 173 190 0.0 0.0 J01GB Other aminoglycosides 0.09 0.09 0.10 0.10 0.07 222 185 198 173 190 0.0 0.0 J01GB01 tobramycin (0.24 g P/0.3 g inhal.sol./ 0.112 g inhal.powder) 0.02 0.01 0.01 0.01 0.01 172 140 158 138 141 0.0 0.0 J01GB03 gentamicin (0.24 g) 0.07 0.08 0.09 0.09 0.06 32 33 29 29 (1 g) 0.00 0.00 0.00 0.00 0.45 0.41 0.36 0.30 0.27 45 649 42 078 37 406 32 425 29 444 8.7 5.5 J01MA Fluoroquinolones 0.45 0.41 0.36 0.30 0.27 45 649 42 078 37 406 32 425 29 444 8.7 5.5 J01MA01 ofloxacin (0.4 g) 0.01 0.01 0.01 0.01 0.01 941 832 849 709 593 0.2 0.1 86 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 g O/0.8 g P) 0.43 0.39 0.33 0.28 0.25 43 221 39 388 34 464 29 819 27 075 8.2 5.0 J01MA12 levofloxacin (0.5 g) 0.00 0.00 0.00 0.00 0.01 60 83 82 78 92 0.0 0.0 J01MA14 moxifloxacin (0.4 g) 0.01 0.01 0.01 0.01 0.01 1 600 1 939 2 154 1 935 1 800 0.3 0.3 J01X OTHER ANTIBACTERIALS 4.47 4.40 3.71 4.18 4.25 66 806 796 64 833 12.7 12.0 J01XA Glycopeptide antibacterials 0.02 0.02 0.02 0.02 0.01 43 43 47 32 30 0.0 0.0 J01XA01 vancomycin (2 g) 0.02 0.02 0.02 0.02 0.01 42 43 47 32 30 0.0 0.0 J01XB Polymyxins 0.01 0.01 0.01 0.01 0.01 111 104 126 144 136 0.0 0.0 J01XB01 colistin (3 MU inhal/9 MU P) 0.01 0.01 0.01 0.01 0.01 111 104 126 144 136 0.0 0.0 J01XC Steroid antibacterials 0.00 0.00 0.00 0.00 0.00 359 32 18 0.1 0.0 J01XD Imidazole derivatives 0.04 0.04 0.04 0.04 0.03 27 31 36 44 27 0.0 0.0 J01XD01 metronidazole (1.5 g) 0.04 0.04 0.04 0.04 0.03 27 31 36 44 27 0.0 0.0 J01XE Nitrofuran derivatives 0.28 0.25 0.24 0.26 0.24 37 003 30 853 31 831 33 834 34 576 7.0 6.4 J01XE01 nitrofurantoin (0.2 g) 0.28 0.25 0.24 0.26 0.24 37 003 30 853 31 831 33 834 34 576 7.0 6.4 J01XX Other antibacterials 4.12 4.09 3.41 3.86 3.95 35 522 36 348 34 000 35 508 35 775 6.8 6.6 J01XX01 fosfomycin (8 g) 0.00 0.00 0.00 0.00 methenamine (hippurat 2 g) 4.11 4.08 3.39 3.85 3.94 35 183 35 980 33 618 35 160 35 379 6.7 6.6 J01XX08 linezolid (1.2 g) 0.01 0.01 0.01 0.01 0.01 314 339 340 301 322 0.1 0.1 J01XX09 0.00 0.00 0.00 25 inhabitants/Year 2017 2018 2019 88.22 90.56 99.61 94.03 41 379 40 484 40 519 39 863 39 004 7.9 7.2 J02A ANTIMYCOTICS FOR SYSTEMIC USE 89.06 88.22 90.56 99.61 94.03 41 379 40 484 40 519 39 863 39 004 7.9 7.2 J02AA Antibiotics 2.44 2.61 2.67 (0.2 75.90 81.87 78.24 41 008 40 091 40 077 39 274 38 392 7.8 7.1 J02AC02 itraconazole (0.2 g) 1.69 1.56 1.91 2.07 1.97 365 348 382 483 530 0.1 0.1 J02AC03 voriconazole (0.4 g) 2.27 2.31 3.10 2.57 1.85 97 96 111 108 80 0.0 0.0 J02AC04 posaconazole (0.3 g) 2.74 2.71 3.19 4.32 4.91 106 111 139 178 189 (0.2 g) 0.08 0.34 0.73 1.83 1.75 <5 16 31 73 65 - 0.0 87 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 systemic use 2.68 2.72 3.06 3.94 3.20 10 20 20 20 18 0.0 0.0 0.66 0.63 <5 anidulafungin (0.1 g) 0.96 1.71 1.99 2.63 2.60 5 11 10 14 0.0 J04 ANTIMYCOBACTERIALS 82.37 76.99 79.01 75.36 67.70 1 998 1 938 1 923 1 914 1 778 0.4 0.3 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 53.41 49.20 47.45 47.50 42.05 1 517 1 471 1 433 1 458 1 312 0.3 0.2 J04AA Aminosalicylic acid and derivatives 0.02 0.03 0.00 0.01 0.01 0 0 0 0 <5 0.0 - J04AA01 4-aminosalicylic acid (12 g) 0.02 0.03 0.00 0.01 0.01 0 0 0 0 <5 0.0 - J04AB Antibiotics 24.49 23.20 22.48 23.37 19.67 1 031 1 044 1 006 1 055 912 0.2 0.2 J04AB01 cycloserine (0.75 g) 0.98 0.49 0.34 0.07 0.35 12 10 8 <5 0.73 0.38 0.51 J04AB05 rifapentine (0.11 g) 6.59 6.20 6.87 7.16 5.50 293 0.1 0.1 J04AC Hydrazides 9.74 8.99 9.20 9.55 7.70 378 377 414 453 367 0.1 0.1 J04AC01 isoniazid (0.3 g) 9.74 8.99 9.20 9.55 7.70 378 377 414 453 367 0.1 0.1 J04AD Thiocarbamide derivatives 0.68 0.35 0.18 0.05 0.02 11 9 6 <5 0 0.0 0.0 J04AD01 protionamide (0.75 g) 0.68 0.35 0.18 0.05 0.02 11 9 6 <5 0 0.0 0.0 J04AK Other drugs for treatment of tuberculosis 5.11 5.03 4.76 4.51 5.38 177 160 152 139 174 0.0 J04AK01 pyrazinamide (1.5 g) 0.93 0.96 0.88 0.84 34 ethambutol (1.2 g) 3.89 3.82 3.68 3.59 3.63 162 145 142 122 158 0 8 - 0.0 J04AM Combinations of drugs for treatment of tuberculosis 13.37 11.60 10.84 10.03 9.93 471 407 398 (2 UD/4 UD) 1.08 0.68 rifampicin, pyrazinamide, ethambutol and isoniazid (4 UD) 1.95 1.71 1.48 1.51 0.72 128 126 97 105 63 0.0 0.0 J04B FOR TREATMENT OF LEPRA 28.96 27.79 31.56 27.85 25.65 485 473 500 464 for treatment of lepra 28.96 27.79 31.56 27.85 485 473 500 0.1 J04BA01 clofazimine (0.1 g) 0.43 0.44 0.40 0.37 1.15 9 6 9 10 22 0.0 J04BA02 dapsone (50 mg) 28.53 27.34 31.16 27.48 24.50 476 467 491 454 459 0.1 0.1 88 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 194 59 798 62 304 63 679 67 420 10.1 ACTING 657.62 59 67 420 10.1 12.5 47 52 803 57 089 8.3 10.6 J05AB01 aciclovir (4 g) 18.27 18.27 18.94 18.43 18.57 13 519 14 000 14 203 14 072 14 477 2.6 2.7 J05AB06 ganciclovir 0.02 0.03 0.03 <5 6 <5 <5 <5 147.44 30 907 33 685 36 653 39 439 43 284 5.9 8.0 J05AB12 cidofovir (25 mg) 0.26 0.11 0.18 0.25 0.13 J05AB14 valganciclovir (0.9 g) 9.78 8.47 9.67 8.16 9.70 439 409 472 384 515 0.1 0.1 J05AB16 remdesivir (0.1 g) 0.40 0.00 J05AD Phosphonic acid derivatives 0.21 0.16 0.24 0.17 0.23 0 0 0 <5 0 0.0 0.0 J05AD01 foscarnet (6.5 g) 0.21 0.16 0.24 0.17 0.23 0 0 0 <5 0 0.0 0.0 J05AE Protease inhibitors 28.20 19.10 13.51 0.0 J05AE01 saquinavir (1.8 g) 0.08 <5 0 0 0 0 J05AE03 g) 1.94 1.29 0.93 0.76 (0.3 g) 20.00 12.92 8.63 6.02 3.67 353 228 149 108 72 0.1 0.0 J05AE10 darunavir (1.2 g) 6.18 4.89 3.95 3.61 3.21 148 124 94 83 82 0.0 0.0 J05AF Nucleoside 0.69 0.48 0.41 0.24 0.11 19 15 18 10 0.0 J05AF05 lamivudine (0.3 g) 2.70 3.41 9.54 5.12 2.45 75 103 208 162 68 0.0 0.0 J05AF06 abacavir (0.6 g) 3.37 2.91 2.36 2.14 1.82 58 45 43 J05AF08 adefovir dipivoxil (10 mg) 0.29 0.14 0.16 <5 <5 tenofovir alafenamide (25 mg) 4.20 6.15 4.35 4.60 4.75 121 130 80 80 82 0.0 0.0 -nucleoside reverse transcriptase inhibitors 11.26 11.73 21.66 375 265 J05AG01 nevirapine (0.4 g) 5.94 5.04 5.53 4.76 3.96 99 89 83 75 65 0.0 0.0 J05AG03 efavirenz (0.6 g) 2.50 2.24 1.97 1.24 1.00 46 38 36 25 22 0.0 0.0 J05AG04 etravirine (0.4 g) 1.22 1.18 1.07 1.21 1.02 24 18 20 19 19 0.0 0.0 J05AG05 rilpivirine (25 mg) 1.60 3.27 13.03 10.54 7.60 31 85 239 188 138 0.0 0.0 J05AG06 doravirine (0.1 g) 0.06 0.44 1.15 0 0 <5 9 23 0.0 0.0 89 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 inhibitors 4.50 8.36 6.61 8.02 0.52 1 923 3 571 2 987 2 214 248 0.4 0.01 J05AH02 oseltamivir (0.15 g) 4.50 8.36 6.61 8.02 0.52 1 923 3 571 2 987 2 214 2 48 0.4 0.0 J05AJ cabotegravir (30 mg O/10 mg P) 0.46 0 0 0 0 11 0.0 0.0 J05AP Antivirals for treatment of HCV infections 36.79 48.52 30.57 19.44 12.74 1 955 3 189 2 248 1 439 981 0.4 0.2 J05AP01 ribavirin (1 g) 6.05 1.25 0.52 0.42 0.10 380 88 36 28 9 0.1 0.0 J05AP05 simeprevir (0.15 g) 0.03 <5 0 0 0 0 - 0.0 J05AP07 daclatasvir (60 mg) 0.54 47 0 0 0 0 0.0 0.0 J05AP08 sofosbuvir (0.4 g) 1.24 0.05 0.06 0.02 101 <5 <5 <5 0 0.0 0.0 J05AP09 dasabuvir (0.5 g) 1.17 0.60 0.03 105 54 5 0 0 0.0 0.0 J05AP51 sofosbuvir and ledipasvir (1 UD) 0.46 1.15 6.99 4.84 1.78 29 98 620 453 162 0.0 0.0 J05AP53 ombitasvir, paritaprevir and ritonavir (2 UD) 1.20 0.61 0.03 107 55 6 0 0 0.0 0.0 J05AP54 elbasvir and grazoprevir (1 UD) 18.13 14.27 3.23 1.23 2.77 1 152 990 257 82 182 0.2 0.0 J05AP55 sofosbuvir and velpatasvir (1 7.96 30.16 18.85 12.18 0.0 J05AP57 glecaprevir and pibrentasvir (3 UD) 0.01 0.42 0.32 0.39 <5 30 27 33 313 - 0.1 J05AR Antivirals for treatment of HIV infections, combinations 287.09 308.15 346.49 359.72 353.37 4 821 5 322 5 921 6 267 6 584 0.9 1.2 J05AR01 zidovudine and lamivudine (2 UD) 3.53 2.39 1.74 1.36 1.06 64 46 30 23 16 0.0 0.0 J05AR02 lamivudine and abacavir (1 UD) 7.35 9.75 25.89 13.48 7.65 131 262 469 298 145 0.0 627 2 130 3 160 3 218 0.3 0.6 J05AR04 zidovudine, lamivudine and abacavir (2 tenofovir disoproxil, elvitegravir and cobicistat (1 UD) 4.27 2.75 1.72 1.37 1.18 104 52 37 25 21 0.0 0.0 J05AR10 lopinavir and ritonavir (0.8 g) 4.18 2.63 2.32 2.16 0.85 89 62 43 46 17 0.0 0.0 90 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 1 200 1 230 941 1 178 1 150 0.2 0.2 J05AR14 0.31 0.82 2.98 dolutegravir and rilpivirine (1 UD) 0.35 4.79 6.52 11 11 0.0 disoproxil and doravirine (1 UD) 0.10 5 69 96 0.0 J05AR25 lamivudine and dolutegravir (1 UD) 1.18 28.05 51.13 0 antivirals 0.42 0.47 0.52 0.3 J05AX05 inosine pranobex (3 g) 0.19 0.17 0.14 0.14 0.17 13 9 5 <5 6 0.0 0.0 J05AX09 maraviroc (0.6 g) 0.23 0.30 0.23 0.34 0.22 6 7 6 5 5 0.0 0.0 J05AX18 letermovir (0.48 g) 0.15 0.34 0.18 0 0 6 10 9 0.0 0.0 91 4.9 L Antineoplastiske og immunmodulerende midler L01 Antineoplastiske (m\u00e5lt flere pasienter kan tilbys og glatiramer acetate (L03AX13) tilgjengelige, legemidlene 30 -60 \u00e5r som behandles. Figure 4.9. Sales o f drugs in ATC -groups L03 and L04 indicated for treatment of multiple and glatiramer acetate ( interferon beta Norwegian Drug Wholesales Statistics 00,20,40,60,811,2 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018 2020DDD/1000 inhabitants/day Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 gram of ingredient/year ATC 2017 2021 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS 9 955 10 466 11 488 13 111 16 882 1.9 3.1 L01A ALKYLATING AGENTS 1 247 1 252 1 326 1 267 1 189 0.2 0.2 L01AA Nitrogen mustard analogues 599 541 622 587 473 0.1 0.1 L01AA01 cyclophosphamide 18 728 17 952 19 088 18 073 17 405 223 227 304 275 219 0.0 0.0 L01AA02 chlorambucil 41 35 35 32 30 84 79 68 64 51 0.0 0.0 L01AA03 melphalan 148 124 150 141 141 175 144 155 155 131 0.0 0.0 L01AA06 ifosfamide 10 943 10 786 11 105 10 104 12 040 - - - - - - - L01AA07 trofosfamide 1 668 1 700 1 348 1 355 1 053 123 98 104 99 83 0.02 0.02 L01AA09 bendamustine 447 484 546 479 568 <5 0 - 0.0 L01AB Alkyl sulfonates <5 7 5 11 9 - 0.0 L01AB01 busulfan 64 79 54 51 33 <5 7 5 11 9 - 0.0 L01AB02 treosulfan 2 577 2 947 4 061 5 776 6 535 - - - - - - - L01AC Ethylene imines - - - - - - - L01AC01 thiotepa 10 12 21 16 21 - - - - - - - L01AD Nitrosoureas 125 117 122 119 149 0.0 0.0 L01AD01 carmustine 50 38 47 40 44 - - - - - - - L01AD02 lomustine 158 129 143 145 178 125 117 122 119 149 0.02 0.03 L01AD04 streptozocin 248 203 144 142 129 - - - - - - - L01AX Other alkylating agents 593 659 645 622 640 0.11 0.12 L01AX03 temozolomide 5 181 5 879 5 575 5 325 5 442 593 659 645 622 640 0.11 0.12 L01AX04 dacarbazine 1 134 1 001 960 847 894 L01B ANTIMETABOLITES 2 525 2 625 3 200 4 344 7 688 0.5 1.4 L01BA Folic acid analogues 25 0 0.0 0.0 L01BA011) methotrexate 8 463 6 399 9 825 7 334 6 283 25 17 <5 <5 0 0.0 0.0 L01BA04 pemetrexed 1 210 1 256 2 566 3 818 4 392 L01BB Purine analogues 500 510 498 442 404 0.1 0.1 L01BB02 mercaptopurine 6 181 6 048 5 931 5 507 5 241 459 473 449 403 379 0.1 0.1 L01BB03 tioguanine 95 106 135 75 32 43 53 56 36 11 0.0 0.0 L01BB04 cladribine 3 3 4 3 2 L01BB05 fludarabine 87 90 110 110 101 38 35 45 38 26 0.0 0.0 L01BB06 clofarabine 0 1 1 0 - - - - - - - L01BC Pyrimidine analogues 2 002 2 098 2 701 3 901 7 285 0.4 1.4 L01BC01 cytarabine 8 455 8 918 8 671 8 888 7 749 5 <5 <5 <5 0 0.0 0.0 L01BC02 fluorouracil 61 987 64 856 69 357 76 328 86 297 98 68 166 742 4 018 0.0 0.8 L01BC05 gemcitabine 14 024 14 189 14 062 14 866 14 768 15 0 0 0 0 0.0 0.0 1) i L04AX03 94 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 gram ATC L01BC06 capecitabine 215 430 209 256 253 557 257 007 240 231 1 215 1 175 1 292 1 303 1 280 0.2 0.2 L01BC07 azacitidine 811 827 969 1 119 <5 <5 33 26 25 19 <5 0 0 0 0 - 0.0 L01BC52 fluorouracil, combinations 20 23 34 52 54 651 784 1 171 1 773 1 894 0.1 0.4 L01BC53 tegafur, combinations 24 36 28 72 116 6 5 5 11 20 0.0 0.0 L01BC59 trifluridine, combinations 78 268 258 339 545 24 74 73 92 135 0.0 0.0 L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS 1 250 1 216 990 903 706 0.2 0.1 L01CA Vinca alkaloids and analogues 792 765 528 347 192 0.2 0.0 L01CA01 vinblastine 22 21 18 17 15 - - - - - - - L01CA02 vincristine 13 12 13 12 13 <5 0 0 0 0 - 0.0 L01CA04 vinorelbine 529 485 399 260 145 789 765 528 347 192 0.2 0.0 L01CA05 vinflunine 61 14 1 13 31 - - - - - - - L01CB Podophyllotoxin derivatives 430 438 444 544 500 0.1 0.1 L01CB01 etoposide 3 627 3 630 3 844 4 123 3 918 430 438 444 544 500 0.1 0.1 L01CB02 teniposide 22 14 3 - - - - - - - L01CD Taxanes 15 <5 <5 <5 <5 0.0 - L01CD01 paclitaxel 4 459 4 121 4 630 4 665 4 888 9 <5 <5 0 <5 0.0 - L01CD02 docetaxel 909 903 1 6 0 <5 <5 <5 0.0 - L01CD04 cabazitaxel 10 34 38 48 44 - - - - - - - L01CE Topoisomerase 1 (TOP1) inhibitors 22 18 19 24 25 0.0 0.0 L01CE01 topotecan 1 1 1 2 3 17 18 19 24 25 0.0 0.0 L01CE02 irinotecan 3 671 3 443 3 574 3 855 3 952 5 0 0 0 0 0.0 0.0 L01CX Other plant alkaloids and natural products - - - - - - - L01CX01 trabectedin 0,3 0,4 0,3 0,3 - - - L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES 16 14 6 0 0 0.0 0.0 L01DA Actinomycines - - - - - - - L01DA01 dactinomycin 0.2 0.3 0.2 0.2 0.3 - - - - - - - L01DB Anthracyclines and related substances 14 <5 0 0 0 0.0 0.0 L01DB01 doxorubicin 564 575 678 672 678 6 <5 0 0 0 0.0 0.0 L01DB02 daunorubicin 52 60 44 52 47 - - - - - - - L01DB03 epirubicin 1 127 1 006 988 1 013 1 022 7 0 0 0 0 0.0 0.0 L01DB06 idarubicin 6 5 5 5 3 <5 <5 0 0 0 - 0.0 L01DB07 mitoxantrone 4 3 3 3 3 - - - - - - - L01DB11 pixantrone 1 1 1 2 - - - - - - - 95 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 gram ATC 2017 2020 2021 L01DC Other cytotoxic 0 <5 0 0 <5 0.0 - L01DC011) bleomycin 47 250 42 450 39 300 32 985 42 165 0 <5 0 0 0 0.0 0.0 L01DC03 mitomycin 53 57 60 63 67 0 <5 0 0 <5 0.0 - DDD/1000 inhabitants/year ATC 2017 2018 2019 2020 2021 L01E PROTEIN KINASE INHIBITORS 2 925 3 227 3 641 3 839 4 264 0.6 0.8 L01EA BCR-ABL tyrosine kinase inhibitors 739 769 29.83 32.13 dasatinib (0.1 g) 3.88 4.49 4.88 5.48 5.53 95 106 123 127 155 0.0 0.0 L01EA03 nilotinib (0.6 g) 5.22 5.39 5.62 4.86 4.38 108 113 108 97 89 0.0 0.0 L01EA04 bosutinib (0.4 g) 0.13 0.42 0.69 1.01 1.13 5 15 19 22 27 0.0 0.0 L01EA05 ponatinib (45 mg) 0.39 0.50 0.61 0.64 0.62 14 16 17 18 22 0.0 L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 205 198 169 164 191 0.0 0.0 L01EB01 gefitinib (0.25 g) 1.38 3.05 3.54 2.53 1.62 36 93 95 64 40 0.0 0.0 L01EB02 erlotinib (0.15 g) 4.09 2.62 1.62 1.12 0.89 138 86 48 40 26 0.0 0.0 L01EB03 afatinib (40 mg) 1.40 0.95 1.11 0.70 0.34 49 38 37 21 14 0.0 0.0 L01EB04 osimertinib (80 mg) 0.02 0.28 0.49 0.61 3.58 <5 6 9 15 115 - 0.0 L01EB07 dacomitinib (45 mg) 0.01 1.03 0.78 0 0 0.0 0.0 L01EC B-Raf serine -threonine kinase (BRAF) inhibitors (1.92 g) 0.41 0.34 0.74 dabrafenib (0.3 g) 4.11 4.03 3.20 3.33 3.76 164 162 126 158 164 0.0 0.0 L01EC03 encorafenib (0.45 g) 0.05 0.78 2.42 0 0 6 48 139 0.0 0.0 L01ED Anaplastic lymphoma kinase (ALK) inhibitors 65 71 81 103 143 0.0 0.0 L01ED01 crizotinib (0.5 g) 1.72 1.44 0.89 1.13 1.01 54 39 24 26 30 0.0 0.0 L01ED02 ceritinib (0.45 g) 0.96 0.63 0.31 0.36 0.25 21 13 8 8 9 0.0 0.0 L01ED03 alectinib (1.2 g) 0.22 0.82 2.38 2.79 3.19 9 32 55 64 76 0.0 0.0 L01ED04 brigatinib (0.18 g) 0.01 0.41 0.74 0 0 <5 13 25 0.0 0.0 L01ED05 lorlatinib (0.1 g) 0.05 1.06 0 0 0 0 28 0.0 0.0 L01EE Mitogen -activated protein kinase (MEK) inhibitors 157 159 154 186 227 0.0 0.0 L01EE01 trametinib (2 mg) 4.23 4.19 3.32 3.45 4.23 155 156 126 150 163 0.0 0.0 L01EE02 cobimetinib (45 mg) 0.17 0.22 0.63 0.62 0.30 10 10 41 34 7 0.0 0.0 L01EE03 binimetinib (90 mg) 0.06 0.87 2.11 0 0 6 43 93 0.0 0.0 1) Salg angitt i TU (tusen enheter) virkestoff/\u00e5r 96 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 L01EF02 ribociclib (0.45 g) 3.19 8.62 7.78 5.00 0 143 317 228 134 0.0 0.0 L01EF03 abemaciclib (0.3 g) 0.34 2.10 0 0 0 16 147 0.0 0.0 L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors 238 210 239 241 237 everolimus (10 mg) 5.78 5.37 6.29 5.68 5.86 239 241 237 0.1 0.0 L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors 18 6 14 10 14 0.0 0.0 L01EH01 lapatinib (1.25 g) 0.36 0.20 0.17 0.13 0.22 18 6 14 10 14 0.0 0.0 L01EJ Janus -associated kinase (JAK) inhibitors 213 262 320 353 390 0.0 0.1 L01EJ01 ruxolitinib (30 mg) 8.90 11.16 12.60 14.18 14.50 213 262 320 353 390 0.0 L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors 43 24 25 78 168 0.0 0.0 L01EK01 axitinib (10 mg) 1.30 0.81 0.72 1.56 4.87 43 24 23 71 164 0.0 0.0 L01EK03 tivozanib (1 mg) 0.03 0.09 0.21 0 0.0 0.0 L01EL Bruton's tyrosine kinase (BTK) inhibitors 153 207 0.1 L01EL01 ibrutinib (0.42 g) 6.36 8.69 10.01 11.07 11.88 153 270 286 0.0 0.1 L01EM Phosphatidylinositol -3- kinase (Pi3K) inhibitors 26 27 23 idelalisib (0.3 g) 0.62 0.88 0.86 0.69 0.49 26 23 21 14 0.0 0.0 L01EX Other protein kinase inhibitors 704 790 947 976 936 0.1 0.2 L01EX01 sunitinib (33 mg) 4.89 7.03 5.86 4.29 3.05 177 253 187 139 101 0.0 0.0 L01EX02 sorafenib (0.8 g) 1.15 1.22 1.68 1.22 0.98 76 74 90 68 46 0.0 0.0 L01EX03 pazopanib (0.8 g) 5.42 3.92 4.92 4.67 2.85 212 159 225 203 140 0.0 0.0 L01EX04 vandetanib (0.3 g) 0.10 0.05 0.02 0.10 <5 <5 5 - g) 1.22 0.92 1.04 1.10 0.82 77 59 68 73 57 0.0 0.0 L01EX07 cabozantinib (60 mg) 1.79 2.83 3.79 3.63 3.54 78 135 172 162 172 0.0 0.0 L01EX08 lenvatinib (18 mg) 0.16 0.45 0.51 1.39 1.99 7 14 25 85 97 (0.38 g) 4.67 6.62 9.47 10.96 276 320 362 0.0 0.1 L01EX10 midostaurin(0.1 g) 0.14 0.12 0.35 0.54 0 <5 5 19 19 0.0 0.0 L01EX13 gilteritinib (0.12 g) 0.07 0 0 0 0 5 0.0 0.0 L01EX14 entrectinib (0.6 g) 0.03 0.07 0 0 0 <5 <5 0.0 - L01EX22 selpercatinib (0.32 g) 0.09 0 0 0 0 <5 0.0 - L01X OTHER ANTINEOPLASTIC AGENTS 2 407 2 585 2 610 2 911 3 260 0.5 0.6 L01XA Platinum compounds 20 19 0 <5 0 0.0 0.0 97 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 gram ATC 2017 2018 2020 2021 L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES 216 115 63 37 20 0.0 0.0 L01FA CD20 (Clusters of Differentiation 20) inhibitors 161 55 11 10 5 0.0 0.0 L01FA01 rituximab 13 552 14 155 13 660 13 655 14 166 161 55 11 10 <5 0.0 0.0 L01FA02 ofatumumab 27 4 - - - - - - - L01FA03 obinutuzumab 53 226 330 337 322 0 0 0 0 <5 - 0.0 L01FB CD22 (Clusters of Differentiation 22) inhibitors - - - - - - - L01FB01 inotuzumab ozogamicin 0.02 0.01 0.01 0.02 - - - - - - - L01FC CD38 (Clusters of Differentiation 38) inhibitors 0 <5 <5 <5 5 0.0 0.0 L01FC01 daratumumab 515 2 533 3 251 5 408 9 792 0 <5 <5 <5 5 0.0 0.0 L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors 21 35 21 14 5 0.0 0.0 L01FD01 trastuzumab 6 794 6 798 6 221 6 135 5 918 21 34 21 14 5 0.0 0.0 L01FD02 pertuzumab 1 055 1 085 1 491 2 873 2 594 <5 <5 0 0 0 - 0.0 L01FD03 trastuzumab emtansine 70 169 165 199 384 - - - - - - - L01FD04 trastuzumab deruxtecan 20 - - - - - - - L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors 5 <5 0 0 0 0,0 0,0 L01FE01 cetuximab 1 223 1 166 993 1 131 1 275 0 <5 0 0 0 0.0 0.0 L01FE02 panitumumab 849 813 880 895 947 5 0 0 0 0 0.0 0.0 L01FF PD-1/PDL -1 (Programmed cell death protein 1/death ligand 1) inhibitors 23 22 27 7 <5 0.0 - L01FF01 nivolumab 1 027 1 663 2 074 3 263 3 112 19 21 23 6 <5 0.0 - L01FF02 pembrolizumab 885 1 017 1 044 <5 <5 <5 <5 - - L01FF03 durvalumab 52 992 1 295 0 0 0 0 <5 0.0 - L01FF04 avelumab 18 26 27 76 - - - - - - - L01FF05 atezolizumab 1 667 3 038 2 946 3 308 - - - - - - - L01FF06 cemiplimab 4 82 L01FG 0.0 - L01FG01 bevacizumab 4 030 3 997 4 227 4 650 5 528 7 <5 <5 <5 <5 0 - L01FG02 ramucirumab 34 12 30 16 3 - - - - - - - L01FX Other monoclonal antibodies and antibody drug <5 <5 - - 112 <5 5 <5 <5 <5 - - 98 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 gram 2020 2021 L01FX05 brentuximab vedotin 23 24 30 29 32 - - - - - - - L01FX07 blinatumomab 0,00 0,00 0,00 0,01 - - - L01FX08 elotuzumab 2 5 - - - - - - - L01FX14 polatuzumab vedotin 28 - - - - - - - L01FX15 belantamab mafodotin 1 - - - - - - - L01X OTHER ANTINEOPLASTIC AGENTS 2 370 2 496 2 849 3 228 3 578 0.5 0.7 L01XA Platinum compounds 19 0 <5 0 0 0.0 0.0 L01XA01 cisplatin 618 600 607 552 599 - - - - - - - L01XA02 carboplatin 6 058 5 979 6 296 6 261 6 428 7 0 0 0 0 0.0 0.0 L01XA03 oxaliplatin 1 899 1 835 1 978 2 151 2 252 12 0 <5 0 0 0.0 0.0 L01XB Methylhydrazines 126 94 102 109 128 0.0 0.0 L01XB01 procarbazine 680 503 680 683 735 126 94 102 109 128 0.0 0.0 L01XD Sensitizers used in photodynamic/radiation therapy <5 47 193 176 154 - 0.0 L01XD03 methyl aminolevulinate 1 259 1 026 1 140 1 358 1 672 <5 37 141 175 151 - 0.0 L01XD04 aminolevulinic acid 289 490 453 430 385 0 11 53 <5 <5 - 0.0 L01XF Retinoids for cancer treatment 43 31 32 28 20 0.0 0.0 L01XF01 tretinoin 178 114 133 157 25 32 22 24 19 14 0.0 0.0 L01XF03 bexarotene 1 035 998 720 885 683 11 9 8 9 6 0.0 0.0 L01XG Proteasome inhibitors 36 38 34 84 79 0.0 0.0 L01XG01 bortezomib 34 38 45 51 52 33 35 32 44 42 0.0 0.0 L01XG02 carfilzomib 105 314 334 420 387 <5 0 0 0 0 - 0.0 L01XG03 ixazomib 0.0 0.2 0.2 1.5 1.7 <5 37 - 0.0 L01XH Histone deacetylase (HDAC) inhibitors 26 12 12 13 12 0.0 0.0 L01XH03 panobinostat 10 4 4 6 3 26 12 12 13 12 0.0 0.0 L01XJ Hedgehog pathway inhibitors 22 21 25 21 29 0.0 0.0 L01XJ01 vismodegib 340 307 361 491 559 22 21 25 21 29 0.0 0.0 L01XJ02 sonidegib 18 0 0 0 0 <5 - - L01XK Poly (ADP -ribose) polymerase (PARP) inhibitors 53 62 69 241 358 0.0 0.1 L01XK01 olaparib 7 750 8 893 8 372 21 409 34 432 53 62 69 196 273 0.0 0.1 L01XK02 niraparib 1 000 3 203 0 0 0 47 85 0.0 0.0 L01XK04 talazoparib 0.4 0 0 0 0 6 0.0 Other antineoplastic L01XX01 amsacrine 61 37 28 46 21 - - - - - - - L01XX02 asparaginase 2 850 3 640 2 380 940 3 460 - - - - - - - L01XX05 hydroxycarbamide 475 390 512 300 550 520 581 770 611 40 0 1866 2009 2163 2254 2391 0.4 0.4 99 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 L01XX23 mitotane 7 300 4 750 5 800 6 550 6 350 14 13 15 13 13 0.0 0.0 L01XX24 pegaspargase 1 695 1 216 390 258 272 - - - - - - - L01XX27 arsenic trioxide 8 3 6 13 9 - - - - - - - L01XX35 anagrelide 104 103 108 113 118 218 215 224 242 258 0.0 0.1 L01XX41 eribulin 2 1 1 1 2 - - - - - - - L01XX52 venetoclax 1 605 2 094 6 782 11 087 0 9 45 120 221 0.0 0.0 L01XY Combinations of antineoplastic agents - - - - - - - L01XY02 pertuzumab and trastuzumab 30 - - - - - - - DDD/1000 inhabitants/year 2017 2018 2019 2020 2021 L02 ENDOCRINE THERAPY 2 298 2 247 2 315 2 255 31639 32537 33413 34285 35580 6.0 6.6 L02A HORMONES 554 548 10832 11026 11251 11897 2.0 2.2 L02AB Progestogens 6 7 5 7 7 130 162 144 150 151 0.0 0.0 L02AB01 megestrol (0.16 g) 6 7 5 7 7 130 162 144 150 151 0.0 0.0 L02AE Gonadotropin releasing hormone 2.2 L02AE01 buserelin (1.2 mg) 2 1 1 0 335 252 127 34 0 0.1 0.0 L02AE02 leuprorelin (0.134 mg depot inj./ 0.06 mg depot inj./0.1 mg P) 1 1 1 1 4 479 573 670 890 1415 0.1 0.3 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 1 744 1 702 1 804 1 767 5.4 L02BA Anti -estrogens 333 337 347 365 337 5 439 5 544 5 675 5 745 5 791 1.0 1.1 L02BA01 tamoxifen (20 mg) 288 287 301 318 286 4 963 5 062 5 214 5 295 5 279 0.9 1.0 L02BA03 fulvestrant (8.3 mg) 45 50 46 47 51 522 521 487 485 549 0.1 0.1 L02BB Anti -androgens 737 681 721 651 624 7 007 7 020 6 884 6 818 6 807 1.3 1.3 L02BB01 flutamide (0.75 g) 4 3 2 1 1 82 64 55 46 31 0.0 0.0 L02BB03 bicalutamide (50 mg) 694 634 672 599 567 6 041 5 945 5 762 5 605 5 437 1.2 1.0 L02BB04 enzalutamide (0.16 g) 39 44 47 51 56 1 093 1 188 1 219 1 296 1 333 0.2 0.3 L02BB05 apalutamide 4 0 0 0 16 135 0.0 0.0 L02BB06 darolutamide 4 0 0 0 <5 38 0.0 0.0 L02BG Aromatase inhibitors 614 630 685 701 693 12 995 13 880 14 668 15 462 16 391 2.5 3.0 L02BG03 anastrozole (1 mg) 41 34 35 28 26 757 652 574 527 497 0.1 0.1 L02BG04 letrozole (2.5 mg) 521 542 593 613 603 11 537 12 524 13 348 14 136 15 007 2.2 2.8 L02BG06 exemestane (25 mg) 52 54 57 60 64 974 1 041 1 078 1 206 1 264 0.2 0.2 L02BX Other hormone antagonists and related agents 60 54 51 50 52 1 273 1 180 1 147 1 125 1 166 0.2 0.2 L02BX02 degarelix (2.7 mg) 44 40 38 39 40 837 786 778 827 853 0.2 0.2 L02BX03 abiraterone (1 g) 16 14 13 11 12 473 430 398 319 345 0.1 0.1 100 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 L03 IMMUNOSTIMULANTS 177 168 164 174 168 6 431 6 432 6 510 7 080 7 241 1.2 1.3 L03A IMMUNOSTIMULANTS 177 168 164 174 168 6 431 6 432 6 510 7 080 7 241 1.2 1.3 L03AA Colony stimulating factors 4 775 4 932 5 169 5 769 6 015 0.9 1.1 L03AA02 filgrastim (0.35 mg) 4 4 4 4 4 588 594 671 633 673 0.1 0.1 L03AA13 pegfilgrastim (0.3 mg) 61 23 47 83 85 3 947 1 811 3 208 5 206 5 489 0.8 1.0 L03AA14 lipegfilgrastim (0.3 mg) 5 45 24 1 0 370 3 086 1 997 111 <5 0.1 - L03AB Interferons 952 763 668 676 665 0.2 0.1 L03AB03 interferon gamma (40 mcg) 1 1 1 1 1 10 9 8 9 14 0.0 0.0 L03AB04 interferon alfa -2a (2 MU) 1 0 21 0 0 0 0 0.0 0.0 L03AB05 interferon alfa -2b (2 MU) 1 1 1 1 0 40 27 22 12 8 0.0 0.0 L03AB07 interferon beta -1a (4.3 mcg) 44 37 33 28 25 372 323 273 233 199 0.1 0.0 L03AB08 interferon beta -1b (4 MU) 9 6 5 4 4 134 95 65 57 47 0.0 0.0 L03AB10 peginterferon alfa -2b (7.5 mcg) 2 2 1 1 50 40 28 33 <5 0.0 - L03AB11 peginterferon alfa -2a (26 mcg) 5 5 6 8 10 214 184 203 276 336 0.0 0.1 L03AB13 peginterferon beta -1a (8.9 mcg) 3 2 2 2 2 135 100 75 70 61 0.0 0.0 L03AX Other immunostimulants 722 761 685 642 572 0.1 0.1 L03AX03 BCG vaccine (1.8 mg) 8 8 9 11 10 5 8 5 8 8 0.0 0.0 L03AX13 glatiramer acetate (20 mg) 33 34 31 30 27 717 753 680 634 564 0.1 0.1 L04 IMMUNOSUPPRESSANTS 5 229 5 471 5 746 6 192 6 520 68 190 71 244 74 825 77 919 82 665 13.0 15.3 L04A IMMUNOSUPPRESSANTS 5 229 5 471 5 746 6 192 6 520 68 190 71 244 74 825 77 919 82 665 13.0 15.3 L04AA Selective immunosuppressants 712 736 732 740 716 10 851 11 856 12 234 12 371 13 064 2.1 2.4 L04AA06 mycophenolic acid (2 g) 233 238 248 249 248 5 164 5 375 5 473 5 654 5 803 1.0 1.1 L04AA10 sirolimus (3 mg) 12 12 12 13 13 295 297 293 312 321 0.1 0.1 L04AA13 leflunomide (20 mg) 102 98 81 107 89 2 256 2 238 2 121 2 013 1 922 0.4 0.4 L04AA18 everolimus (1.5 mg) 49 53 54 50 53 481 508 480 458 458 0.1 0.1 L04AA23 natalizumab (10 mg) 58 60 61 55 54 <5 <5 0 <5 0 - 0.0 L04AA24 abatacept (27 mg) 11 10 9 8 8 283 268 215 188 188 0.1 0.0 L04AA25 eculizumab (64 mg) 18 18 22 22 19 0.0 0.0 L04AA26 belimumab (25 mg) 3 3 4 5 5 0 0 0 0 60 0.0 0.01 L04AA27 fingolimod (0.5 mg) 82 82 77 69 62 1 411 1 380 1 263 1 104 1 012 0.3 0.2 L04AA28 belatacept (12.5 mg) 1 1 1 2 1 0 <5 <5 <5 0 0.0 0.0 L04AA29 tofacitinib (10 mg) 1 24 33 24 19 87 835 672 481 383 0.0 0.1 L04AA31 teriflunomide (14 mg) 78 80 80 75 69 1 427 1 465 1 358 1 272 1 160 0.3 0.2 L04AA32 apremilast (60 mg) 1 1 0 0 0 27 15 6 11 12 0.0 0.0 L04AA33 vedolizumab (5.4 mg) 61 78 96 106 112 0 0 0 14 360 0.0 0.1 L04AA34 alemtuzumab (0.13 mg) 22 21 9 1 2 - - - - - - - L04AA36 ocrelizumab (3.29 mg) 0 1 1 3 - - - - - - - 101 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 L04AA37 baricitinib (4 mg) 1 2 16 31 36 28 56 553 793 830 0.0 0.2 L04AA38 ozanimod (0.92 mg) 1 0 0 0 <5 32 0 0.01 L04AA40 cladribine (0.34 mg) 14 39 50 54 0 182 510 649 704 0.0 0.1 L04AA44 upadacitinib 3 0 0 0 <5 116 0.0 0.0 L04AA45 filgotinib 0 0 0 0 0 447 0.0 0.1 L04AB Tumor necrosis factor alpha (TNF -) inhibitors 1 814 1 979 2 187 2 415 2 561 16 505 16 764 20 473 23 506 26 500 3.1 4.9 L04AB01 etanercept (7 mg) 329 377 343 342 353 7 350 8 196 7 228 7 203 7 532 1.4 1.4 L04AB02 infliximab (3.75 mg) 920 1 086 1 127 1 160 1 154 <5 <5 <5 6 <5 - - L04AB04 adalimumab (2.9 mg) 256 255 500 740 902 4 376 4 430 10 828 14 580 17 606 0.8 3.3 L04AB05 certolizumab pegol (14 mg) 195 157 131 100 86 3 646 2 990 2 577 2 010 1 703 0.7 0.3 L04AB06 golimumab (1.66 mg) 114 104 86 73 66 1 684 1 514 1 308 1 071 953 0.3 0.2 L04AC Interleukin inhibitors 173 197 197 346 493 2 673 3 062 3 002 3 779 4 724 0.5 0.9 L04AC01 daclizumab (5 mg) 1 0 14 5 0 0 0 0.0 0.0 L04AC03 anakinra (0.1 g) 9 8 10 13 14 197 208 270 323 377 0.0 0.1 L04AC05 ustekinumab (0.54 mg) 69 79 78 226 361 814 805 752 1 190 1 673 0.2 0.3 L04AC07 tocilizumab (20 mg) 41 42 38 39 42 608 618 543 561 585 0.1 0.1 L04AC08 canakinumab (2.7 mg) 2 4 4 5 6 24 37 37 42 50 0.0 0.0 L04AC10 secukinumab (10 mg) 51 64 64 59 58 1 102 1 430 1 368 1 277 1 262 0.2 0.2 L04AC12 brodalumab (15 mg) 0 3 4 12 0 15 85 80 286 0.0 0.1 L04AC13 ixekizumab (2.9 mg) 1 18 28 0 0 22 398 570 0.0 0.1 L04AC18 risankizumab (1.67 mg) 5 0 0 0 57 94 0.0 0.0 L04AD Calcineurin inhibitors 310 320 337 338 341 6 274 6 449 6 612 6 685 6 754 1.2 1.3 L04AD01 ciclosporin (0.25 g) 118 110 108 101 97 2 954 2 893 2 788 2 654 2 552 0.6 0.5 L04AD02 tacrolimus (5 mg) 192 210 229 237 244 3 383 3 628 3 886 4 092 4 249 0.6 0.8 L04AX Other immunosuppressants 2 220 2 239 2 293 2 353 2 409 45 478 47 018 48 044 48 615 50 049 8.7 9.3 L04AX01 azathioprine (0.15 g) 312 300 276 283 240 8 280 8 214 8 003 7 498 7 075 1.6 1.3 L04AX02 thalidomide (0.1 g) 2 1 1 1 1 90 63 63 37 40 0.0 0.0 L04AX03 methotrexate (2.5 mg) 1 865 1 890 1 967 2 014 2 103 35 139 36 511 37 749 38 707 40 479 6.7 7.5 L04AX04 lenalidomide (10 mg) 33 39 39 44 49 810 987 957 1 088 1 168 0.2 0.2 L04AX05 pirfenidone (2.4 g) 3 4 5 6 11 78 98 120 170 235 0.0 0.0 L04AX06 pomalidomide (3 mg) 4 5 5 5 5 178 191 202 211 208 0.0 0.0 L04AX07 dimethyl fumarate (0.48 g) 63 62 63 60 57 1 160 1 213 1 180 1 111 1 009 0.2 0.2 102 4.10 M Muskler og har hovedtrekk g\u00e5tt ned 2021 har g\u00e5tt ned over tid. I 2004 24 % av den eldre befolkningen utlevert et diklofenak % hver m\u00e5lt i DDD. Figure 4.10 .1: Proportion of the population (prevalence %) of most prescribed antirheumatic products, non -steroids (NSAIDs, M01A) in 2017 Reseptregisteret viser fra legemiddelstatistikk. Behandling - CelecoxibM01AH05 - EtoricoxibProportion (%) of the population2017 2018 2020 har \u00f8kt fra 10 % i 2004 til 18 % i 2021. Kalsium og vitamin D er i 2006 .9 2021 til 1. 7 % av eldre kvinner. Figure 4.10.2: Sales of Calcium/vitamin (H0 5AA02), and p roportion of users (prevalence %) of all treatments for osteoporosis to women 60 years and older in Norway for the years 2004 -2021. Source: Norwegian Prescription 020406080100120140160180 2004 2006 2008 2010 2012 2014 2016 2018 2020 Proportion (%) of women 60 years with at least one prescriptionDDD/1000 inhabitants, women 60 years/dayTeriparatide Denosumab Bisphosphonates Calcium/Vit D All treatments for osteoporosis 105 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 51.79 859 738 158.7 159.5 M01AB Acetic acid derivatives and related substances 7.75 7.16 6.74 6.39 6.25 341 369 324 894 0.06 0.07 0.08 0.08 1 282 1 302 1 466 1 445 1 466 0.2 0.3 M01AB02 sulindac 5.92 5.62 5.46 323 120 307 380 290 645 273 256 277 953 61.5 51.6 M01AB15 ketorolac (30 mg) 0.03 0.04 0.04 0.04 0.04 25 48 35 34 39 0.0 0.0 M01AB55 diclofenac, combinations (0.1 g) 0.80 0.75 0.71 0.65 0.67 19 896 18 774 17 808 17 450 16 770 3.8 3.1 M01AC Oxicams 1.19 1.07 0.73 0.79 0.72 31 649 27 443 23 545 20 431 18 559 6.0 3.4 M01AC01 piroxicam (20 mg) 0.75 0.69 0.56 0.57 0.51 25 189 21 552 19 409 17 861 15 953 4.8 3.0 M01AC06 meloxicam (15 mg) 0.44 0.38 0.17 0.22 0.21 6 577 5 991 4 349 2 732 2 654 1.3 0.5 M01AE 99 739 94 127 93 013 90 760 90 214 19.0 16.7 M01AE03 ketoprofen (0.15 g) 0.49 0.45 0.43 0.39 0.37 3 766 3 559 3 432 3 280 3 111 0.7 0.6 M01AE14 dexibuprofen (0.8 g) 0.00 0.00 0.00 0.00 dexketoprofen (75 mg) 0.00 0.00 0.00 0.00 17 6 0 and esomeprazole (0.5 g) 9.17 9.96 11.04 142 741 154 156 190 454 208 439 27.2 38.7 M01AG Fenamates 0.01 0.01 0.01 0.01 0.01 494 484 616 712 687 0.1 0.1 M01AG02 tolfenamic acid (0.3 g) 0.01 0.01 0.01 0.01 0.01 494 484 616 712 687 0.1 0.1 M01AH Coxibs 4.71 4.99 5.55 5.90 6.42 101 372 104 774 112 423 121 232 130 931 19.3 24.3 M01AH01 celecoxib (0.2 g) 0.86 0.88 0.99 1.04 1.10 14 719 14 942 16 566 18 170 20 319 2.8 3.8 M01AH04 parecoxib (40 mg) 0.01 0.01 0.01 0.01 0.02 <5 <5 <5 <5 0 4.54 4.84 5.31 87 661 90 828 97 099 104 488 112 232 16.7 20.8 M01AX Other antiinflammatory and antirheumatic agents, non -steroids 3.69 3.38 2.99 2.85 3.03 30 244 28 000 24 546 23 046 22 742 5.8 4.2 M01AX01 nabumetone (1 g) 0.20 0.17 0.16 0.15 0.13 2 175 1 935 1 753 1 728 1 559 0.4 0.3 M01AX05 glucosamine (1.5 g) 3.50 3.21 2.83 2.70 2.90 27 221 25 322 22 116 20 669 20 615 5.2 3.8 M01C SPECIFIC ANTIRHEUMATIC AGENTS 0.01 0.01 0.00 0.00 0.00 49 35 29 22 19 0.0 0.0 M01CB Gold preparations 0.01 0.01 0.00 0.00 0.00 42 29 22 14 11 0.0 sodium aurothiomalate (2.4 mg) 0.00 0.00 0.00 0.00 13 11 6 (6 mg) 0.00 0.00 0.00 0.00 0.00 29 18 16 14 11 0.0 0.0 106 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 6 7 (0.5 g) 0.00 0.00 0.00 0.00 0.00 RELAXANTS 0.86 0.84 0.89 0.88 0.86 8 991 10 310 11 347 12 178 13 495 1.7 2.5 M03A MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS 0.14 0.13 0.12 0.11 0.09 3 170 4 216 5 055 5 582 6 602 0.6 1.2 M03AX Other muscle relaxants, peripherally acting agents 3 169 4 215 5 054 5 582 6 601 0.6 1.2 M03AX01 botulinum toxin - - - - - 3 169 4 215 5 054 5 582 6 601 0.6 1.2 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 0.73 0.72 0.77 0.76 0.77 5 883 6 164 6 358 6 670 6 982 1.1 1.3 M03BA Carbamic acid esters 0.05 0.04 0.04 0.04 0.04 421 401 387 386 367 0.1 0.1 M03BA02 carisoprodol (1.4 g) 0.05 0.04 0.04 0.04 0.04 421 401 387 383 365 0.1 (1.5 g) 0.00 0.00 0.00 0.00 0.00 44 57 91 126 188 Other centrally acting agents 0.68 0.67 0.72 0.72 0.73 5 430 5 716 5 892 6 169 6 437 1.0 1.2 M03BX01 baclofen (50 mg O/0.55 mg P) 0.66 0.66 0.71 0.71 0.71 5 357 5 637 5 819 6 085 6 337 1.0 1.2 M03BX02 tizanidine (12 mg) 0.02 0.01 0.01 0.01 0.02 103 108 105 114 126 0.0 0.0 M04 ANTIGOUT PREPARATIONS 4.95 4.87 4.96 5.62 5.43 59 343 61 965 64 438 67 951 70 845 11.3 13.1 M04A ANTIGOUT PREPARATIONS 4.95 4.87 4.96 5.62 5.43 59 343 61 965 64 438 67 951 70 845 11.3 13.1 M04AA Preparations inhibiting uric acid production 4.22 4.23 4.20 4.88 4.74 53 155 55 688 58 024 61 235 64 251 10.1 11.9 M04AA01 allopurinol (0.4 g) 4.18 4.15 4.11 4.79 4.64 52 795 55 177 57 435 60 599 63 527 10.0 11.8 M04AA03 febuxostat increasing uric acid excretion 0.20 0.19 0.19 0.19 0.18 1 788 1 752 1 710 1 666 1 562 0.3 0.3 M04AB01 probenecid (1 g) 0.20 0.19 0.19 0.19 0.18 1 788 1 748 1 702 1 662 1 0.3 (0.2 g) 0.00 0.00 0.00 0 <5 8 5 0 0.0 0.0 M04AC Preparations with no effect on uric acid metabolism 0.53 0.45 0.57 0.55 0.51 9 200 9 576 9 870 10 709 10 593 1.8 2.0 M04AC01 colchicine (1 mg) 0.53 0.45 0.57 0.55 0.51 9 200 9 576 9 870 10 709 10 593 1.8 2.0 M05 DRUGS FOR TREATMENT OF BONE DISEASES 9.52 9.43 9.43 9.34 9.55 64 868 66 175 67 014 66 357 68 213 12.3 12.7 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 9.52 9.43 9.43 9.34 9.55 64 868 66 175 67 014 66 357 68 213 12.3 12.7 M05BA Bisphosphonates 7.75 7.56 7.33 7.07 7.05 57 746 57 407 56 785 54 962 55 492 11.0 10.3 M05BA03 pamidronic acid (60 alendronic acid (10 mg) 7.65 7.46 7.24 6.99 6.97 51 864 50 714 49 788 47 792 48 249 9.9 9.0 M05BA06 ibandronic acid (5 mg O/6 mg P) 0.04 0.03 0.03 0.03 0.02 597 556 488 441 374 0.1 0.1 M05BA07 risedronic acid (5 mg) 0.04 0.04 0.04 0.03 0.03 309 280 264 218 197 0.1 0.0 M05BA08 zoledronic acid (4 mg) 0.02 0.02 0.02 0.02 0.03 5 613 6 475 6 856 7 057 7 276 1.1 1.4 107 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 M05BX Other drugs affecting bone structure and mineralization 1.77 1.87 2.11 2.27 2.50 7 906 9 608 10 998 12 145 13 546 1.5 2.5 M05BX04 denosumab (0.33 mg) 1.77 1.87 2.11 2.27 2.50 7 906 9 608 10 998 12 134 13 529 1.5 2.5 M05BX05 burosumab - - - - - 0 0 0 11 14 0.0 0.0 M05BX06 romosozumab (7 mg) 0.00 m\u00e5lt i et NSAID, 11 % minst informasjon om totalt salg av paracetamol. Figure 4.11 .1: Proportion of the population (prevalence, %) having dispensed various analgesics ; anti-inflammatory drugs (M01A), opioids (N02A), and % av befolkningen salget i 2 021 (44 % av DDD), etterfulgt av rizatriptan og zolmitriptan som utgjorde ca. 20 % DDD som vanedannende. Figure 4.11.2 : Proportion of the population (prevalence, % ) of most prescribed hypnotics and sedatives (N05C) in the period 201 7-2021. Source: Norwegian Prescription Database. men bruken \u00f8kte noe i 2020 og 2021 kan ha sammenheng med koronapandemien 11 % av eldre ( 65 \u00e5r 4.11.3 : Proportion of the population ( prevalence, ) of most prescribed antidepressants (N06A) i n the period 201 7-2021. Source: Norwegian Prescription Database. Midler ved ADHD Bruk -midler har \u00f8kt over - () of the population 2017 2018 2019 2020 2021 112 Figure 4.11.4 : Proportion of the population (prevalence, %) having dispensed drugs for groups in the period 201 7-2021. Source: Norwegi an Prescription Database. 00,511,522,533,54 15-19 years 20-64 years 65 yearsProportion (%) of the population 2017 2018 2019 2020 2021 C02AC02 - () of the population 2017 2018 2019 2020 2021 113 Figure 4.11. 5: Proportion of the population (prevalence, ) having dispensed drugs for ADHD in the period 2017 -2021. Source: Norwegian Prescription Database. 1) Debernard KAB, Frost J, Roland PH. Quetiapine is not a sleeping pill. Tidsskr Nor Laegeforen. 2019 Sep 16;139(13). 114 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 3.99 4.14 4.04 4.04 57 193 62 111 67 118 69 247 76 651 10.9 14.2 N02AA01 morphine (0.03 g P/0.1 g O) 1.08 1.06 1.12 1.09 1.06 8 200 8 068 8 722 9 513 9 857 1.6 1.8 N02AA03 hydromorphone (20 mg O) 0.19 0.18 0.18 0.17 0.16 123 60 12 16 19 0.0 0.0 N02AA05 oxycodone (75 mg O) 2.40 2.42 2.49 2.44 2.45 48 755 53 411 57 732 59 135 65 951 9.3 12.2 N02AA08 dihydrocodeine (0.15 g) 0.01 0.01 0.01 0.01 0.01 37 34 39 34 34 0.0 0.0 N02AA55 oxycodone and naloxone (75 mg) 0.30 0.32 0.33 0.33 0.36 7 246 7 726 8 380 8 978 9 846 1.4 1.8 N02AB Phenylpiperidine derivatives 1.50 1.46 1.43 1.36 1.36 12 405 11 975 11 564 10 687 10 506 2.4 2.0 N02AB01 ketobemidone (50 mg) 0.08 0.08 0.07 0.07 0.06 3 604 3 241 2 889 2 675 2 574 0.7 0.5 N02AB02 pethidine (0.4 g) 0.02 0.02 0.02 0.00 0.01 948 976 856 264 217 0.2 0.0 N02AB03 fentanyl (1.2 mg TD/0.6 mg N/SL) 1.40 1.36 1.34 1.29 1.29 8 180 8 036 8 070 7 961 7 908 1.6 1.5 N02AD benzomorphan derivatives 0.00 0.00 0.00 0.00 (0.2 g) 0.00 0.00 0.00 0.00 derivatives 0.78 0.77 0.77 0.77 0.78 18 403 17 999 17 972 18 047 18 222 3.5 3.4 N02AE01 buprenorphine (1.2 mg) 0.78 0.77 0.77 0.77 0.78 18 403 17 999 17 972 18 047 18 222 3.5 3.4 N02AG Opioids in combination with antispasmodics 0.05 0.05 0.05 0.05 0.05 1 688 1 546 1 511 1 619 1 457 0.3 0.3 N02AG02 ketobemidone and antispasmodics 0.05 0.05 0.05 0.05 0.05 1 688 1 546 1 511 1 619 1 457 0.3 0.3 N02AJ Opioids in combination with non -opioid analgesics 8.41 8.04 8.28 7.98 7.82 356 278 345 232 351 539 342 674 349 982 67.8 64.9 N02AJ06 codeine and paracetamol 8.31 7.94 8.17 7.88 7.72 351 291 339 937 345 968 338 137 345 989 66.8 64.2 N02AJ07 codeine and acetylsalicylic acid 0.00 0.00 0.00 0.00 0.0 N02AJ13 tramadol and paracetamol 0.09 0.10 0.11 0.10 0.10 6 698 6 878 7 354 5 778 4 902 1.3 0.9 N02AX Other opioids 4.56 4.46 4.38 4.17 4.16 228 155 229 799 267 214 647 221 186 43.4 796 214 467 42.8 39.8 N02AX06 tapentadol (0.4 g) 0.16 0.19 0.20 0.20 0.22 4 613 5 304 5 970 6 638 8 657 0.9 1.6 and derivatives 0.13 0.13 0.18 0.18 0.17 1 261 1 195 1 258 1 237 1 373 0.2 0.3 N02BA01 acetylsalicylic acid (3 g) 0.13 0.13 0.18 0.18 0.17 1 257 1 191 1 254 1 232 1 367 0.2 0.3 N02BA11 Pyrazolones 1.35 1.27 1.17 1.03 0.93 1 550 1 551 1 521 1 449 1 513 0.3 0.3 g) 0.00 0.00 0.00 0.00 0.0 N02BB51 phenazone, combinations excl. psycholeptics 1.35 1.27 1.17 1.02 0.93 1 485 1 492 1 448 1 384 1 460 0.3 0.3 115 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 analgesics and antipyretics 0.04 0.04 0.06 0.06 0.07 472 541 841 945 1 006 0.1 0.2 N02BG10 cannabinoids 0.04 0.04 0.06 0.06 0.07 472 540 840 997 0.1 0.2 ANTIMIGRAINE PREPARATIONS 4.28 4.36 4.61 5.56 6.17 115 0.0 N02CA72 ergotamine, combinations with psycholeptics 0.00 240 31 0 0 0.1 0.0 serotonin (5HT1) agonists 3.87 3.91 4.02 4.20 4.36 111 321 114 871 121 160 126 349 134 438 21.2 24.9 N02CC01 sumatriptan (50 mg O/6 mg P/ 20 mg N) 1.70 1.72 1.79 1.85 1.92 58 093 59 990 64 377 67 553 72 060 11.1 13.4 N02CC02 naratriptan (2.5 mg) 0.07 0.09 0.09 0.09 0.10 2 485 2 847 3 171 3 427 4 096 0.5 0.8 N02CC03 zolmitriptan (2.5 mg) 0.81 21 635 3.7 (10 mg) 0.73 0.75 0.80 0.81 0.89 31 217 32 744 34 523 36 170 38 520 5.9 7.1 N02CC05 almotriptan (12.5 mg) 0.07 0.08 0.07 0.07 0.08 2 934 3 023 3 214 3 413 3 683 0.6 0.48 0.52 0.51 13 275 13 651 14 317 14 946 15 851 2.5 2.9 N02CC07 frovatriptan (2.5 mg) 0.00 0.00 0.00 Calcitonin gene -related peptide (CGRP) antagonists 0.02 0.16 1.28 1.75 0 399 1 488 6 626 9 012 0.0 1.7 N02CD01 erenumab (2.5 mg) 0.02 0.16 1.01 1.10 0 399 1 468 5 276 5 030 0.0 0.9 N02CD02 galcanezumab (4 mg) 0.00 0.08 0.24 0 0 <5 991 2 111 0.0 0.4 N02CD03 fremanezumab (7.5 mg) 0.00 0.20 0.40 0 0 82 2 103 3 502 0.0 0.7 N02CX Other antimigraine preparations 0.41 0.43 0.43 0.08 0.06 4 844 5 343 5 489 1 675 983 0.9 0.2 N02CX01 pizotifen (1.5 mg) 0.01 0.00 0.00 0.00 0.00 45 35 31 31 32 0.0 0.0 N02CX02 clonidine (0.1 mg) 0.41 0.43 0.43 0.07 0.06 4 802 5 308 5 458 1 644 951 0.9 0.2 N03 ANTIEPILEPTICS 17.58 17.90 18.51 19.17 19.93 131 955 148 772 156 253 25.1 0.34 0.44 0.34 006 1 901 1 825 1 743 1 641 0.4 0.3 N03AA02 phenobarbital (0.1 g) 0.47 0.44 0.32 0.43 0.33 1 630 1 519 1 387 1 287 1 197 0.3 0.2 N03AA03 primidone (1.25 g) 0.02 0.02 0.02 0.02 0.02 385 391 445 464 450 0.1 0.1 N03AB Hydantoin derivatives 0.21 0.19 0.18 0.16 0.15 1 118 1 022 981 914 870 0.2 0.2 N03AB02 phenytoin (0.3 g) 0.21 0.19 0.18 0.16 0.15 1 118 1 022 981 914 870 0.2 0.2 N03AD Succinimide derivatives 0.02 0.03 0.03 0.03 0.03 289 294 305 341 361 0.1 0.1 N03AD01 ethosuximide (1.25 g) 0.02 0.03 0.03 0.03 0.03 289 294 305 341 361 0.1 0.1 N03AE Benzodiazepine derivatives 0.28 0.25 0.23 0.21 0.18 7 198 6 416 5 885 5 459 5 081 1.4 0.9 N03AE01 clonazepam (8 mg) 0.28 0.25 0.23 0.21 0.18 7 198 6 416 5 885 5 459 5 081 1.4 0.9 116 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 N03AF Carboxamide derivatives 1.74 1.70 1.75 1.68 1.60 14 894 14 432 14 218 13 844 13 455 2.8 2.5 N03AF01 carbamazepine (1 g) 1.11 1.03 0.99 0.93 0.86 11 495 10 461 9 734 9 310 8 813 2.2 1.6 N03AF02 oxcarbazepine (1 g) 0.50 0.50 0.55 0.53 0.51 2 968 3 388 3 732 3 669 3 743 0.6 0.7 N03AF03 rufinamide (1.4 g) 0.01 0.01 0.01 0.01 0.01 90 83 78 79 77 0.0 0.0 N03AF04 eslicarbazepine (0.8 g) 0.12 0.15 0.19 0.21 0.22 590 783 955 1 031 1 081 0.1 0.2 N03AG Fatty acid derivatives 1.79 1.79 1.79 1.78 1.76 15 197 15 073 14 939 14 785 14 650 2.9 2.7 N03AG01 valproic acid (1.5 g) 1.78 1.78 1.78 1.77 1.74 15 118 15 015 14 859 14 684 14 502 2.9 2.7 N03AG03 aminobutyric acid (1 g) 0.00 0.00 0.00 0.00 8 17 36 73 0.0 0.0 N03AG04 vigabatrin (2 g) 0.01 0.01 0.01 0.01 0.01 87 78 90 92 103 0.0 0.0 N03AG06 tiagabine (30 mg) 0.00 0.00 0.00 0.00 0.00 antiepileptics 13.04 13.50 14.19 14.87 15.86 104 042 109 602 117 023 124 154 132 264 19.8 24.5 N03AX03 sultiame (0.4 g) 0.03 0.03 0.03 0.03 0.03 323 343 347 366 342 0.1 0.1 N03AX09 lamotrigine (0.3 g) 4.36 4.38 4.54 4.68 4.75 30 145 30 746 31 739 32 428 33 085 5.7 6.1 N03AX10 felbamat (2.4 g) 0.00 0.00 0.00 0.00 N03AX11 topiramate (0.3 g) 0.31 0.31 0.32 0.32 0.31 4 617 4 814 5 751 6 207 6 454 0.9 (1.8 2.97 3.23 3.58 3.93 4.38 42 711 46 051 50 467 55 381 61 683 8.1 11.4 N03AX14 levetiracetam (1.5 g) 1.60 1.68 1.76 1.82 1.87 9 761 10 306 10 896 11 324 11 553 1.9 2.1 N03AX15 zonisamide (0.2 g) 0.17 0.16 0.17 3.49 3.58 3.94 23 571 24 468 24 994 25 906 26 937 4.5 5.0 N03AX17 stiripentol (1 g) 0.01 0.01 0.01 0.01 0.01 33 34 40 40 42 0.0 0.0 N03AX18 lacosamide (0.3 g) 0.12 0.13 0.16 0.17 0.20 703 770 935 1 027 1 150 0.1 0.2 N03AX22 perampanel (8 mg) 0.04 0.04 0.05 0.05 0.06 360 361 406 426 441 0.1 0.1 N03AX23 brivaracetam (0.1 g) 0.04 0.06 0.08 0.09 0.13 201 289 347 403 N03AX24 cannabidiol - - 0.00 0.00 0.00 0 0 14 drugs 4.22 23 24 380 25 176 4.2 4.7 N04A Anticholinergic agents 0.16 0.15 0.15 0.14 0.13 2 071 1 990 1 906 1 868 1 804 0.4 0.3 N04AA Tertiary amines 0.16 0.15 0.15 0.14 0.13 2 055 1 979 1 899 1 860 1 795 0.4 0.3 N04AA01 trihexyphenidyl (10 mg) 0.01 0.01 0.01 0.01 0.01 54 39 48 43 47 0.0 0.0 N04AA02 biperiden (10 mg) 0.15 0.14 0.14 0.13 0.13 2 000 1 939 1 852 1 818 1 748 0.4 0.3 N04AB 0.00 (0.2 g) 0.00 0.00 0.00 0.0 N04B Dopaminergic agents 4.06 4.13 4.17 4.15 4.05 20 262 21 150 21 850 22 569 23 445 3.9 4.4 N04BA Dopa and dopa derivatives 1.62 1.74 1.84 1.86 1.89 10 093 10 586 10 900 11 028 11 328 1.9 2.1 N04BA02 levodopa and decarboxylase inhibitor (0.6 g) 1.30 1.42 1.51 1.54 1.57 9 513 10 003 10 328 10 509 10 853 1.8 2.0 N04BA03 levodopa, decarboxylase inhibitor and comt inhibitor (0.45 g) 0.32 0.32 0.32 0.32 0.32 1 387 1 380 1 314 1 278 1 260 0.3 0.2 N04BB Adamantane derivatives 0.03 0.03 0.03 0.02 0.02 207 178 175 169 166 0.0 0.0 N04BB01 amantadine (0.2 g) 0.03 0.03 0.03 0.02 0.02 207 178 175 169 166 0.0 0.0 117 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 N04BC Dopamine agonists 1.18 1.16 1.13 1.10 1.05 13 281 13 773 14 142 14 632 15 100 2.5 2.8 (6 mg) 0.59 0.56 0.53 0.49 0.45 2 923 2 914 2 800 2 716 2 598 0.6 0.5 N04BC05 pramipexole (2.5 mg) 0.49 0.49 0.50 0.51 0.50 10 013 10 581 11 126 11 665 12 211 1.9 2.3 N04BC06 cabergoline (3 mg) 0.01 0.00 80 61 0 0 0 0.0 0.0 N04BC07 apomorphine (20 mg) 0.02 0.02 0.03 0.03 0.03 62 60 66 60 61 0.0 0.0 N04BC09 rotigotine (6 mg) 0.08 0.08 0.08 N04BD Monoamine oxidase B inhibitors 1.21 1.19 1.16 1.15 1.08 4 304 4 302 4 171 4 130 4 017 0.8 0.8 N04BD01 selegiline (5 mg) 0.85 0.85 0.83 0.77 2 439 2 465 2 376 2 373 2 309 0.5 0.4 N04BD02 rasagiline (1 mg) 0.34 0.31 0.34 0.30 1 807 1 747 1 697 0.4 0.3 N04BD03 safinamide (75 mg) 0.01 0.02 0.01 0.01 0.01 101 86 68 56 50 0.0 0.0 N04BX Other dopaminergic agents 0.02 0.02 0.02 0.02 0.02 142 157 141 158 146 0.0 0.0 N04BX01 tolcapone (0.45 g) 0.00 0.00 0.00 5 <5 0.0 - N04BX02 entacapone (1 g) 0.02 0.02 0.02 0.02 0.02 134 151 136 153 142 0.0 0.0 N05 PSYCHOLEPTICS 69.59 68.18 70.25 70.24 73.06 002 23.7 26.2 N05AA Phenothiazines with aliphatic side -chain 0.17 0.15 0.14 0.13 0.11 15 331 13 921 10 482 7 107 6 114 2.9 1.1 N05AA01 chlorpromazine (0.3 g O,R/0.1 g P) 0.01 0.01 0.00 0.00 0.00 202 202 176 133 204 0.0 0.0 N05AA02 levomepromazine (0.3 g O/0.1 g P) 0.16 0.15 0.13 0.12 0.11 15 135 13 727 10 312 6 979 5 917 2.9 1.1 N05AB Phenothiazines with piperazine structure 0.29 0.27 0.27 0.24 0.24 9 108 8 691 8 394 7 892 7 905 1.7 1.5 N05AB02 fluphenazine (10 mg O/1 mg perphenazine (30 mg O/10 mg P/ 7 mg P (depot)) 0.24 0.23 0.22 0.20 0.20 1 577 1 507 1 454 1 320 1 231 0.3 0.2 N05AB04 prochlorperazine (0.1 g O,R/50 mg P) 0.04 0.04 0.04 0.04 0.04 7 529 7 186 6 936 6 575 6 680 1.4 1.2 N05AC Phenothiazines with piperidine structure 0.00 0.00 0.00 (0.3 g) 0.00 0.00 0.00 0.00 29 26 0.0 N05AD Butyrophenone derivatives 0.22 0.20 0.18 0.18 0.17 3 835 3 628 3 750 4 385 4 251 0.7 0.8 N05AD01 haloperidol (8 mg O,P/ 3.3 mg P (depot)) 0.21 0.19 0.18 0.18 0.17 3 822 3 608 3 740 4 376 4 242 0.7 0.8 N05AD03 melperon (0.3 g) 0.00 0.00 0.00 0.00 10 7 8 0.0 0.0 N05AE Indole derivatives 0.17 0.19 0.20 0.19 0.19 1 006 1 091 1 186 1 172 1 157 0.2 0.2 N05AE03 sertindole (16 mg) 0.01 0.01 0.01 0.01 0.01 79 72 65 55 56 0.0 0.0 N05AE04 ziprasidone (80 mg O/40 mg P) 0.11 0.11 0.11 0.10 0.09 586 550 560 505 496 N05AE05 lurasidone (60 mg) 0.05 0.06 0.08 0.09 0.09 347 Thioxanthene derivatives 0.95 0.87 0.83 0.80 0.75 19 329 17 745 16 803 16 237 15 186 3.7 2.8 N05AF01 flupentixol (6 mg O/4 mg P) 0.21 0.19 0.19 0.18 0.17 3 486 3 171 3 025 2 860 2 648 0.7 0.5 N05AF03 chlorprothixene (0.3 g O/50 mg P) 0.34 0.31 0.28 0.27 0.24 13 822 12 619 11 908 11 640 10 830 2.6 2.0 118 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 0.37 0.36 0.35 0.34 2 470 2 314 2 208 2 080 1 994 0.5 0.4 N05AG Diphenylbutylpiperidine derivatives 0.01 0.01 0.01 0.01 0.01 104 101 103 96 86 0.0 0.0 N05AG02 pimozide (4 mg) 0.01 0.01 0.01 0.01 0.01 101 97 100 93 84 0.0 0.0 99 503 13.8 18.5 N05AH02 clozapine (0.3 g) 0.60 0.60 0.59 0.58 0.57 2 651 2 700 2 718 2 773 2 771 0.5 0.5 N05AH03 olanzapine (10 mg) 3.01 2.97 3.05 3.08 3.08 17 421 17 673 18 174 18 823 19 196 3.3 3.6 N05AH04 quetiapine (0.4 g) 2.82 2.89 3.02 3.09 3.18 55 638 63 126 69 337 74 652 81 199 10.6 0.11 0.11 0.13 624 637 692 717 871 0.1 0.2 N05AN Lithium 1.18 1.17 1.19 1.17 1.16 7 628 7 639 7 797 7 798 7 745 1.5 1.4 N05AN01 lithium (24 mmol) 1.18 1.17 1.19 1.17 1.16 7 628 7 639 7 797 7 798 7 745 1.5 1.4 N05AX Other antipsychotics 1.78 1.80 1.84 1.89 1.93 14 943 14 999 15 532 16 022 16 663 2.8 3.1 N05AX08 risperidone P (depot)) 0.64 0.62 0.62 0.61 0.60 8 141 8 040 8 225 8 302 8 464 1.6 1.6 N05AX12 aripiprazole (15 mg O,P/13.3 mg P (depot)) 0.85 0.87 0.90 0.93 0.95 6 375 6 530 6 825 7 142 7 550 1.2 1.4 N05AX13 paliperidone (6 mg O/2.5 mg P (depot)) 0.30 0.31 0.32 0.33 0.35 936 973 1 013 1 035 1 055 0.2 0.2 N05AX15 cariprazine (3 mg) 0.00 0.01 0.02 0 0 11 49 120 0.0 0.0 N05AX16 brexpiprazole (3 mg) 0.00 0.01 0.02 0 0 59 0.0 0.0 N05B ANXIOLYTICS 13.10 12.41 12.03 11.96 11.78 252 789 247 452 238 570 239 720 48.1 44.5 N05BA Benzodiazepine derivatives 11.88 11.23 10.89 10.79 10.55 229 065 223 642 220 145 212 671 211 583 43.6 39.2 N05BA01 diazepam (10 mg) 5.44 5.02 5.18 4.93 4.73 100 854 95 872 106 454 87 023 84 732 19.2 15.7 N05BA04 oxazepam (50 mg) 5.39 5.20 4.71 4.85 4.82 136 950 135 936 131 846 133 364 133 738 26.0 24.8 N05BA06 lorazepam (2.5 mg) 0.03 0.04 0.04 0.05 0.05 142 148 164 202 210 0.0 0.0 N05BA08 N05BA09 clobazam (20 mg) 0.13 0.13 0.14 0.14 0.14 896 936 1 042 1 088 1 101 0.2 0.2 N05BA12 alprazolam (1 mg) 0.89 0.84 0.81 0.82 0.80 2 587 2 409 2 494 2 435 2 429 0.5 0.5 N05BB Diphenylmethane derivatives 1.05 1.02 0.98 1.01 1.06 29 716 29 178 29 986 31 966 34 391 5.7 6.4 N05BB01 hydroxyzine (75 mg) 1.05 1.02 0.98 1.01 1.06 29 716 29 178 29 986 31 966 34 391 5.7 6.4 N05BE Azaspirodecanedione derivatives 0.17 0.16 0.16 0.16 0.16 2 119 2 053 2 138 2 122 2 201 0.4 0.4 N05BE01 buspirone (30 mg) 0.17 0.16 0.16 0.16 0.16 2 119 2 053 2 138 2 122 2 201 0.4 0.4 N05C HYPNOTICS AND SEDATIVES 45.19 44.55 46.80 46.82 49.76 435 943 437 475 446 899 457 195 465 708 82.9 86.4 N05CC Aldehydes and derivatives - - - - - 13 12 13 13 7 0.0 0.0 N05CC01 chloral hydrate - - - - - 13 12 13 13 7 0.0 0.0 119 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2.76 2.67 2.34 2.58 26 433 25 703 25 482 25 412 24 456 5.0 4.5 N05CD01 flurazepam (30 mg) 0.00 0.00 0.00 7 10 8 0.0 0.0 N05CD02 nitrazepam (5 mg) 2.57 2.41 2.32 1.78 2.24 19 139 17 915 17 146 15 978 15 082 3.6 2.8 N05CD03 flunitrazepam (1 mg) 0.11 0.10 0.09 0.08 0.05 645 559 516 470 418 0.1 0.1 N05CD05 triazolam (0.25 mg) 0.01 0.01 0.01 0.01 0.01 49 49 43 64 53 0.0 0.0 N05CD08 midazolam (15 mg) 0.24 0.24 0.25 0.47 0.28 7 125 7 702 8 300 9 479 9 513 1.4 1.8 N05CF Benzodiazepine related drugs 32.06 30.65 31.18 30.36 30.23 350 093 345 212 343 760 283 706 278 062 272 722 55.2 50.6 N05CF02 zolpidem (10 mg) 5.81 5.78 5.88 6.21 6.10 70 841 72 358 74 824 76 477 76 473 13.5 14.2 N05CH Melatonin receptor agonists 10.02 10.97 12.78 13.93 16.80 94 753 101 660 114 056 132 406 148 064 18.0 27.5 N05CH01 melatonin (2 mg) 10.02 10.97 12.78 13.93 16.80 94 753 101 660 114 056 132 406 148 064 18.0 27.5 N05CM Other hypnotics and sedatives 0.17 0.16 0.16 0.18 0.16 1 961 1 948 1 849 1 865 1 785 0.4 0.3 N05CM02 clomethiazole (1.5 g) 0.15 0.14 0.14 0.13 0.12 1 835 1 824 1 707 1 727 1 586 0.4 0.3 N05CM05 scopolamine (0.9 mg) 0.00 0.00 0.00 10 <5 0.0 - N05CM06 propiomazine (25 mg) 0.01 0.01 0.01 0.01 0.02 77 97 121 129 195 0.0 0.0 N06 PSYCHOANALEPTICS 71.28 70.65 70 267 71 208 75 288 79 933 85 569 13.4 15.9 N06AA02 imipramine (0.1 g) 0.00 0.00 0.00 0.00 18 9 11 0.0 0.0 N06AA04 clomipramine (0.1 g) 0.19 0.17 0.17 0.15 0.15 2 122 1 953 1 835 1 734 1 654 0.4 0.3 N06AA05 opipramol (0.15 g) 0.00 0.00 0.00 0.00 8 11 14 0.0 0.0 N06AA06 trimipramine (0.15 g) 0.26 0.24 0.20 0.23 0.19 7 521 7 105 6 628 6 383 5 889 1.4 N06AA07 lofepramine 2.93 3.03 3.34 57 811 59 417 64 298 69 184 75 280 11.0 14.0 N06AA10 nortriptyline (75 mg) 0.14 0.14 0.15 0.15 0.16 2 143 2 422 2 476 2 596 2 667 0.4 0.5 N06AA12 doxepin (0.1 g) 0.11 0.09 0.08 0.08 0.07 1 454 1 184 761 191 145 34.9 35.5 N06AB03 fluoxetine (20 mg) 2.36 2.29 2.25 2.44 2.62 12 055 11 817 12 097 12 609 13 582 2.3 2.5 N06AB04 citalopram (20 mg) 3.41 3.11 2.89 2.70 2.52 18 571 17 008 15 942 14 953 14 315 3.5 2.7 N06AB05 paroxetine (20 mg) 2.42 2.30 2.22 2.14 2.04 12 510 12 050 11 570 11 139 10 840 2.4 2.0 N06AB06 sertraline (50 mg) 7.94 8.06 8.79 9.47 10.48 34 076 35 157 38 158 41 412 45 471 6.5 8.4 N06AB08 fluvoxamine (0.1 mg) 20.42 19.61 19.74 19.52 19.84 110 559 107 724 108 644 111 048 21.0 20.6 N06AF Monoamine oxidase inhibitors, non -selective 0.02 0.02 0.01 0.01 0.02 93 97 87 78 67 0.0 0.0 N06AF03 phenelzine (60 mg) 0.01 0.01 0.01 0.01 0.01 88 89 83 66 51 0.0 0.0 N06AF04 tranylcypromine (10 mg) 0.00 0.00 0.00 0.01 0.01 8 9 6 26 17 0.0 0.0 N06AG Monoamine oxidase A inhibitors 0.12 0.11 0.10 0.10 0.09 634 569 540 517 490 0.1 0.1 120 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 g) 0.12 0.11 0.10 0.10 0.09 634 569 540 517 490 0.1 0.1 N06AX Other antidepressants 17.08 17.26 18.33 18.63 19.46 115 819 118 416 086 127 200 134 022 22.0 24.9 N06AX01 oxitriptan - - - - - 90 78 58 69 48 0.0 0.0 N06AX02 tryptophan - - - - - 17 18 26 36 24 0.0 0.0 N06AX03 mianserin (60 mg) 1.44 1.29 1.34 1.14 1.03 23 176 22 034 21 432 19 304 17 375 4.4 3.2 N06AX05 trazodone (0.3 g) 0.00 0.00 0.00 0.00 nefazodone (0.4 g) 0.00 0.00 0.00 mirtazapine (30 mg) 5.68 5.83 6.25 6.32 6.65 45 123 46 334 48 445 53 692 56 566 8.6 10.5 N06AX12 bupropion (0.3 g) 1.12 1.10 1.13 1.18 1.23 11 958 11 934 12 103 12 309 13 374 2.3 2.5 N06AX14 tianeptine (37.5 mg) 0.00 0.00 0.00 0.00 11 8 0.0 0.0 N06AX16 venlafaxine (0.1 g) 7.13 7.01 7.14 7.17 7.32 32 906 32 734 33 226 33 851 34 985 6.3 6.5 N06AX18 reboxetine (8 mg) 0.03 0.03 0.02 0.02 0.02 263 262 197 213 200 0.1 0.0 N06AX21 duloxetine (60 mg) 0.68 0.77 0.88 0.93 1.13 6 119 7 206 8 096 8 623 10 190 1.2 1.9 N06AX22 agomelatine (25 mg) 0.00 0.00 0.00 0.00 16 17 0.0 0.0 N06AX26 vortioxetine (10 mg) 1.00 1.24 1.56 1.85 2.07 7 126 8 703 10 809 12 134 13 397 1.4 2.5 N06B Psychostimulants, agents 15.74 45 899 48 609 52 711 58 257 67 875 8.7 12.6 N06BA Centrally acting sympathomimetics 10.79 11.40 12.65 13.60 15.70 45 520 48 281 52 382 57 916 67 526 8.7 12.5 N06BA01 amfetamine (15 mg) 0.14 0.13 0.13 0.16 0.16 348 327 335 358 371 0.1 0.1 N06BA02 dexamfetamine (15 mg) 0.83 0.90 0.97 1.06 1.16 2 589 2 861 3 233 3 712 4 420 0.5 0.8 N06BA04 methylphenidate (30 mg) 8.20 8.23 8.48 8.40 9.08 37 698 38 784 40 246 42 445 47 754 7.2 8.9 N06BA07 modafinil (0.3 814 852 N06BA09 atomoxetine (80 mg) 0.26 0.25 0.28 0.27 0.28 3 707 3 621 3 812 3 900 4 564 0.7 0.9 N06BA12 lisdexamfetamine (30 mg) 1.29 1.82 2.70 3.63 4.94 5 884 8 217 11 933 15 889 21 881 1.1 4.1 N06BC Xanthine derivatives 0.01 0.01 0.01 0.01 0.01 300 269 263 263 269 0.1 0.1 N06BC01 caffeine (0.4 g) 0.01 0.01 0.01 0.01 0.01 300 269 263 263 269 0.1 0.1 N06BX Other psychostimulants and nootropics 0.03 0.02 0.02 0.02 0.02 98 78 85 104 103 0.0 0.0 N06BX03 piracetam (2.4 g) 0.02 0.02 0.02 0.02 0.02 81 64 71 94 88 0.0 0.0 N06BX13 idebenone (0.9 g) 0.00 0.00 0.00 0.00 10 0.0 N06D Anti -dementia drugs 3.16 3.05 3.03 2.90 2.82 15 281 15 356 15 138 14 525 14 800 2.9 2.8 N06DA Anticholinesterases 2.32 2.25 2.24 2.18 2.13 12 630 12 729 12 570 12 175 12 476 2.4 2.3 N06DA02 donepezil (7.5 mg) 1.50 1.45 1.48 1.43 1.39 7 449 7 546 7 569 7 273 7 413 1.4 N06DA03 rivastigmine (9 mg) 0.79 0.77 0.74 0.72 0.72 5 380 5 404 5 214 5 258 5 269 1.0 1.0 N06DA04 galantamine (16 mg) 0.03 0.02 0.02 0.03 0.02 172 139 131 152 139 0.0 0.0 121 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 0.70 3 818 3 685 3 540 3 233 3 111 0.7 0.6 N06DX01 memantine (20 mg) 0.84 0.80 0.79 0.72 0.70 3 818 3 685 3 540 3 233 3 111 0.7 0.6 N07 Other nervous system drugs 13.01 12.99 13.23 14.15 14.19 38 745 37 138 35 785 36 316 31 830 7.4 5.9 N07A Parasympathomimetics 0.17 0.17 0.18 0.19 0.19 874 928 991 1 053 1 065 0.2 0.2 N07AA Anticholinesterases 0.15 0.15 0.16 0.17 0.17 737 770 825 882 907 0.1 0.2 N07AA02 pyridostigmine (0.18 g) 0.13 0.13 0.14 0.15 0.15 733 767 818 873 900 0.1 0.2 N07AX Other parasympathomimetics 0.02 0.02 0.02 0.02 0.02 137 158 165 170 158 0.0 0.0 N07AX01 pilocarpine (15 mg) 0.01 0.02 0.02 0.02 0.02 130 152 159 165 153 0.0 0.0 N07AX03 cevimeline (90 mg) 0.00 0.00 0.00 0.00 0.00 7 6 6 5 5 0.0 0.0 N07B Drugs used in addictive disorders 12.38 12.34 12.55 13.45 13.47 35 133 33 382 31 851 32 167 27 433 6.7 5.1 N07BA Drugs used in nicotine dependence 8.34 8.39 8.60 9.35 9.35 16 000 14 702 13 546 14 250 9 645 3.0 1.8 N07BA01 nicotine (14 mg TD/30 mg gum) 7.90 7.99 8.23 8.96 9.18 1 168 1 284 1 287 1 390 1 579 0.2 0.3 N07BA03 varenicline (2 mg) 0.45 0.40 0.37 0.39 0.18 14 902 13 507 12 329 12 935 8 113 2.8 1.5 N07BB Drugs used in alcohol dependence 0.47 0.44 0.41 0.46 0.41 11 498 11 158 10 729 10 495 10 530 2.2 2.0 N07BB01 disulfiram (200 mg) 0.37 0.34 0.31 0.35 0.29 4 146 4 003 3 788 3 797 3 529 0.8 0.7 N07BB03 acamprosate (2 g) 0.02 0.02 0.02 0.02 0.02 435 384 374 394 453 0.1 0.1 N07BB04 naltrexone (50 mg) 0.07 0.07 0.08 0.08 0.09 6 483 6 407 6 332 6 156 6 361 1.2 1.2 N07BB05 nalmefene (18 mg) 0.01 0.01 0.01 0.01 0.01 695 583 488 413 441 0.1 0.1 N07BC Drugs used in opioid dependence 3.56 3.50 3.54 3.64 3.71 7 933 7 791 7 829 7 697 7 461 1.5 1.4 N07BC01 buprenorphine (8 mg) 1.09 1.15 1.17 1.33 1.43 3 321 3 485 3 607 3 633 3 604 0.6 0.7 N07BC02 methadone (25 mg) 2.02 1.97 2.02 1.99 1.97 3 346 3 295 3 330 3 315 3 236 0.6 0.6 N07BC05 levomethadone (15 mg) 0.01 0.02 0.03 0.06 0.09 16 16 51 100 144 0.0 0.0 N07BC51 buprenorphine, combinations (8 mg) 0.44 0.37 0.33 0.26 0.22 1 774 1 455 1 286 1 101 849 0.3 0.2 N07C Antivertigo preparations 0.11 0.11 0.11 0.12 0.11 0.11 0.12 849 900 0.2 N07CA01 betahistine 0.11 0.00 0.00 45 44 drugs 0.36 0.38 0.39 0.40 0.40 2 300 2 388 2 424 2 481 2 659 0.4 0.5 N07XX Other nervous system drugs 0.36 0.38 0.39 0.40 0.40 2 300 2 388 2 481 2 659 0.4 0.5 N07XX02 riluzole (0.1 g) 0.05 0.05 0.05 0.05 0.05 353 359 351 386 419 0.1 0.1 N07XX04 sodium oxybate (7.5 g) 0.02 0.02 0.02 0.02 0.03 142 141 151 168 200 0.0 0.0 N07XX05 amifampridine (40 mg) 0.00 0.00 0.00 0.00 18 20 22 0.0 0.0 N07XX06 tetrabenazine (0.1 g) 0.01 0.01 0.01 0.01 0.01 44 57 48 53 62 0.0 0.0 N07XX07 fampridine (20 mg) 0.28 0.30 0.30 0.29 0.29 1 751 1 796 1 819 1 806 1 868 0.3 0.4 122 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 pitolisant (18 mg) 0.00 0.00 0.01 0.01 0.01 6 29 51 61 104 0.0 0.0 N07XX59 dextromethorphan, combinations (40 mg) 0.00 0.00 0.00 0.00 0.00 8 9 8 5 <5 P Antiparasit\u00e6re midler, insekticider P01 fra vel 35 000 i 2019 til vel 12 000 i 2021, men med en stigende trend en reseptfritt. : Sales of scabies treatments in 2017 -2021. Source: Norwegian Drug Wholesales statistics 1) Amato et al. Increase of scabies infestations, Norway, - Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 93 329 94 332 97 747 85 987 84 977 17.8 15.8 P01 ANTIPROTOZOALS 0.81 0.78 0.79 0.75 0.68 86 800 87 87 487 67 629 64 845 16.5 12.0 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 0.22 0.21 0.22 0.21 0.21 53 658 52 535 52 598 52 607 52 913 10.2 9.8 P01AB Nitroimidazole derivatives 0.22 0.21 0.22 0.21 0.21 53 655 52 529 52 596 52 602 52 910 10.2 9.8 P01AB01 (2 g) 0.22 0.21 0.22 0.21 0.21 53 649 52 508 52 591 52 592 52 903 10.2 P01AB02 tinidazole (2 g) 0.00 0.00 0.00 0.00 0.59 0.57 0.57 0.54 0.47 33 624 35 594 35 394 15 299 12 170 6.4 2.3 P01BA Aminoquinolines 0.45 0.44 0.44 0.50 0.44 6 280 6 298 6 308 7 394 7 444 1.2 1.4 P01BA01 chloroquine (0.5 g) 0.00 0.00 0.00 0.00 hydroxychloroquine (0.516 g) 0.45 0.44 0.44 0.50 0.44 6 260 6 279 6 286 7 374 7 434 1.2 1.4 P01BA03 primaquine (15 mg) 0.00 0.00 0.00 0.00 15 19 10 0.0 0.0 P01BB Biguanides 0.13 0.12 0.13 0.04 0.03 25 145 27 088 27 080 7 282 3 815 4.8 0.7 P01BB51 proguanil, combinations 0.13 0.12 0.13 0.04 0.03 25 144 27 088 27 080 7 282 3 815 4.8 0.7 P01BC Methanolquinolines 0.01 0.01 0.01 0.00 0.00 2 323 2 336 2 110 667 942 0.4 0.2 P01BC01 quinine (1.5 g) 0.00 0.00 0.00 and derivatives, combinations 0.00 0.00 0.00 0.00 14 8 lumefantrine (0.28 g) 0.00 0.00 0.00 13 16 14 8 0.0 P02 ANTHELMINTICS 0.17 0.17 0.19 0.20 0.20 3 231 3 438 6 332 14 895 17 059 0.6 3.2 P02B ANTITREMATODALS 0.00 0.00 0.00 0.00 derivatives and related substances 0.00 0.00 0.00 0.00 56 63 83 (3 g) 0.00 0.00 0.00 0.00 83 39 28 0.0 0.0 P02C ANTINEMATODAL AGENTS 0.17 0.17 0.19 0.20 0.20 3 167 3 370 6 234 14 843 17 017 0.6 3.2 P02CA Benzimidazole derivatives 0.17 0.16 0.17 0.17 0.17 2 696 2 457 2 535 2 261 2 159 0.5 0.4 P02CA01 mebendazole (0.2 g) 0.17 0.16 0.17 0.17 0.16 2 294 2 065 2 026 1 764 1 599 0.4 0.3 P02CA03 albendazole (0.4 0.00 0.00 0.00 0.00 P02CF Avermectines 0.00 0.00 0.01 0.03 0.03 324 769 3 552 12 430 14 819 0.1 2.8 P02CF01 ivermectin (12 mg) 0.00 0.00 0.01 0.03 0.03 324 769 3 552 12 430 14 819 antinematodals 0.00 0.00 0.00 0.00 (0.35 g) 0.00 0.00 0.00 0.00 0.00 177 167 180 184 67 0.0 0.0 126 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 Salicylic acid derivatives 0.00 0.00 0.00 0.00 0.00 22 16 24 (2 g) 0.00 0.00 0.00 0.00 0.00 22 16 24 26 23 0.0 0.0 number of packages ATC 2017 2018 2019 2020 2021 P03 INCL. 82 741 140 293 102 218 3 561 3 681 4 977 6 019 7 606 0.7 1.4 P03A ECTOPARASITICIDES, INCL. SCABICIDES 50 164 47 209 82 741 140 293 102 218 3 561 3 681 4 977 6 019 7 606 0.7 1.4 P03AA Sulfur containing products 7 630 0 0 0 165 2 561 0.0 0.5 P03AA54 disulfiram, combinations 863 7 630 0 0 0 165 2 561 0.0 0.5 P03AC Pyrethrines, incl. synthetic compounds 41 770 46 007 80 644 128 787 78 325 3 507 3 622 4 837 5 420 4 322 0.7 0.8 P03AC04 permethrin 41 770 46 007 80 644 128 787 78 325 3 507 3 622 4 837 5 420 4 322 0.7 0.8 P03AX Other ectoparasiticides, incl. scabicides 8 394 1 202 2 097 11 506 16 263 71 73 187 557 1 087 0.0 0.2 P03AX01 benzyl benzoate 33% 485 1 202 2 097 11 506 16 263 44 73 187 557 1 087 0.0 0.2 P03AX03 malathion 7 909 27 0 0 0 0 0.0 0.0 127 4.13 gruppe ATC gruppe m\u00e5lt i 39 %, 30 % og 27 % av solgt DDD in nen ATC gruppe R. utlevert legemiddelet gikk ned fra 260 000 i 2019 til 130 000 128 i 2020, men \u00f8kte igjen i 2021 til 1 133% fra 2017 til 2021 . Figure 4.13 .1 Sales of inhalation products for the treatment of obstructive lung disease (R03A and R03B) in 2017 -2021. Source: Anticholinergics (R03AK)Adrenergics in 2019 2020 2021 129 Figure 4.13.2 : Proportion of the population (prevalence, %) who had dispensed at least one antiallergic drug (R06A, R01AC, R01AD, R01B, S01G) in the solgt mens i topp\u00e5ret 2015 ble det solgt mer enn 121 000 pakninger. Kenacort T har indikasjoner tilsvarende trepollen j\u00f8rk) slikt legemiddel, p\u00e5 bl\u00e5resept fra 2020. 02468101214161820 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021Proportion (%) of the population Year 130 Figure 4.13. 3: Number of users who had dispensed at least one allergen extract for the treatment of grass pollen (V01AA02) or tree pollen (V01AA05) allergy in the last 10 years. Source: Norwegian Prescription Database 00,511,522,533,5 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021Proportion () of the populationGrass pollen (V01AA02) Tree pollen (V01AA05) 131 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 87.6 99.0 64.94 72.30 395 123 405 2 698 3 486 0.6 0.7 R01AA05 oxymetazoline (0.4 mg) 1.00 0.88 0.88 0.91 0.79 1 563 2 241 2 388 1 641 2 294 0.3 0.4 R01AA07 xylometazoline (0.8 mg) 36.63 39.52 1 746 0.3 0.2 R01AB Sympathomimetics, combinations excl. corticosteroids 1.99 1.83 1.90 1.46 382 403 361 0.1 0.1 R01AB06 xylometazoline (0.8 mg) 1.99 1.83 1.90 1.46 1.64 435 382 403 325 361 0.1 0.1 R01AC Antiallergic agents, excl. corticosteroids 1.08 0.98 1.11 1.21 1.36 46 164 45 902 50 805 52 188 58 521 8.8 10.9 R01AC01 cromoglicic acid (40 mg) 0.16 0.06 7 607 4 927 <5 0 0 1.5 0.0 R01AC02 levocabastine (0.6 mg) 0.92 0.92 1.11 1.21 1.36 38 774 41 371 50 803 52 188 10 11 0.0 0.0 R01AD05 budesonide (0.2 mg) 2.21 2.02 2.30 1.10 0.94 25 004 20 345 18 032 13 112 10 382 4.8 1.9 R01AD08 fluticasone (0.2 mg) 1.81 1.65 1.63 1.98 1.88 21 209 20 342 21 776 21 798 22 445 4.0 4.2 R01AD09 mometasone (0.2 mg) 9.62 10.11 10.73 11.09 11.78 171 090 176 302 190 474 183 890 197 592 32.5 36.7 R01AD11 triamcinolone (0.22 mg) 0.30 0.28 0.28 0.29 0.26 5 719 5 523 5 608 5 208 5 321 1.1 1.0 R01AD12 fluticasone furoate (0.11 mg) 3.64 3.55 3.79 3.93 4.04 92 014 91 495 98 912 99 053 102 451 17.5 19.0 R01AD58 fluticasone, combinations 2.45 3.02 3.94 55 895 67 754 90 619 100 731 117 182 10.6 21.7 R01AX Other nasal preparations 0.02 0.02 0.03 0.03 0.03 1 923 2 047 2 123 2 021 1 945 0.4 0.4 R01AX03 ipratropium bromide (0.24 mg) 0.02 0.02 0.03 0.03 0.03 791 910 1 024 1 042 1 231 0.2 0.2 R01AX06 mupirocin - - - - - 1 134 1 137 1 099 979 714 0.2 0.1 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 1.44 1.36 1.44 1.02 1.15 105 358 106 140 112 359 71 332 83 500 20.0 15.5 R01BA Sympathomimetics 1.44 1.36 1.44 1.02 1.15 105 358 106 140 112 359 71 332 83 500 20.0 15.5 R01BA01 phenylpropanolamine (0.1 g) 1.44 1.36 1.44 1.02 1.15 105 358 106 140 112 359 71 332 83 500 20.0 15.5 R02 THROAT PREPARATIONS 1.07 1.14 1.16 0.73 0.74 959 718 859 448 563 0.2 0.1 R02A THROAT PREPARATIONS 1.07 1.14 1.16 0.73 0.74 959 718 859 448 563 0.2 0.1 R02AA Antiseptics 0.24 0.17 0.05 0.00 0.00 242 174 104 24 <5 0.1 - R02AA03 dichlorobenzyl alcohol (6 tab) 0.24 0.17 0.05 0.00 242 174 104 24 <5 0.1 - R02AX Other preparations 0.83 0.97 1.11 0.1 R02AX01 flurbiprofen (44 mg) 0.09 0.15 0.17 0.12 0.12 90 105 166 134 132 0.0 0.0 R02AX03 benzydamine (9 mg) 0.74 0.82 0.94 0.60 0.62 639 456 603 294 427 0.1 0.1 132 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 68.86 67.65 457 872 422 712 426 183 78.1 79.1 R03AA Alpha - and beta - adrenoreceptor agonists 0.01 0.01 0.01 0.00 0.00 52 55 32 35 30 0.0 0.0 R03AA01 epinephrine 0.01 0.01 0.01 0.00 0.00 52 55 32 35 30 0.0 0.0 -2- adrenoreceptor agonists 16.53 311 310 534 58.8 57.6 R03AC02 mg solution) 12.38 12.32 12.88 12.62 12.34 270 499 274 667 278 831 280 773 51.4 52.1 R03AC03 terbutaline (2 mg aerosol/powder/ 20 mg solution) 1.35 1.24 1.32 1.30 1.18 25 686 23 882 22 509 22 127 19 638 4.9 3.6 R03AC04 fenoterol (0.6 0.00 0.00 0.00 0.00 0.00 11 13 13 mg aerosol/powder 0.85 0.82 0.79 0.79 0.74 8 238 8 111 7 881 7 684 7 377 1.6 1.4 9 400 9 088 8 323 2.0 1.5 R03AC18 indacaterol (0.15 mg) 0.86 0.74 0.63 0.54 0.48 5 163 4 402 3 775 3 279 2 852 1.0 0.5 R03AC19 olodaterol (5 mcg inhal sol) 0.11 0.11 0.12 0.13 0.13 1 029 1 070 1 114 1 058 1 041 0.2 0.2 R03AK Adrenergics in 434 37.3 37.2 R03AK06 salmeterol and fluticasone 8.90 8.29 7.56 7.42 6.88 78 843 73 829 70 729 68 863 64 968 15.0 12.1 R03AK07 formoterol and budesonide 7.66 7.45 7.19 7.16 6.78 78 736 75 828 73 355 73 159 69 R03AK08 formoterol and beclometasone 1.61 1.90 2.19 2.49 2.78 17 061 20 625 23 854 27 015 30 414 3.2 5.6 R03AK10 vilanterol and fluticasone furoate 3.08 3.56 3.97 4.33 4.43 166 30 322 34 015 35 810 37 082 5.0 0.39 4 482 4 767 5 039 5 065 5 002 0.9 0.9 R03AL Adrenergics in combination with 3.91 5.21 5.84 6.63 22 168 28 395 35 286 39 146 44 241 4.2 8.2 R03AL03 vilanterol and umeclidinium bromide 0.81 1.02 1.20 1.25 1.29 6 634 8 310 9 174 9 261 9 761 1.3 1.8 R03AL04 indacaterol and glycopyrronium bromide 1.04 1.00 0.89 0.77 0.70 7 435 6 766 5 956 5 184 4 661 1.4 0.9 R03AL05 formoterol and aclidinium 2 463 0.5 0.4 R03AL06 olodaterol and tiotropium bromide 0.70 0.98 1.27 1.35 1.40 5 969 7 631 9 040 9 686 10 146 1.1 1.9 R03AL07 formoterol and glycopyrronium bromide 0.03 0.10 0.15 0 0 458 985 1 372 0.0 0.3 R03AL08 vilanterol, umeclidinium bromide and fluticasone furoate 0.16 0.65 0.86 1.02 0 1 802 5 167 6 208 7 387 0.0 1.4 R03AL09 0.85 1.22 1.69 337 3 221 6 270 8 637 11 849 0.1 2.2 133 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 and 0.0 0.1 R03AL12 indacaterol, glycopyrronium bromide and mometasone 0.05 0 0 0 <5 434 0.0 0.1 R03B OTHER DRUGS FOR OBSTRUCTIVE 19.20 18.25 157 402 31.5 29.2 R03BA Glucocorticoids 7.97 7.66 7.74 7.82 7.64 103 028 102 567 103 183 98 962 101 435 19.6 18.4 R03BA01 beclometasone (0.8 mg) 0.14 0.13 0.14 0.13 0.12 3 817 3 889 3 860 3 743 3 547 0.7 0.7 R03BA02 budesonide (0.8 mg) 1.43 1.31 1.24 1.20 1.10 16 579 15 784 15 185 14 685 13 532 3.2 2.7 R03BA05 fluticasone (0.6 mg) 2.64 2.58 2.52 2.50 2.41 67 460 67 035 67 778 63 315 66 730 12.8 11.8 R03BA07 mometasone (0.4 mg) 0.04 0.04 0.04 0.04 0.03 348 348 331 314 307 0.1 0.1 R03BA08 ciclesonide (0.16 mg) 3.72 3.60 3.81 3.95 3.98 16 702 17 330 17 635 18 18 3.2 3.4 R03BB Anticholinergics 12.99 12.38 12.19 11.38 10.61 69 975 69 276 67 424 64 526 62 825 13.3 12.0 R03BB01 ipratropium bromide (0.12 mg powder/aerosol/ 6.22 6.15 5.89 5.47 30 696 31 013 31 498 31 183 30 720 5.8 5.8 R03BB04 tiotropium 36 258 957 30 828 7.2 6.0 R03BB05 aclidinium bromide (0.644 mg) 0.37 0.33 0.28 0.25 0.22 2 929 2 575 2 210 1 915 1 704 0.6 0.4 R03BB06 glycopyrronium bromide (44 mcg) 0.25 0.22 0.19 0.16 0.14 1 705 1 506 1 283 1 089 923 0.3 umeclidinium bromide (55 mcg) 0.39 0.46 0.41 0.40 0.37 072 3 589 3 228 2 973 2 781 0.6 0.0 0.0 R03BC01 cromoglicic acid (40 mg aerosol/ 80 mg powder/solution) 0.00 0.00 0.00 0.00 10 28 35 25 13 0.0 R03C ADRENERGICS FOR SYSTEMIC USE 0.16 0.11 0.08 0.07 0.07 4 772 3 574 2 585 1 401 1 503 0.9 0.3 R03CA Alpha - and beta - adrenoreceptor agonists 0.10 0.08 0.07 0.07 0.07 3 636 2 746 2 232 1 192 1 302 0.7 0.2 R03CA02 ephedrine (50 mg) 0.10 0.08 0.07 0.07 0.07 3 636 2 746 2 232 1 192 1 302 0.7 0.2 R03CC Selective beta -2- adrenoreceptor agonists 0.06 0.03 0.01 0.00 0.00 1 161 845 360 215 208 0.2 salbutamol (12 mg) 0.00 0.00 0.00 0.00 286 147 153 terbutaline (15 mg) 0.04 0.02 0.00 0.00 0.00 536 342 73 69 52 0.1 0.0 R03CC12 bambuterol (20 mg) 0.01 0.01 150 145 0 0 0 0.0 0.0 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 5.41 5.46 5.56 5.79 5.85 39 924 39 923 40 875 41 798 42 489 7.6 7.8 R03DA Xanthines 0.43 0.37 0.32 0.28 0.25 2 017 1 874 1 611 1 376 1 206 0.4 0.3 R03DA04 theophylline (0.4 g) 0.43 0.37 0.32 0.28 0.25 2 006 1 865 1 604 1 370 1 197 0.4 (0.6 g) 0.00 0.00 0.00 0.00 receptor antagonists 4.66 4.73 4.80 5.01 5.03 36 373 36 185 36 955 37 585 37 768 6.9 R03DC01 zafirlukast (40 mg) 0.00 0.00 0.00 13 14 13 R03DC03 montelukast (10 mg) 4.65 4.72 4.80 5.01 5.03 36 357 36 171 36 942 37 571 37 755 6.9 7.0 134 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 R03DX Other systemic drugs for obstructive airway diseases 0.32 0.37 0.43 0.50 0.57 2 691 3 066 3 636 4 277 5 011 0.5 0.8 R03DX05 omalizumab (16 mg) 0.15 0.17 0.21 0.25 0.31 1 519 1 812 2 214 2 702 3 294 0.3 0.5 R03DX07 roflumilast (0.5 mg) 0.15 0.15 0.14 0.14 0.13 997 981 946 837 820 0.2 0.2 R03DX08 reslizumab (7.1 mg) 0.00 0.01 0.00 0.00 <5 17 12 9 0 - 0.0 R03DX09 mepolizumab (3.6 mg) 0.02 0.04 0.06 0.10 0.12 197 247 443 704 856 0.0 0.1 R03DX10 benralizumab (0.54 mg) 0.00 0.01 0.01 0.02 0 34 78 89 112 0.0 0.0 R05 COUGH AND COLD PREPARATIONS 10.47 10.53 10.45 7.86 8.63 389 149 385 142 381 215 314 273 825 74.0 50.8 R05C EXPECTORANTS, SUPPRESSANTS 7.70 7.69 7.61 6.29 6.53 101 730 98 301 96 031 68 101 72 229 19.4 13.4 R05CA Expectorants 1.43 1.27 1.19 0.78 0.81 5 064 4 035 4 005 2 220 3 178 1.0 0.6 R05CA10 combinations 1.43 1.27 1.19 0.78 0.81 5 064 4 035 4 005 2 220 3 178 1.0 0.6 R05CB Mucolytics 6.27 6.42 6.42 5.51 5.72 66 347 69 669 18.5 12.9 R05CB01 17.7 12.2 R05CB02 (24 mg) 1.51 1.47 1.45 1.10 1.32 4 689 4 927 4 487 2 733 4 010 0.9 0.7 R05CB13 dornase alfa (desoxyribonuclease) (2.5 mg) 0.02 0.02 0.02 0.03 0.03 165 182 191 192 197 0.0 0.0 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 2.25 2.31 2.31 1.29 1.74 273 933 271 087 268 764 137 971 189 169 52.1 35.1 R05DA Opium alkaloids and derivatives 2.25 2.31 2.31 1.29 1.74 273 933 271 087 268 764 137 971 189 169 52.1 35.1 R05DA01 ethylmorphine (50 1.34 265 341 262 533 259 897 130 (0.1 g) 0.08 0.08 0.08 0.09 0.10 6 853 6 858 7 181 6 961 8 273 1.3 1.5 R05DA07 noscapine (0.125 g) 0.81 0.92 0.95 0.52 0.75 2 270 2 102 2 463 1 426 1 990 0.4 0.4 R05DA20 combinations 0.02 0.02 0.01 0.01 0.01 2 369 2 265 2 048 938 935 0.5 0.2 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 0.52 0.53 0.53 0.29 0.36 55 933 56 948 57 425 28 492 35 606 10.6 6.6 R05FA Opium derivatives and expectorants 0.52 0.53 0.53 0.29 0.36 55 933 56 948 57 425 28 492 35 606 10.6 6.6 R05FA02 opium derivatives and expectorants 0.52 0.53 0.53 0.29 0.36 55 933 56 948 57 425 28 492 35 606 10.6 6.6 R06 Aminoalkyl ethers 0.15 0.19 0.23 0.24 0.42 8 784 9 372 10 235 11 210 17 998 1.7 3.3 R06AA02 diphenhydramine (2 mg) 0.00 0.00 0.00 0.00 19 21 21 0.0 0.0 R06AA09 doxylamine (25 mg) 0.15 0.19 0.23 0.24 0.42 8 741 9 303 10 186 11 152 17 925 1.7 3.3 R06AA52 diphenhydramine, combinations - - - - - 20 14 0 0 0 0.0 0.0 R06AB Substituted alkylamines 0.16 0.16 0.14 0.15 0.14 5 347 4 573 4 299 3 796 3 544 1.0 0.7 R06AB02 dexchlorpheniramine (6 mg) 0.16 0.16 0.14 0.15 0.14 5 347 4 573 4 299 3 796 3 544 1.0 0.7 135 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 702 74 512 78 985 82 606 59 117 13.8 11.0 R06AD01 alimemazine (30 mg) 2.98 2.96 3.04 3.39 2.94 66 923 68 855 73 109 75 902 46 382 12.7 8.6 R06AD02 promethazine (25 mg) 1.18 1.13 1.12 1.26 2.38 6 324 6 186 6 438 8 187 17 044 1.2 3.2 R06AE Piperazine derivatives 35.30 35.64 37.43 39.22 40.32 291 698 313 227 55.4 58.1 R06AE03 cyclizine (0.1 g) 0.17 0.03 0.01 0.06 0.08 1 098 475 93 379 833 0.82 3 838 4 355 5 046 5 352 6 023 0.7 1.1 R06AE07 cetirizine (10 mg) 34.29 34.68 36.49 38.36 306 471 54.5 56.8 R06AE09 levocetirizine (5 mg) 0.08 0.07 0.07 0.07 0.09 612 602 609 634 686 0.1 0.1 343 951 369 0.00 0.00 loratadine (10 mg) 5.97 5.77 5.88 6.00 5.88 54 389 52 598 53 363 52 756 52 063 10.3 9.7 R06AX17 ketotifen (2 mg) 0.00 0.00 0.00 (10 mg) 1.97 1.97 2.19 2.39 2.60 12 808 13 182 14 694 15 789 16 938 2.4 3.1 R06AX26 fexofenadine (12 mg) 5.56 5.80 6.59 7.44 7.85 42 308 44 851 50 127 55 468 61 172 8.1 11.4 R06AX27 desloratadine (5 mg) 20.33 22.34 26.55 29.71 33.63 243 334 267 222 311 465 337 003 370 321 46.3 68.7 R06AX28 0.00 23 25 33 49 69 0.0 0.0 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 0.01 0.01 0.01 0.01 0.01 49 57 65 62 60 0.0 0.0 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0.01 0.01 0.01 0.01 0.01 49 57 65 62 60 0.0 0.0 R07AX Other respiratory system products 0.01 0.01 0.01 0.01 0.01 41 45 49 48 49 0.01 0.01 R07AX02 ivacaftor (0.3 g) 0.00 0.00 0.00 0.00 16 R07AX30 ivacaftor and lumacaftor (4 tab) 0.00 0.00 0.01 0.01 0.00 28 30 32 32 31 0.01 136 DDD og er midler ikke inkludert i hovedtabellen. Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 119.0 S01A ANTIINFECTIVES - - - - - 243 441 238 057 243 137 195 321 201 389 46.3 37.4 S01AA Antibiotics - - - - - 239 977 234 634 239 489 192 352 198 692 45.6 36.9 S01AA01 chloramphenicol - - - - - 193 942 193 285 200 108 163 886 169 018 36.9 31.4 S01AA11 gentamicin - - - - - 17 24 22 27 18 0.0 0.0 S01AA12 tobramycin - - - - - 1 293 1 260 1 076 913 846 0.3 0.2 S01AA13 fusidic acid - - - - - 48 485 41 986 38 966 25 653 26 197 9.2 4.9 S01AA26 azithromycin - - - - - 5 330 4 876 4 564 3 101 2 832 1.0 0.5 S01AA30 combinations of different antibiotics - - - - - 6 446 8 651 9 932 10 937 11 170 1.2 2.1 S01AD Antivirals - - - - - 3 375 3 300 3 191 2 734 2 279 0.6 0.4 S01AD03 aciclovir - - - - - 3 374 3 299 3 188 2 732 2 278 0.6 0.4 S01AE Fluoroquinolones - - - - - 3 082 3 016 3 346 2 691 2 752 0.6 0.5 S01AE03 ciprofloxacin - - - - - 3 082 3 016 3 346 2 689 2 746 0.6 0.5 S01AE07 moxifloxacin - - - - - 0 0 0 <5 6 0.0 0.0 S01AX Other antiinfectives - - - - - <5 5 7 13 <5 - - S01AX18 povidone -iodine - - - - <5 <5 10 0 <5 - - S01B ANTIINFLAMMATORY AGENTS - - - - - 67 149 70 182 77 071 75 793 80 287 12.8 14.9 S01BA Corticosteroids, plain - - - - - 48 920 53 707 61 287 60 334 64 534 9.3 12.0 S01BA01 dexamethasone - - - - - 36 013 37 430 41 254 39 466 42 811 6.9 7.9 S01BA02 hydrocortisone - - - - - 60 4 618 7 419 7 953 7 880 0.0 1.5 S01BA04 prednisolone - - - - - 17 943 18 288 20 193 20 520 21 284 3.4 4.0 S01BA07 fluorometholone - - - - - 17 16 16 16 14 0.0 0.0 S01BA09 clobetasone - - - - - 14 13 13 14 12 0.0 0.0 S01BA13 rimexolone - - - - - 83 0 0 0 0 0.0 0.0 S01BC Antiinflammatory agents, non -steroids - - - - - 28 399 29 078 30 564 29 740 31 894 5.4 5.9 S01BC03 diclofenac - - - - - 7 732 7 782 9 009 8 869 8 636 1.5 1.6 S01BC10 nepafenac - - - - - 17 423 17 753 18 092 17 091 18 377 3.3 3.4 S01BC11 bromfenac - - - - - 3 545 4 061 3 938 4 045 5 173 0.7 1.0 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION - - - - - 43 762 43 174 40 541 39 750 40 545 8.3 7.5 S01CA Corticosteroids and antiinfectives in combination - - - - - 43 762 43 174 40 541 39 750 40 545 8.3 7.5 S01CA01 dexamethasone and antiinfectives - - - - - 43 762 43 174 40 541 39 750 40 545 8.3 7.5 S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS 19.02 19.38 19.28 19.50 19.52 099 76 885 80 754 14.5 15.0 S01EA Sympathomimetics in glaucoma therapy 0.70 0.65 0.67 0.66 0.65 4 787 4 647 4 752 4 802 4 783 0.9 0.9 S01EA03 apraclonidine 0.01 0.01 0.01 0.01 0.01 205 178 224 237 272 0.0 0.1 138 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 571 4 620 4 577 0.9 0.9 S01EB Parasympathomimetics 0.04 0.04 0.04 0.04 0.03 910 841 858 804 823 0.2 0.2 S01EB01 pilocarpine (0.4 0.04 0.04 0.03 858 804 823 0.2 1.90 2.02 2.13 2.23 2.34 13 374 13 984 14 820 14 684 15 178 2.5 2.8 S01EC01 acetazolamide (0.75 g) 0.11 0.11 0.13 0.11 0.12 2 065 2 107 2 253 1 726 1 637 0.4 0.3 S01EC02 diclofenamide (0.1 g) 0.00 0.00 0.00 0.00 0 7 10 11 15 0.0 0.0 S01EC03 dorzolamide (0.3 ml) 0.43 0.46 0.52 0.60 0.70 3 152 3 443 3 777 4 292 4 586 0.6 0.9 S01EC04 brinzolamide (0.2 ml) 1.08 1.14 1.06 1.06 1.03 7 290 7 108 7 205 6 851 6 798 1.4 1.3 S01EC54 brinzolamide, combinations 0.28 0.31 0.43 0.46 0.49 2 062 2 594 2 936 3 151 3 541 0.4 0.7 S01ED Beta blocking agents 10.21 10.40 10.19 10.40 10.35 51 703 52 160 53 151 53 778 55 130 9.8 10.2 S01ED01 timolol 4.94 4.79 4.40 4.43 4.18 21 098 20 267 19 563 19 357 4.0 3.6 S01ED02 betaxolol 0.12 0.11 0.10 0.08 0.07 723 combinations 5.15 5.50 5.68 5.88 6.10 32 044 33 251 34 694 35 904 37 576 6.1 7.0 S01EE Prostaglandin analogues 6.17 6.27 6.26 6.17 6.15 38 665 38 696 39 101 38 996 39 512 7.4 7.3 S01EE01 latanoprost 3.88 3.86 3.90 3.97 4.00 24 257 24 S01EE03 bimatoprost 0.41 0.43 444 2 604 2 564 2 496 0.5 0.5 S01EE04 travoprost 0.65 0.69 0.56 0.51 0.43 4 520 4 026 3 633 3 231 2 861 0.9 0.5 S01EE05 tafluprost 1.24 1.31 1.36 1.28 1.30 8 197 8 698 9 384 9 177 9 330 1.6 1.7 S01F MYDRIATICS AND CYCLOPLEGICS - - - - - 4 995 4 918 5 061 4 912 5 407 1.0 1.0 S01FA Anticholinergics - - - - - 4 976 4 910 5 048 4 885 5 394 1.0 1.0 S01FA01 atropine - - - - - 1 336 1 120 1 075 1 245 904 0.3 0.2 S01FA04 cyclopentolate - - - - - 3 749 3 907 4 006 3 444 4 555 0.7 0.8 S01FA06 tropicamide - - - - - 86 93 156 461 142 0.0 0.0 S01FA54 cyclopentolate, combinations - - - - - <5 9 <5 9 0 - 0.0 S01FB Sympathomimetics excl. antiglaucoma preparations - - - - - 51 30 37 46 24 0.0 0.0 S01FB01 phenylephrine - - - - - 51 30 37 46 24 0.0 0.0 S01G DECONGESTANTS AND ANTIALLERGICS - - - - - 201 407 202 111 236 257 232 735 255 411 38.3 47.4 S01GA Sympathomimetics used as decongestants - - - - - 20 161 19 732 23 417 21 838 22 833 3.8 4.2 S01GA01 naphazoline - - - - - 12 11 21 11 17 0.0 0.0 S01GA52 tetryzoline, combinations - - - - - 20 152 19 723 23 400 21 828 22 817 3.8 4.2 S01GX Other antiallergics - - - - - 185 118 186 024 218 054 215 693 237 803 35.2 44.1 S01GX01 cromoglicic acid - - - - - 23 718 22 328 25 368 22 358 24 199 4.5 4.5 S01GX02 levocabastine - - - - - 97 537 98 785 114 471 114 971 125 808 18.6 23.3 S01GX06 emedastine - - - - - 413 430 497 507 532 0.1 0.1 S01GX08 ketotifen - - - - - 23 557 24 107 30 054 29 636 32 743 4.5 6.1 S01GX09 olopatadine - - - - - 45 550 45 756 55 332 55 087 62 073 8.7 11.5 139 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 S01H LOCAL ANESTHETICS - - - - - 111 123 135 164 191 0.0 0.0 S01HA Local anesthetics - - - - - 111 123 135 164 191 0.0 0.0 S01HA02 oxybuprocaine - - - - - 85 100 99 127 156 0.0 0.0 S01HA03 tetracaine - - - - - 13 16 20 11 14 0.0 0.0 S01HA04 proxymetacaine - - - - - 13 10 17 29 26 0.0 0.0 S01J DIAGNOSTIC AGENTS - - - - - 32 31 36 28 21 0.0 0.0 S01JA Colouring agents - - - - - 32 31 36 28 21 0.0 0.0 S01JA01 fluorescein - - - - - 31 30 33 26 21 0.0 0.0 S01X OTHER OPHTHALMOLOGICALS - - - - - 79 807 88 992 98 296 105 619 116 904 15.2 21.7 S01XA Other ophthalmologicals - - - - - 79 807 88 992 98 296 105 619 116 904 15.2 21.7 S01XA03 sodium chloride, hypertonic - - - - - 39 63 105 113 103 0.0 0.0 S01XA18 ciclosporin - - - - - 2 697 3 881 4 252 4 807 5 945 0.5 1.1 S01XA20 artificial tears and other indifferent preparations - - - - - 79 216 87 932 97 241 104 551 115 546 15.1 21.4 S01XA21 mercaptamine - - - - - 6 10 10 10 9 0.0 0.0 S01XA25 lifitegrast - - - - - 0 6 26 17 <5 0.0 - S02 OTOLOGICALS - - - - - 19 013 21 659 28 244 31 307 36 144 3.6 6.7 S02A ANTIINFECTIVES - - - - - 5 224 4 987 4 676 3 669 3 587 1.0 0.7 S02AA Antiinfectives - - - - - 5 224 4 987 4 676 3 669 3 587 1.0 0.7 S02AA03 boric acid - - - - - 20 5 <5 <5 <5 0.0 - S02AA15 ciprofloxacin - - - - - 5 204 4 983 4 672 3 668 3 586 1.0 0.7 S02B CORTICOSTEROIDS - - - - - <5 0 5 377 9 495 12 553 - 2.3 S02BA Corticosteroids - - - - - <5 0 5 377 9 495 12 553 - 2.3 S02BA07 betamethasone - - - - - <5 0 3 712 6 057 7 173 - 1.3 S02BA08 fluocinolone acetonide - - - - - 0 0 1 703 3 524 5 543 0.0 1.0 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION - - - - - 14 369 17 171 19 308 19 597 21 735 2.7 4.0 S02CA Corticosteroids and antiinfectives in combination - - - - - 14 369 17 171 19 308 19 597 21 735 2.7 4.0 S02CA02 flumetasone and antiinfectives - - - - - 59 <5 42 44 14 0.0 0.0 S02CA05 fluocinolone acetonide and antiinfectives - - - - - 14 314 17 169 19 270 19 554 21 723 2.7 4.0 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS - - - - - 75 534 74 841 74 063 64 206 65 110 14.4 12.1 S03B CORTICOSTEROIDS - - - - - 1 352 1 429 800 349 186 0.3 0.0 S03BA CORTICOSTEROIDS 1 352 1 429 800 349 186 0.3 0.0 S03BA03 betamethasone - - - - - 1 352 1 429 800 349 186 0.3 0.0 140 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION - - - - - 74 488 73 693 73 385 63 916 64 953 14.2 12.1 S03CA Corticosteroids and antiinfectives in combination - - - - - 74 488 73 693 73 385 63 916 64 953 14.2 12.1 S03CA01 dexamethasone and antiinfectives - - - - - 10 854 9 588 8 414 5 562 6 230 2.1 1.2 S03CA04 hydrocortisone and antiinfectives - - - - - 65 319 65 569 66 243 59 331 59 711 12.4 11.1 141 4.15 V Varia V01 Allergener \u00f8kning \u00e5rene; fra 1 569 pakninger \u00e5r 2000 til 90 599 pakninger av preparater til hyposensibilisering kap R Respirasjonsorganer. 142 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2021 Numbers of 2017 2018 2019 2020 2021 V VARIOUS V01 ALLERGENS 14 582 16 203 18 981 23 711 29 570 2.8 5.5 V01A ALLERGENS 38 110 44 034 52 573 68 990 90 599 14 582 16 203 18 981 23 711 29 570 2.8 5.5 V01AA Allergen extracts 38 110 44 034 52 573 68 990 90 599 14 582 16 203 18 981 23 711 29 570 2.8 5.5 V01AA02 grass pollen 24 275 27 020 30 772 36 573 43 306 11 002 12 021 13 800 16 263 18 840 2.1 3.5 V01AA03 house dust mites 2 052 3 776 5 914 7 053 8 570 933 1 544 2 180 2 710 3 267 0.2 0.6 V01AA05 tree pollen (bj\u00f8rk) 10 232 11 260 13 039 22 243 35 186 6 259 6 585 7 227 10 703 15 188 1.2 2.8 V01AA07 insects 510 552 623 670 680 144 136 144 157 156 0.0 0.0 V01AA10 flowers 36 151 164 209 <5 10 32 35 43 - 0.0 V01AA11 animals 1 041 1 390 2 074 2 287 2 648 513 581 712 809 921 0.1 0.2 DDD/1000 inhabitants/day 2017 2018 2019 2020 PRODUCTS 0.30 0.33 0.40 0.48 0.54 3 866 4 205 4 719 5 210 5 747 0.7 1.1 V03A ALL OTHER THERAPEUTIC PRODUCTS 0.30 0.33 0.40 0.48 0.54 3 866 4 205 4 719 5 210 5 747 0.7 1.1 V03AB Antidotes - - - - - 82 122 87 98 64 0.0 0.0 V03AC Iron chelating agents - - - - - 144 157 188 205 196 0.03 0.04 V03AC01 deferoxamine - - - - - 31 26 26 32 35 0.01 0.01 V03AC02 deferiprone - - - - - 21 23 25 30 37 0.00 0.01 V03AC03 deferasirox - - - - - 109 122 158 169 156 0.02 0.03 V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 0.25 0.27 0.33 0.39 0.45 2 965 3 072 3 466 3 735 4 118 0.56 0.76 V03AE01 polystyrene sulfonate (45 g) 0.03 0.03 0.02 0.01 0.01 951 876 683 376 234 0.18 0.04 V03AE02 sevelamer (6.4 g 0.14 0.15 0.16 0.16 0.17 1 987 2 014 2 126 2 228 2 380 0.38 0.44 V03AE03 lanthanum carbonate (2.25 g) 0.07 0.07 0.07 0.07 0.07 562 590 592 649 615 0.11 0.11 V03AE04 calcium acetate and oxyhydroxide (1.5 g) 0.01 0.01 0.01 0.01 0.01 122 115 119 120 110 0.02 0.02 V03AE09 patiromer calcium (8.4 g) 0.02 0.07 0.07 0.05 <5 257 747 606 393 - 0.07 V03AE10 sodium zirconium cyclosilicate (7.5 g) 0.00 0.01 0.07 1 61 38 35 41 41 0.01 0.01 V03AF01 mesna - - - - - 10 12 8 5 9 0.00 0.00 V03AF03 calcium folinate (60 mg) 0.06 0.06 0.07 51 26 27 36 mg) 0.00 for treatment - - - 0.01 0.01 579 736 865 1 030 1 255 0.11 0.23 V03AG05 sodium phosphate (8 g) 0.01 0.01 579 736 865 1 030 1 255 0.11 0.23 og med dagligvaregrossister. Lovhjemler : Fra m\u00e5ned. til dags dato et som s\u00e5kalt alle historiske v\u00e6rt tilgjengelig 1994 Finland Danmark, og siden legemidler for (hjemlet i ases 10 (ICD -10) eller International Classification of Primary ATC/DDD- systemet anbefalt av WHO og i 1982 opprettet WHO et koordineringssen ter ved Norsk medisinaldepot ( WHO Collaborating Centre for Drug Statistics Methodology ) med tilknytning til WHOs Europakontor med medlemmer fra 12 ulike land. Bakgrunnen for opprettelse av DDD er at statistikk i (kroner) for ATC classification and DDD assignment (https://www.whocc.no/filearchive/publications/2021_guidelines_web.pdf ) for mer informasjon. 1) Sommerschild et al. Data resource profile: Norwegian Drug and Pharmacoepidemiology . 2021;29(1 146 (per 1. januar) Year 2017 2018 2019 2020 2021 Population 5 276 847 5 311 797 5 328 212 5 367 580 5 391 369 Men Women 2021 2 719 259 Statistisk H\u00f8ivik ML. First -line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scand J Gastroenterol. 2021;56(10):1163 -8. Askar M, Ca\u00f1adas RN, Svendsen K. An introduction to network analysis for studies of medication use. Res Social Adm Pharm. 2021;17(12):2054 -61. Bachmann CS, Risnes Association of Preterm Birth With Prescription of Psychot ropic Drugs in Adolescence and Young Adulthood. JAMA 2021;4(3):e211420. Beckstr\u00f8m S, Svendsen K, Sm\u00e5brekke L. Antibacterial use by birth year and birth season in children 0 -2 years in Norway. Norsk epidemiologi. 2021;29(1 -2):35- 43. Binde CD, Tvete IF, Klemp M. Time until Need for Levodopa among New Users of Dopamine Agonists or MAO- B Inhibitors. Parkinsons Dis. 2021;2021:9952743. av antibiotika under covid -19- pandemien. (Use of antibiotics I, Raaum O. Impact of the School Environment on Medical Treatment of Attention Deficit Hyperactivity Disorder: A Population -Wide Register Data Study of School -Wide Positive Behavioral Interventions and Supports. Child Dev. 2021;92(5):2089 -105. Brakedal B, Tzoulis C, Tysnes OB, Haugarvoll use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. PLoS One. TE. Metformin use and lung cancer survival: a population -based study in Norway. Br J Cancer. 2021;124(5):1018 -25. Buajordet I, Kildemoes HW, Kristiansen IS. Societal cost of cancer in Norway -Results of taking a broader cost perspective. Health Policy. 2021;125(8):1100 -7. B\u00e4ckryd E, Heilig M, Hoffmann M. Opioid availability statistics from the International Narcotics Control Board do not reflect the medical use of opioids: comparison with sales data from Scandinavia. Scand J H, Karlsson P. Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia. Acta Obstet Gynecol Scand. Soiland H, Mellgren G, Helland T, H ertz DL. Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. J 2021;11(6):507. Cohen JM, P, Andersen M, Furu Hj ellvik V. A common data model for harmonization in the Nordic Pregnancy Drug Safety Studies (NorPreSS). Norsk epidemiologi. 2021;29(1- 2):117 -123. Dong Sociodemographic Correlates of Human Papillomavirus Vaccine Uptake: Opportunistic and Catch -Up Vaccination in Norway. Cancers (Basel). 2021;13(14):3483. Efjestad AS, Ihle- Hansen H, Hjellvik V, Engedal K, Salvesen Blix H. Sex differences in psychotropic and analgesic drug use before and after initiating treatment with acetylcholinestera se inhibitors. PLoS One. 2021;16(9):e0243804. El Khalil N, Lupattelli A, Nordeng H. Antithyroid drug treatment and pregnancy outcomes among women with hyperthyroidism in pregnancy: A Norwegian population - based registry- Morch K, Ruths S, Rortveit G. Antibiotics for gastroenteritis in general practice and out -of-hour services in Norway 2006 - 15. Fam Hjellvik V, Kv\u00e5le R, Bj\u00f8rge T. Prescribed drugs in 27 000 individuals after diagnosis of colorectal cancer: A population -based cohort study. Pharmacoepidemiol Drug Saf. Fismen KI, Peyrot M, Iversen MM. Pharmacologically treated diabetes and hospitalization among older Norwegians receiving homecare services from 2009 to 2014: a nationwide register study. BMJ Open Diabetes Res Care. 2021;9(1):e002 000. Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5 -aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian co O, L\u00f8yland Kristiansen IS, St\u00f8vring H. Persistence of statin treatment - the impact of analytic method when estimating drug survival. Norsk epidemiologi. 2021;29(1 -2):107 riptions of analgesics during chronic cancer disease trajectories: A complete national cohort study. Pharmacoepidemiol Drug Saf. Furu K, Aares EB, Hjellvik Karlstad contraceptive use in Norway, 2006 -2020, by contraceptiv e 148 type, age and county: J, Bukten A, Clausen T, Skurtveit S. Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. BMJ Open. 2021;11(5):e047028. Ghanima W, Schultze A, Donaldson R, Brodin E, Halvorsen S, Graham S, Carroll R, Ulvestad M, Lambrelli D. Oral Antic oagulation Therapy for Venous -90.e3. Gillis RD, Botteri AI, Chung NC, Pon CK, Shackleford DM, Andreassen BK, Halls ML, Baker JG, Sloan EK. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. Eur J Cancer. 2021;147:106 - 16. G\u00f3mez -Lumbreras A, Morros Pedr\u00f3s R. Psychotropic use in children and adolescents in Scandinavia and Catalonia: a 10 -year population -based study. Psychopharmacology Engdahl B. A possible effect of montelukast on neurological aging examined by the use of register data. Int J Clin Pharm. 2021;43(3):541 -8. Hamina Chen LC, Skurtveit S. Filled prescriptions for opioids among children and adolescents - A nationwide study from 2010 to 2018. Acta Anaesthesiol Scand. 2021;65(10):1475 -83. Hansen Smith - Sivertsen T, Ruths S. GPs' drug treatment for depression by patients' educational registry study. G, Wensaas KA. Consultations and antibiotic treatment for urinary tract infections in Norw egian primary care 2006 E, Nordeng H. Prenatal exposure to non -steroidal anti - inflammatory drugs and risk of attention - deficit/hyperactivity di sorder: A follow -up study in the Norwegian mother, father and child cohort. Pharmacoepidemiol Drug Saf. 2021;30(10):1380 -90. Hoff M, Skovlund Syversen U, Holvik K, Abrahamsen B, Schei B. Does treatment with bisphospho nates protect against fractures in real life? The HUNT study, Norway. Osteoporos Int. 2021;32(7):1395 V, Skurtveit S. Association Between Prescribed Hypnotics in Infants and Toddlers and Later ADHD: A Large Cohort Study from Norway. Child Psychiatry Hum Dev. 2021;52(4):533 -43. Holmberg Following Lumbar Spine Surgery: Observ ational Study with Prospectively Collected Data from Two Norwegian Nationwide Registries. Spine (Phila Pa 1976). 2021. Ianevski A, Yao H, Oksenych V, Tenson T, Bj\u00f8r\u00e5s M, Kainov D. Active Components of Commonly Prescribed Medicines Affect Influenza A Virus -Host Cell Interaction: A Pilot Study. Viruses. 2021;13(8):1537. Indseth V, Telle K, Kj\u00f8llesdal M. COVID -19 among immigrants in Norway, notified infections, related hospitaliza tions and associated mortality: A register -based study. Scand Health. 2021;49(1):48 Sen A. Assessing short -term ris k of ischemic stroke in relation to all prescribed medications. Sci Rep. 2021;11(1):21673. Jensen HK, Rasmussen L, Furu K, Karlstad \u00d8, of non -insulin antidiabetic drugs in children and young adults - A Scandinavian drug utilization study from 2010 -2019. Br \u00c5. COVID -19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population - Based Study From Norway. Front Oncol. 2021;11:652535. Kerola AM, Sexton J, Wibetoe TK, AG. penetration of rheumatoid art hritis and psoriatic arthritis in Norway. \u00d8, to non -vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021 Nystr\u00f6m T, Birkeland KI, Eriksson JW. Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two -Country Nationwide Observational Study. Diabetes Care. 2021;44(5):1211 -8. Laug esen K, Ludvigsson A, S\u00f8rensen HT. Nordic Health Registry -Based Research: A Review of Health Care Systems and Key Epidemiol. 2021;13:533 -54. Lindstad M, K, Melberg HO. Incidence and Prevalence of Inflammatory Bowel Disease in N orway and the Impact of Different Case Definitions: A Nationwide Registry Study. Clin Epidemiol. 2021;13:287 - Reichborn - Kjennerud T, Nordeng H. Attention -deficit/hyperactivity disorder in children following pre natal exposure to antidepressants: results from the Norwegian mother, father and child cohort study. BJOG. 2021;128(12):1917 - 27. Magliano DJ, Chen L, Islam RM, Carstensen B, Gregg EW, Pavkov ME, Andes LJ, Balicer R, M, Hird TR, Jermendy Kim DJ, Kiss Kravchenko VI, Leventer -Roberts M, Lin CY, Luk AOY, Mata -Cases M, Mauricio D, Nichols GA, Nielen MM, Pang D, Paul SK, Pelletier C, Pildava S, Porath A, Read SH, Roncaglioni MC, -Doriga Ruiz P, Shestakova M, Vikulova O, Wang KL, Wild SH, Yekutiel N, Shaw JE. Trends in the incidence of 149 diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in hi gh-income and middle - income settings. Lancet Diabetes Endocrinol. 2021;9(4):203 -11. Nebghouha EK, Lupattelli A, Nordeng H. Antithyroid drug treatment and pregnancy outcomes among women with hyperthyroidism in pregnancy: A Norwegian population - Skurtveit S, Lund I -O, Handal M. An 11 - year nationwide regis try-linkage study of opioid maintenance treatment in pregnancy The Use of Antidepressants, Antipsychotics, and Stimulants in Youth Residential Care. J 2021;31(5):350 -7. Olsen K, Dansie LS, Litleskare I, Blix HS. Consumption of oral anticancer drugs in Norway compared by different units of measurements - introduction of new DDDs. Norsk epidemiologi. 2021;29(1 -2):13 Andersson O, Cesta CE. Investigating the association between prenatal exposure to folic acid and risk of neonatal diabetes/hyperglycemia and type 1 diabetes: A Norwegian register -based study. Pediatr Diabetes. Self -reported medication use among coronary heart disease patients showed high validity compared with dispensing data. J Clin Epidemiol. 2021;135:115 -24. Haavik J, Klungs\u00f8yr K. Male to female ratios in autism spectrum disorders by age, intellectual disability and attention - deficit/hyperactivity disorder. Gravningen K. carriage of in a general adult population: a cross -sectio nal study of risk factors and bacterial genomic diversity. Gut Microbes. 2021;13(1):1939599. Riiser S, Smith \u00d8, Ruths S. Variation in general practitioners' depression care following certification of sickness abse nce: a registry - based cohort study. Fam Pract. -45. Robertson LJ, Jore S, Lund V, Grahek -Ogden D. Risk assessment of parasites in Norwegian drinking water: opportunities and challenges. Food Waterborne Parasitol. 2021;22:e00112. Rognli EB, Br amness JG, von Soest T. Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and Hansen AB, Riiser S, Meling HM, Baste V. Trends in treatment for patients with depression in general practice in Norway, 2009 -2015: nationwide registry -based cohort study (The Norwegian GP -DEP Study). BMC Health Serv Res. S, Helseth R. Impact of Preinjury Antithrombotic Therapy on 30-Day Mortality in Older Patients Hospitalized With Traumatic Brain Injury (TBI). Front Neuro l. 2021;12:650695. I. Influenza vaccination and risk for cardiovascular events: a nationwide self - controlled case series study. BMC Cardiovasc Disord. 2021;21(1):31. Engeland A, Haavik J, Klungs\u00f8yr K. Sex differences in parent -offspring recurrence of attention -deficit/hyperactivity disorder. J Child Psychol Psychiatry. 2021;62(8):1010 -8. Solli O, Halkinrud M. enk el metode for utvidet innsikt. [Health data - a simple Weiderpass E, Friis S, Potteg\u00e5rd A, Andreassen BK. Drug Use and Cancer Risk: A Drug -Wide Association Study Andreassen BK, Botteri E. Use of non -cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry -based study in Retterst\u00f8l K. Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia. Atheroscl erosis. 2021;316:48 M, A, Nordeng H. Perinatal use of triptans and other drugs for migraine- A nationwide drug utilization study. PLoS One. 2021;16(8):e0256214. Rosseland LA. Pre- injury dispensing of psychoactive prescription drugs in a ten years trauma population: a retrospective registry analysis. Scand J Trauma 2021;29(1):125. Trinh interrupted time -series ana lysis to characterise antibiotic prescription fills across pregnancy: a Norwegian nationwide cohort study. BMJ Open. Ystrom E, Nordeng H. Association of Timing and Duration of Prenatal Analgesic Opioid Exposure With Attention - Deficit/Hyperactivity Disorder in Children. JAMA Netw Open. 2021;4(9):e2124324. van den Broek S, Lupattelli A, Frank AS, Haug LS, Nordeng H. Thyroid hormone replacement therapy in pregnancy and motor function, commun ication skills, and behavior of preschool children: The Norwegian Mother, Father, and Child Cohort Study. Pharmacoepidemiol Drug Saf. 2021;30(6):716 -26. van Gelder M, Nordeng H. Antiemetic Prescription Fills in Pregnancy: A Drug Utilization Study Among 762 ,437 Pregnancies in Norway. Clin Epidemiol. 2021;13:161 -74. Husebye ES, \u00d8ksnes M. Primary Ovarian Reutfors J, Damkier P, Bliddal M, Potteg\u00e5rd A. Use of hypnotic drugs among children, adolescents, and young adults in Scandinavia. Acta Psychiatr Scand. 2021;144(2):100 -12. Haugen M, Madsen L, Egeland GM. Intakes of Fish and Long -chain n -3 Polyunsaturated Fatty Acid Supplements During Pregnancy and Subsequent Risk of Type 2 Diabetes in a Large Prospective Cohort Study of Norwegian Women. Diabetes Care. 20 21. \u00d8ymar K, Karlstad \u00d8, behandling recommendations on Possible opioid-saving effect of cannabis -based medicine using individual -based data from the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol. 2021. Burdzovic Skurtveit S, Handal M, Martinez P, Laslett AM, Lund IO. Parental risk constellations and future alcohol use disorder (AUD) in offspring: A combined HUNT survey and health registries study. Psychol Addict Behav. 2022. Emberland Ruths S, Ro rtveit G. Antibiotics for gastroenteritis in general practice and out -of-hour services in Norway 2006 - 15. Fam W, Gislason G, SH, Jenkins A, Al -Khalili F, Tell GS, Ehrenstein V. Effectiveness and safety of non- vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a scandinavian population -based cohort study. Eur Heart J Qual Care Clin Outcomes. 2022. Hjorth N\u00f6rby U, Nordeng H. Prenatal exposure to nitrofurantoin and risk of childhood leukaemia: a registry- based cohort study in four Nordic countries. Int J Epidemiol. 2022. Letnes JM, Effect of 5 y ears of exercise training on the cardiovascular risk profile of older adults: the Generation 100 randomized trial. Eur Heart J. 2022. Oberprieler NG, Farahmand B, Cameron J, Brobert G, Jonasson C, Atar D. Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nation 2020 Anden\u00e6s Ribu L, Vistad I, Helseth S. Associations between menopausal hormone therapy and sleep disturbance in women during the menopausal transition and post -menopause: data from the Norwegian prescription database and the HUNT study. BMC Womens Health 2020;20(1):64. Apalset EM, Lunde A, V, Tell GS. Initiation of anti -osteoporotic drugs in high -risk female patients starting glucocorticoid treatment: a population study in Norway. Arch Handal M, Hauge LJ, Reichborn -Kjennerud T, Skurtveit S. Incidence of diagnosed pediatric anxiety disorders and use of prescription drugs: a nation -wide registry study. Eur Child Adolesc Psychiatry. 2020;29(8):1063 -73 Berge Andreassen BK, Stenehjem JS, Heir T, Furu K, Juzeniene A, et al. Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry -Based Case - Control Study. Epidemiol 2020;12:193 -202. \u00d8, Juzeniene A, et al. Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case - Control E, et al. Metformin use and lung cancer survival: a population -based study in Norway. Br J Cancer 2021;124(5):1018- 1025. B\u00f8dkergaard K, Selmer RM, A, Skovlun d E, St\u00f8vring H. Using the waiting time distribution with random index dates to estimate prescription durations in the presence of seasonal stockpiling. Pharmacoepidemiol Drug Saf 2020;29(9):1072 -1078. Cesta , Furu K. Incidence of malformations after early pregnancy exposure to modafinil in Sweden -Diaz S, Huybrechts K, Kieler H, Leinonen M, Li J, Reutfors R, Schaffer A, Selmer R, Yu Y, Zoega H, Karlstad \u00d8. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006 -2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf 2020 ;29(8):913 - 22. Cohen JM, Selmer R, Furu K, Karlstad \u00d8. Interrupted time series analysis to assess changes in prescription filling around conception and implications for exposure misclassification. Pharmacoepidemiol Drug Saf Urinary with anxiety and depression: the impact of psychotropic drugs in a cross -sectional study from the Norwegian HUNT study. BMC Hjellvik V. Prescription of analgesics to long -term survivors of cancer in early adulthood, adolescence, and childhood in Norway: a national cohort study. Pain 2020;161(5):1083 -91. Gravningen K, Field N, Blix HS, Asfeldt AM, Sm\u00e5brekke L. Non -prescription purchase of antibiotics during travel abroad among a general adult population in Norway: Findings from the seventh Tromso Study. B. A possible effect of montelukas t on neurological aging examined by the use of register data. Int J Clin Pharm 2020. Hansen AB, Baste V, Hetlevik O, Haukenes I, Smith - Sivertsen T, Sabine R. General practitioners' drug treatment for depression by patients' educational level: registry- base d study. BJGP Open 2021;5(2):BJGPO.2020.0122. Harris GE, Wood M, Nordeng H. Modeling exposures of medications used episodically during pregnancy: Triptans as a motivating example. Pharmacoepidemiol Drug Saf 2020;29(9):1111 -9. 151 Hjorth S, Wood M, Tauqeer F, Nordeng H. Fertility treatment and oral contraceptive discontinuation for identification of pregnancy planning in routinely collected health data - an application to analgesic and antibiotic utilisation. BMC Pregnancy Childbirth 2020;20(1):731. Hoff HE, Langhammer A, S\u00f8gaard AJ, et al. Proton pump inhibitors and fracture risk. The HUNT study, Norway. Osteoporos Int 2020;31(1):109- 18. Hold\u00f8 I, Bramness JG, Handal M, BH, Hjellvik V, Skurtveit S. Association Between Prescribed Hypnotics in Infants and Toddlers and Later ADHD: A Large Cohort Study from Norway. Child Psychiatry Hum Dev 2020. Hovland R, Bremer S, Frigaard C, Henjum S, Faksv\u00e5g EM, Kristiansen of a pharmacist -led intervention on adh erence among patients with a first- time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies. impact of hospitalisation to geriatric wards on the use of medications and potentially inappropriate medications - a health register study. BMC Geriatr 2020;20(1):190. Jortveit J, Halvorsen S, Langorgen Skurtveit S. Nationwide Study of Neuropsychiatric Comorbidity and Medicines Use in Children With Autism Spectrum Disorder in Norway. Frontiers in Psychiatry 2020. Kjekshus VHR, Schuster P. Adherence to oral anticoagulant treatment and risk factor assessment six months after DC - conversion of atrial fibrillation. Scand Cardiovasc J 2020;54(3):179 -185. Kieler Odsbu I, N\u00f8rgaard M, \u00d6zt\u00fcrk B, Bateman V, Skurtveit S, Handal M. In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Pharmacoepidemiol Drug Saf (12):1596 Melbye Ariansen I, Langhammer A, Wisloff T, et al. Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources. International Journal of Copd 2020;15:323- 34. Pasternak B, Wintzell H, Ueda P. Use of sodium- g lucose co - transporter 2 inhibitors and risk of serious renal events: Scan dinavian cohort study. BMJ. Lirhus SS, Melberg HO, Halvorsen S. Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016. ESC Heart Fail 2020;7(4):1917 -26. \u00d8rbeck B, -Kjennerud T, Pripp AH, et al. Child and Parental Characteristics of Medication Use for Attention -Deficit/Hyperactivity Disorder. J Child Adolesc JG, Hansen BH, Lien L. The Use of Sleep Medication in Youth Residential Care. J Child Adolesc Psychopharmacol 2020;30(5):335 -41. Raknes G, Sm\u00e5brekke L. No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a Nafstad P, et al. Is the Association of Early Day Care Attendance with Childhood Asthma Explained by Underlying Susceptibility? Epidemiology 2020;31(3):451- 8. Reigstad MM, A, Larsen IK. Validation of Assisted Reproductive Technology in the Medical Birth Registry of Norway Versus the Norwegian Prescription Database. Epidemiology 2020;31(5):681 -6. Reutfors J, Cesta Gissler Huybrechts Man KCC, Pazzagli L, Schaffer A, Schink T, Wang Z, Yu Y, Zoega H, Br\u00f6ms G. Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophr Res 2020;220:106 -15. Rognli EB, Bramness JG, von Soest T. Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, E, Eriksson R. Sex and age differences among tramadol users in three Nordic countries. Dan Med J 2020;67(7):A06190336. Siffel C, Page M, Maxwell T, Thun B, Kolb N, Rosenlund M, et al. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention - Deficit/Hyperactivity Disorder in Europe. J Child Adolesc Psychopharmacol 2020;30(7):439 -47. Skow MAH, Vik I, H\u00f8ye S. Antibiotic switch after treatment with UTI antibiotics in male patients. Infect Dis 2020;52(6):405 -12. Skurtveit S, Hjellvik V, Sakshaug S, Borchgrevink A. The prevalence and incidence of glaucoma in Norway 2004 - 2018: A nationwide population -based study. PLoS ONE [Electronic Engeland A, Haavik J, Klungs\u00f8yr K. Sex differences in parent -offspring recurrence of attention -deficit/hyperactivity disorder. J Child Psychol Psychiatry St\u00f8er Weiderpass E, Frii s S, Potteg\u00e5rd A, Andreassen BK. Drug use and cancer risk: a drug -wide association study (DWAS) in AS, Haug LS, Nordeng H. Thyroid hormone replacement therap y in pregnancy and motor function, communication skills, and behavior of preschool children: The Norwegian Mother, Father, and Child Cohort Study. Pharmacoepidemiol Drug Saf 2021;30(6):716 -726. Vold KA, et al. Dispensations of benzodiazepines, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2017. BMC Health Serv Res C, Johansson KA, Fadnes LT. Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013 -2017): a prospective cohort study. BMC Health Serv Res Chalabianloo F, Halm\u00f8y A, et al. D ispensation of attention deficit hyperactivity 152 disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017. BMC Psychiatry 2020;20(1):119. Vold I, Chalabianloo F, Reutfors J, et al. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register -based prospective cohort study in Norway and Sweden from 2015 to 2017. BMJ Open 2020;10(8):e036860. Wie B\u00f8rsheim A, Engeland A, Gilhus NE. Epilepsy and autoimmune diseases: Comorbidity in a national patient cohort. Seizure. 2020;75:89 -95. W\u00e6rholm AC, Meland E, Kjome RLS. Can subjective well - being and body concern in adolescence predict prescribed medication in adulthood? Findings from the Nord - Tr\u00f8ndelag Health Study and the Norwegian Prescription Database. Scandinavian Journal of Public Health 2020;48(5):559 -66. Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, et al. Uptake and predictors of direc t-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy , \u00d8kland JM, et al. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open 2020;10(8):e036355. 2019 Andreassen BK, St\u00f8er NC, Martinsen JI, Ursin G, Weiderpass E, Thoresen GH, et al. Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry - based study. BMJ Open 2019;9(4):e028504. Amato E, Dansie HH, Soleng A. Increase of scabies infestations, Surveill. 2019 - PG, Johannessen SI, Landmark CJ. Safety aspects of antiepileptic drugs -a population -based study of adverse effects relative to changes in utilisation. Eur J Clin Pharmacol 2019;75(8):1153 -60. Benko R, hado MC, Furtado C, Fungie G, Bordas R, Blix HS. Cross -national comparison of paediatric antibiotic use in Norway, Portugal K, Juzeniene A, et al. Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case - control study. BMJ Open 2019;9(2):e025246. Bergene EH, Nordeng H, Ro TB, Steinsbekk A. Register - based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr Skurtveit S. Tramadol use in Norway: A register -based population study. Pharmacoepidemiol Drug Saf 2019;28(1):54 -61. Bramness JG, von Soest T. A longitudinal study of cannabis use increasing the use of asthma medication in young Norwe gian adults. BMC Pulmonary Medicine Yu Y, Zoega H, Odsbu I. Antidiabetic medication use during pregnancy: an international utilization study. BMJ Open Diabetes Research and Care. 2019 Nov 1;7(1). https://drc.bmj.com/content/7/1/e000759 Diaz E, Omland G, Hannestad Y, Ruths S. Use of hormonal contraceptives among immigrant women and their daughters in Norway: Data from the Norwegian Prescription Engedal K, Blix HS. Drug Use before and after Initiating Treatment wit h Acetylcholinesterase Inhibitors. Dementia and Geriatric Cognitive Disorders Extra 2019;9(1):196 -206. Ekman J, Skjeldestad FE. Do Norwegian providers comply with national recommendations when prescribing combined oral contraceptives to starters? A cohort study. BMJ Open 2019;9(11):e027888. Evandt Oftedal B, Krog NH, Nafstad P, Skovlund E, et al. Agreement between self -reported and registry -based use of sleep medications and tranquilizers. Pharmacoepidemiol Drug Saf 2019;28(10):1336 -43. Evensen JU, Bull H, Martinsen EW, Ueland T, et al. Exploring the potential cost -effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high -income welfare society. BMC Psychiatry 2019;19:140 Fog AF, Straand J, Engedal K, Blix HS. Drug use differs by care level. A cross -sectional comparison between older people living at home or in a nursing home in Oslo, Norway. BMC Geriatrics 2019;19(1):49. Frank AS, Lupattelli A, Brandlistuen RE, Nordeng H. Matern al Thyroid Hormone Replacement Therapy Exposure and Language and Communication Skills of Offspring at 8 Years of Age. JAMA netw 2019;2(10):e1912424. Frank AS, Lupattelli A, Matteson DS, Meltzer HM, Nordeng H. Thyroid hormone replacement therapy patterns i n pregnant women and perinatal outcomes in the offspring. Pharmacoepidemiol Drug Saf 2020;29(1):111 -21. Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. Pain 2019;160(4):852 -9. Hagen KB, Aas T, Kval\u00f8y JT, S\u00f8iland R. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5 -year prospective study. Breast 2019;44:52 -8. Handal Necha L, R, Engeland A, et al. Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway. Pharmacology Research & Perspectives 2019;7(5). Heg gelund L, Singh R, Aballi S, Rosseland CM, Mikkelsen Y, Damas JK. Retrospective analysis of co -medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012 -2018 using the Norwegian populatio n-based prescription database. HIV Med Haugst\u00f8yl ME, Kval\u00f8y JT, K, et al. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescript ion Database. Breast Cancer Res Treat J, Vries F Furu K. Adjusting for unmeasured confounding using validation data: Simplified two- stage calibration for survival and dichotomous outcomes. Statistics in Medicine. 2019 https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8131 Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA. The healthcare costs of treating human papillomavirus - related cancers in Norway. BMC Cancer. 2019 May 7;19(1):426. H\u00f8jlund M, -J\u00f8rgensen Correll CU. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. Br J Clin Pharmacol. FINDRISC as a pred iction tool for diabetes in a contemporary Norwegian population: a 10 -year follow -up of the HUNT study. BMJ Open Diabetes Res Care. 2019 Hagquist C. Leisur e-time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. Eur Child Adolesc Psychiatry 2019;28(2):177 -88. Kravdal \u00d8, Grundy E. Children's age at parental divorce and depressio n in early and mid -adulthood. Population al. Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk P erspective, 2000 -2016: A Drug Utilization Study. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy 2019;39(2):150 -60. Langaas HC, Hurley E, Dyrkorn R, Spigset O. Effectiveness of an academic detailing intervention in primary care on the pre scribing of non- steroidal anti -inflammatory drugs. M, Johannessen SI, Johannessen Landmark C. Therapeutic drug gabapentin in various indications. Acta Neurologica Scandinavica 2019;139(5):446 -54. Lund IO, Skurtveit S, Handal M, et al. Association of Constellations of Parental Risk With Children's Subsequent Anxiety and Depression: Findings From a HUNT Survey and Health Magnus P, et al. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. Thorax W, et al. Airway symptoms and atopy in young children prescribed asthma medications: A large -scale cohort study. Pediatric Pulmonology 2019;54(10):1557 - Muller AE, I, Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006 -2017. Scand J Pain 2019;19(2):345 -53. Pedersen AB, Andersen IT, Overgaard S, Fenstad AM, Lie SA, Gjertsen JE, et al. Optimal duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Association Group. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pn eumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560 -7917.ES.2019.24.46.1900656. Raknes G, in the consumption of antiepileptics and psychotrop ic medicines after starting low dose naltrexone: A nation -wide register -based controlled before -after study. Sci 2019;9(1):15085. Raknes G, Sm\u00e5brekke L. Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register -based controlled quasi -experimental before -after study. Hauge LJ, Kalseth J. Use of prescription medication prior to suicide in Norway. BMC Health Serv Res 2019;19(1):215. Sander SD, Nybo Ander -M, Murray JA, Karlstad \u00d8, Husby S, St\u00f8rdal K. Association Between Antibiotics in the First Year of Life and Celiac Disease. Gastroenterology. 2019 Schou MB, al. Systematic assessment of prescribed medications and short -term risk of myocardial infarction - a pharmacopeia- wide association study from Norway and Sweden. Sci Rep 2019;9(1):8257 Solberg BS, Zenyats T, Posserud MB, J, Klungs\u00f8yr K. Psychiatric comorbidity and genetic correlations provide new insights into differences between attention -deficit/hyperactivity disorder and autism spectrum disorder. Biological Psychiatry 2019; 86: 587 -98. Steens A, Brants\u00e6ter AB, Vestrheim DF. Indirect Effects of Pneumococcal Childhood Vaccination in Individuals Treated With Immunosuppressive Drugs in Ambulatory C are: A Case - cohort Study. Clin Infect Kjennerud T, Stoltenberg C, et al. Tourette syndrome in children in Norway. Tidsskrift for Den Norske Legeforening 2019;139(17). A, Krokstad S, Helvik AS. Factors associated with alcohol consumption and prescribed drugs with addiction potential among older women and men - the Nord -Tr\u00f8ndelag health study (HUNT2 and HUNT3), Norway, a study. Krokstad S, Helvik AS. Mortality in older adults with frequent alcohol 154 consumption and use of drugs with a ddiction potential - The Nord Trondelag Health Study 2006 -2008 (HUNT3), Norway, a population study. PLoS ONE Handal Dyb K. eHealth initiatives; the relationship between project work and institutional practice. BMC Health Serv Res Bliddal, Mette. (2019). Trends i n antidepressant use among children and adolescents: A Scandinavian drug utilization study. Acta Psychiatrica Scandinavica. 141. 10.1111/acps.13116. W\u00e6rholm AC, Meland E, Kjome RLS. Can subjective well - being and body concern in adolescence predict prescrib ed medication in adulthood? Findings from the Nord - Trondelag Health Study and the Norwegian Prescription Database. Scand J Public Health 2019: Aug 13 [Epub ahead of print] 2018 Andersson J, Hofsli M, Gade UL, Heegaard S, Pottegard A. Use of topical ocular antibiotics in young children: a Scandinavian drug Ophthalmol LI, Engeland A, Fasmer OB, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2018;38(11):1759 -64. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly ve rsus younger patients with epilepsy: A pharmacoepidemiological study of CNS -active drugs in Norway, 2004 -2015. Epilepsy Res 2018;139:35 - 42. Bateman BT, Heide- J\u00f8rgensen U, Einarsdottir K, A, Reutfors J, Selmer R, Zoega H. Beta -blocker use in pregnancy and the risk of congenital malformations: An international cohort study. Ann Intern Med 2018; 169: 665 -73. Benko R, Matuz M, MC, Furtado C, Fungie G, Bordas R, Blix HS. Cross -national comparison of paediatric antibiotic use in Norway, Portugal and Clin TB, Steinsbekk A. Registe r- based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr 2018;22:22. Bergene EH, Nordeng H, for new oral antibiotic prescrip tions in children within 2 days: a Norwegian population -based study. Fam Pract 2018;35(6):690 -7. Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong -van den Berg LTW, Jordan S, Klungs\u00f8yr K, Neville AJ, Pierini A, Puccini A, Sin clair M, Thayer D, Dolk H.The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. Eur J Pharmacol 2018; 74:513 -20 Cohen JM, Wood ME, Hernandez -Diaz S, Nordeng H. Agreement between paternal self -reported medication use and records from a national prescription database. Pharmacoepidemiol Drug Saf 2018;27(4):413 -21. Cortese M, Riise T, Engeland A, Ascherio A, Bjornevik K. Urate and the risk of Parkinson's Parkinsonism Relat Disord 2018;52:76 -82. Dalen DM, Locatelli M, Strom An Equilibrium Model Estimated on Pharmaceutical Data. Atl Econ J 2018;46(3):281 ations in women with epilepsy and antiepileptic drugs: a population -based cohort study of first pregnancies in Norway. BMJ Open 2018;8(4):e020998. Diaz E, Omland G, Hannestad Y, Ruths S. Use of hormonal contraceptives among immigrant women and their daugh ters in Norway: Data from the Norwegian Prescription Obstetricia et Gynecologica Scandinavica 2018. Egeland AC, Eide GE, Daltveit AK, Klungsoyr K, et al. Pregnancy -Related Risk Factors Are Associated With a Significan t Burden of Treated Hypertension Within 10 Years of Delivery: Findings From a Population -Based Norwegian Cohort. J Am Heart Assoc 2018;7(10):13. Engeland A, Bjorge T, Klungsoyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pre gnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Lindbaek M. Prescribing antibiotics when the stakes are higher - do GPs prescribe less when patients are pregnant? A retrosp ective observational study. Gjelstad S, Kvaerner KJ. Relationship between Maternal and First Year of Life Dispensations of Antibiotics and Antiasthmatics. Antibiotics (Basel) 2018;7(3):17. Frank AS, Lupattelli A, Matteson DS, Nordeng H. Maternal use of thyroid hormone replacement therapy before, during, and after pregnancy: agreement between self - report and prescription records and group -based trajectory modeling of prescription patterns. Clin Epidemiol 2018;10:1801 -16. Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. Pain 2018;07:07. Gulati S, et al. intracranial hemorrhage (RICH) in users of oral antithrombotic Engeland A. Associations between attention -deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population -based cross -sectional study. Eur Child Adolesc 2018 Ved erhus JK, Bramness JG. Use of drugs for alcohol use disorder in Norway 2004 -16. Tidsskrift for Den Norske Laegeforening 2018;138(18):13. Hoff M, Skurtveit S, Meyer HE, Langhammer A, AJ, Syversen U, et al. Anti -osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. between Methylphenidate and Amphetamine use in Pregnancy and Risk of Congenital Malform ations: A cohort study from the International Pregnancy M, et al. Association of Bariatric Surgery vs Medical Obesity T reatment With Long -term Medical Complications and prescription rates of anxiolytics and hypnotics to survivors of cancer in c hildhood, adolescence, and young adulthood -A population -based study. Pediatr Blood Cancer 2018;65(2). Kasciuskeviciute S, Gumbrevicius G, Vendzelyte A, Sciupokas A, Petrikonis K, Kadusevicius E. Impact of the World Health Organization Pain Treatment Guide lines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti -Inflammatory Drug Use in Lithuania: An Observational Study. (Kaunas) Kjerpeseth Selmer R, Ariansen I, Furu K, Skovlund E. Risk facto rs for stroke and choice of oral anticoagulant in atrial fibrillation. Eur C. Leisure -time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. Eur Child Adolesc NE, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II- IV. J Neurooncol KM. Prospective Cohort Study of Brea stfeeding and the Risk of Childhood SJ, Wilcox AJ, Nystad W, H\u00e5berg SE. Maternal history of miscarriages and measures of fertility in relation to chi ldhood asthma. Thorax. 2019;74(2):106 SJ, Nystad W. Association of Maternal Psychosocial Stress With Increased Risk of Asthma Development in Offspring. Am J Epidemiol.2018;187(6):1199 -209. Mauseth SA, Skurtveit S, Langhammer A, Spigset O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. Int Urogynecol J Pelvic S, Skovlund E, Spigset O. Medication use and association with urinary incontinence in women: Data from the Norwegian Prescription Database and the HUNT study. Neurourol Urodyn 2018;37(4):1448 -57. Iversen Pukkala E, Bolin K, Stavem K, Ersb\u00f8ll AK. Finasteride treatment and male breast cancer: a register- based cohort study in four Nordic children 2004 -2015 [Forskrivning av legemidler mot astma P. Incidence Trends of Atopic Dermatit is in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway. JAMA netw 2018;1(7):e184145. Nakken O, Lindstrom JC, Tysnes OB, Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulso ry nationwide health Gabrhelik R, Engeland A, Handal M. Neonatal Outcomes after Fetal Exposure to Methadone and Buprenorphine: Nat ional Registry Studies from the Czech Republic and Norway. Addiction 2018. Nesvag R, Bramness JG, Handal M, Hartz I, Hjellvik V, Skurtveit S. The incidence, psychiatric co -morbidity and pharmacological treatment of severe mental disorders in children and a dolescents. Eur Psychiatry 2018;49:16 -22. -Blix NA, Haugen M, et al. Vitamin A and D intake in pregnancy, infant supplementation, and asthma development: the Norwegian Mother and Child Cohort. Am J Clin 2018;107(5):789 M, Stephansson O. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death. JAMA 2018. Raknes G, Simonsen P, Smabrekke L. The Effect of Low - Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before- and-After Prescription Dat abase Study. Crohns T,Bushnell Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Potteg\u00e5rd A, Pratt NL, Roughead EE, -Gerons DM, St\u00fcrmer Su CC, Zoega H, Sturkenbroom M, Chan EW, Coghill D, Ip P, Wong I. Regional and national trends in attention -deficit/hyperactivity disorder (ADHD) medication use: a multin ational study in North America, Europe, Asia and Australia. Lancet Psychiatry 2018; 5(10):824 -835. Reset A, Skurtveit S, Furu K, Skovlund E. Effect of the market withdrawal of dextropropoxyphene on use of other prescribed analgesics. Scand J Pain 2018;18( 4):667 -74. Roksvaag Decreasing trends in number of depot medroxyprogesterone acetate starters in Norway - Gulseth HL, et al. Pandemic influenza an d subsequent risk of type 1 diabetes: a nationwide cohort study. Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. O pen Heart 2018;5(2):e000931. Skurtveit Hartz I, Nesvag R, Hauge LJ, et al. Increase in diagnosis of depressive disorders contributes to the increase in antidepressant use in adolescents. Acta Psychiatr Scand 2018;137(5):413 M. Psoriasis and cardiovascular disease risk factors: the HUNT Study, 156 Norway. J Eur Klungs\u00f8yr K. Gender differenc es in Psychiatric Comorbidity Diagnostikk av barn Vorren Samdal H, Garcia B. Adverse dru g reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J for HJ. Is self -rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Trondelag Health Study and the Norwegian Prescription Database. SSM Popul Health 2018;4:144 -52. Walle -Hansen MM, Hoye S. Geographic Variation in Antibiotic Consumption -Is It Due to Doctors' Prescribing or Schmidt M, Karlstad \u00d8, Potteg\u00e5rd A. Trends in Use of Paracetamol Countries. Basic Clin Pharmacol AT, et al. Stratification by interferon -gamma release assay predicts TB. Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2017:333102417748573. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisa - tion and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepide miological study of CNS - active drugs in Norway, 2004 -2015. Epilepsy Res 2017;139:35 - 42. Bakken IJ, Furu K, Gr\u00f6neng GM, Stoltenberg C, \u00d6verland S, et al. General practice consultations and use of prescription drugs after changes to school abse nce policy. TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population - based study. OncoTargets et al. Does progestin -only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective populatio n study. M, Tysland T, Blix HS, Hoye S. Antibiotic switch during treatment with antibiotics against respiratory tract infections in ambulatory care in Norway. Infect Dis (Lond) 2017;49(11 -12):854 -8. Brakedal B, O, Dolle C, Assmus J, et al. Glitazone Use Associated With Reduced Risk of Parkinson's Disease. Mov Disord 2017;32(11):1594 -9. But A, De Bruin Bazelier V, Andersen M, Auvinen A, Starup - Linde J, Schmidt MK, Furu V ries F, Karlstad \u00d8, Ekstr\u00f8m, N, Haukka J. Cancer Risk among insulin users: comparing analogues with human insulin in the CARING five HS. Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors. Dement Geriatr Cogn Dis S, Daltveit AK, Vikse BE, Haugen M. Low Calcium Intake in Midpregnancy Is Associated with Hypertension Develop - ment within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study. Journal of Nutrition 2017;147(9):1757 -63. Engeland A, Furu K. Preterm births and use of medication in early adulthood: a population -based registry study. Pharma- coepidemiology and Drug 2017;26(7):742 P, Schwarze PE, et al. Road traffic noi se and registry based use of sleep medication. Environ Health 2017;16:12. Ezat B, Pihlstrom L, Aasly J, Tysnes OB, Egge A, Dietrichs E. Use of advanced therapies for Parkinson's disease in Norway. Tidsskr Nor Laegeforen 2017;137(9):619 -23. Fadnes LT, Diaz E. Primary healthcare usage and use of medications among immigrant children according to age of arrival to Norway: a population -based study. BMJ of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five- year period 2005 -2009. European Journal of Pain 2017;21(3):530 -40. Fredheim OMS, Skur tveit S, Borchgrevink PC. Provision of analgesics to children before and after the new recommendations on of Stimulants and Atomoxetine for Attention -Deficit/Hyperac - tivity Disorder among 5.4 million Children Using Population- based Longitu - dinal agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004 -2015. Eur J Clin 2017;73(9):1173 -9. , Kieler H. Neuraminidase inhibitors during pregnancy, and the risk of adverse neonatal outcomes and congenital malformations -A population based European register 1;356:j629. http://www.bmj.com/content/356/bmj.j629.long 157 Grinde B, Engda hl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. of Warfarin Use With Lower Overa ll Cancer Incidence Among Patients Older Than 50 Years. JAMA Intern Med 2017;177(12):1774 -80. Halvorsen S, Ghanima W, Tvete IF, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation b eing prescribed oral anticoagulants. Eur Heart J -Cardiovasc Pharmacother 2017;3(1):28 -36. Hoff M, Meyer HE, Skurtveit Sogaard AJ, Syversen U, et al. Validation of FRAX and the impact of self - reported falls among elderly in a general popula tion: the HUNT study, Norway. Osteoporos easy access to contraception and Kjennerud T, Ystrom E, et al. Hypnotics use in children 0 - 18 months: moderate agreement between mother - reported survey data and prescription registry data. J 2017;10:28. Johannsdottir IM, Karlstad O, Loge JH, C, Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A Population -Based TM, Jenum PA. Fecal carriage of extended spectrum beta - lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection - A three year prospective cohort study. PLoS One 2017;12(3):16. and Treatment in Relation to Children's Birth Month: Nationwide Study from Norway. Scand J 2017 Jun;45:343 -9. JH. Employees' drug purchases before and after organizational downsizing: a natural experiment on the Norwegian working population (2004 -2012). Scand J Work Environ Health 2017;43(4):307 -15. Kjerpeseth H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anti coagulants in atrial fibrillation in and use of antidepres - sant medication in late mid -life: a register - based analysis of Norwegian women and men . Aging Ment Health. 2017 May;21(5):477 -486. doi: -Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use in t O. Incidence of and factors associated with anticholinergic drug use among Norweg ian women with urinary incontinence. Urogynecol J Pelvic Floor Dysfunct 2017;04:04. Milenkovic M, Haavik S. Recording of pharmaceutical interventions of potential clinical importance in Norwegian pharmacies. Norsk Farmaceutisk Tidsskrift 2017;125(6):26 Hoff M, Forsmo S, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. Br J Dermatol 2017;176(5):1162 Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depres - sive symptoms: the HUNT Study, 2017;31(12):2062 - 8. M\u00e5rild K, Blix HS, St\u00f6rdal K. Use of antibiotics in children during the period 2005 - 16. T idsskr Nor Laegeforen 2017;137(18):1414 -9. Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral sclerosis & Frontotempor al Degeneration 2017:1 -8. Odsbu I, Selmer R, Lundborg CS, Blix HS. Increased prescribing of systemic tetracyclines and PM, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population -based Cohort. Am J Respir Crit Care Antibiotic - prescribing habits among Norwegian dentists: a survey over 25 years (1990 - 2015). Eur J Oral Sci 2017;125(4):280 -7. Raknes G, Smabrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi -experimental study. PLoS One 2017;12(11):13. naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. Pharmacoepidemiology and Drug Safety 2017;26(6):685 - 93. Raknes G, Smabre kke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteris - tics, and dispense patterns. A drug utilization cohort study. Pharmacoepide - miology and Drug Safety 2017;26(2):136 - 42. Rebno rd, E.W., Strand, E., Midttun, \u00d8. et al. The kynurenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia d AK, Robsahm TE, et al. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status -A Registry -based Cohort Study. Cancer Epidemiology Biomarkers & Prevention 2017;26(6):953 - 62. Sakshaug S, Handal M, Hjellvik V, Berg C, Ripel A, Gustavsen I, et al. Long - term Use of Z -Hypnotics and Co - medication with Benzodiazepines and Opioids. Basic Baz -Lomba JA, Bramness JG. Assessing prescription drug abuse using functional principal co mponent analysis (FPCA) of waste - water data. Pharmacoepidemiology and Drug Safety 2017;26(3):320 - 6. 158 Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug A, Svendsen K, Eggen AE. Pain sensitivity Jason LA, Kirkevold M. From good health to illness with post - infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. BMC family practice 2017;18(1):49. Straiton ML, Rene flot A, Diaz E. Mental Health of Refugees and Non -refu - gees from War -Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. Journal of Immigrant and Minority Health 2017;19(3):582 -9. Svendsen K, Halvorsen KH, Vo Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J Clin Pharmacol 2017;18:18. Svendsen T, SI, Landmark CJ. Therapeu tic Drug Monitoring of Lacosamide tic variability, efficacy and tolerability of eslicarbazepine acetate -A national approach to the evalu - ation of therapeutic drug monitoring data and clinical outcome. Epilepsy Research 2017;129:125 -31. Svendsen T, Brodtkorb E, Reimers variability, efficacy and tolerability of eslicarbazepine acetate- A national approach to the evaluation of therapeutic drug moni - toring data and clinical outcome. Epilepsy in Users of Acetylcholinesterase Inhibitors. Dement Geriatr Cogn Dis K, Seim A, Krokstad S, Helvik AS. Use of alcohol and d rugs with addiction potential among older women and men in a population -based study. The Nord -Trondelag Health Study 2006 benzodiazepine and Z-hypnotic users and disability pension: an eight -year nationwide observational follow -up study. Scand J Prim Health Care 2017;35(3):240 -6. Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription Patterns of Non -Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012 -2015: A Study from the Norwegian Prescription Database. Drugs Aging 2017;34(8):635 -45. Vie TL, Hufthammer KO, Holmen TL, Meland E, HJ. Is self -rated health in adolescence a predicto r of prescribed medication in adulthood? Findings from the Nord Tr\u00f8ndelag Health Study and the Norwegian Prescrip HS, Tong A, Trifir\u00f2 G, Ziv -Baran T, Kim SK. Anti - biotic Use in Children - A Cross -National Analysis of 6 Countries. J Pediatr L. Psychosocial factors are strongly associated with insomnia in users and nonusers of prescribed sleep medication: Evidence from the SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non -epilepsy disorders - a pharmacoepidemiological study and clinical Dorum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: An unselected population - based study. Ruths S. Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. J Am Geriatr Soc AH, al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressan ts, and anxiolytics: Results from a hip N, et al. Opioids for outpatients with cancer in their last year of life: A natio n- wide pharmacoepidemiological study. Journal of Opioid Management 2016;12(1):25 -36. Charlton RA, Klungs\u00f8yr K, Neville AJ, Jordan S, Pierini A, de Jong -van den Berg LTW, et al. Prescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regions. PLoS One 2016; 18;11(5): e0155737. doi: 10.1371/journal.pone.0155737. Charlton RA, Pierini A, Klungs\u00f8yr K, Neville AJ, Jordan S, de Jong -van den Berg LT, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. BMJ Open 2016 Jan 19;6(1):e009237. leiner HF, Bjoro T, Midthjell K, Grill V, Asvold BO. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes : The population -based hunt study in Norway. J Clin Endocrinol S, Lund IO, Handal M. A Unique Opportunity to Study Short and Long Term Consequences in Children Prenatally Exposed to I llicit Drugs and Opioid Maintenance Treat - ment Using Czech and Scandinavian Registers. Cent Eur J Public Health 2016;24(3):248 -51. Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungs\u00f8yr K, Engeland A, et al. Risk of congenital anomalies after exposure to asthma medica - tion in the first trimester of pregnancy - a cohort linkage study. BJOG Revilla -Lopez C, Diaz E. Patterns of pharmaceutical use for immigrants to Spain and Norway : a comparative study of prescription databases in two European countries. International Journal for Equity in Health 2016;15. Halvorsen S, Jortveit J, Hasvold P, Thuresson M, \u00d8ie E. Initiation of and long -term adherence to secondary preventive drugs after acute myocardial Nesv\u00e5g R, Handal M. Antidepressant drug use among adolescents during 2004 - 2013: a population -based register Handal M. Psychotropic drug use among 0 -17 year olds during 2004 - 2014: a nationwide prescription database study. of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A Population -Based Study. J Adolesc Young Adult Oncol 2016;14:14. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM, Linked Databases in Wales, Kieler H, et al. Use of drugs for ADHD among adults -a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol 2016;72(12):1507 - 14. Kaspersen SL, Pape Bjorngaard JH. and initiat ion of psychotropic medication: a case -crossover study of Occup Environ 2016;73(11):719 AK, Green A, Emneus M, Pukkala E, Bolin K, et al. Patterns of finasteride use in the male populations of fo ur Nordic countries: A cross -national drug utilization AM, Owe JF. Does the choice of antiepileptic drug effects of parental deaths among adults in Norway: Purchases of prescription medicine before and after bereavement. SSM Population et al. Pre -eclampsia Nystad W. Prenatal and infant paracetamol exposure and development of asthma: The Norwegian Mother and Child Cohort Study. Int J Epidemiol 2016;45(2):512 - Maternal plasma total neopterin and kynurenine/tryptophan levels during preg nancy in relation to asthma development in the offspring. J Allergy Clin Immunol 2016;138(5):1319 AK, Handal M, Haugen M, H\u00f8iseth G, Knudsen GP, L, Schreuder P, Tambs K, Vold L, Stol tenberg C. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2016;45(2):382 -8. Mellbye A, Borchgrevink Fredheim OMS. The duration and course of opioid therapy in patients with chronic non -malig - Haukeland JW, Dalgard O. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population -Based Study. PLoS One I, Handal M, Skurtveit S. M ental disorder diagnoses among children and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol 2016;26:1412 -8. Olah KS, Kim TH, Lee HH, Kim JM. Re: Use of hormonal contraceptives among immigrant and native women in Norway: data from the Norw e- gian Prescription Database The contraceptive situation in Korea. BJOG 2016;123(5):840. Roman M, Graff -Iversen S, Weiderpass Sakshaug S, Hofvind S, et al. Postmenopausal hormone therapy and breast cancer prognostic char- acteristics: A linka ge between nationwide registries. Prevention -73. Weiderpass E, Ursin G, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. Int J Cancer 2016;138(3):584 -93. Samuelsen PJ, Svendsen K, Wilsgaard T, Stubhaug A, Nielsen CS, Eggen AE. Persistent analgesic use and the association with chronic pain and other risk factors in the population -a longitudinal study from the Tromso Study and the Norwegian Prescription Database. Eur J Clin Pharmacol 2016;72:977 -85. Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual -based versus aggregate meta - analysis in multi -database studies of pregnancy outcomes: the Nordic example o f selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiol Drug Saf 2016;25(10):1160 -9. Skipenes VP, Skjeldestad FE. Prevalence of combined Obstet Gynecol Scand 2016;95(9):1027 -33. S\u00f8rensen M, Arneberg F, Line TM, Berg TJ. Cost of diabetes in Norway 2011. Diabetes Res Clin Pract 2016;122:124 -32. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non -refugees from War -Conflict Countries: Data from Primary Healthcare Servic es and the Norwegian Prescription Database. J Immigr Minor Health 2016;21:21. Tjagvad C, Skurtveit S, Bramness JG, Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. Journal of Substance Use 2016;21(5):515 -20. Tvete IF, Bj\u00f8rner T, Skomedal T. A 5 -year follow -up study of users of benzodiazepine: Starting with diazepam versus oxazepam. Br J Gen Pract 2016;66(645):e241 -e7. \u00d8vre -Eide V, Skjeldestad FE. Norway. Acta Obstet Gynecol Scand V, Handal M. Reduced Prescribing M. prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveil - lance? Epidemiology and Infection. 2015;143(9):1884 -92. P, Skurtveit S, Clausen T, Kun\u00f8e N. The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study. Subst Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, Pierini A, Hansen A, Engeland A et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in 160 seven European regions. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1144 -54. doi: M, Romundstad P, Skurtveit S. Prevalence of use of non - prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and Jordan SE, Klungsoyr K, Loane M, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5 -year survey in Norway. Scand J Prim Health Care. 2015;33(4):252 M. Serotonin -Reuptake Inhibitors and Venlafaxine in early pregnancy and risk of birth defects - a population based cohort study and sibling design. BMJ 2015. A pr 17;350:h1798. TA. Socio -economic inequality in the use of procedures and mortality among AMI patients: Quantifying the effects along different paths. Chron Obstruct Pulmon 2015;10:1695 -702. doi: O, Romundstad PR, Mahic M, et al. Consumptio n of and satisfaction with health care among opioid users with chronic Off - Label Use of Mela - tonin - A Register Linkage Study between the Norwegian Prescription Data - base and Patient Register. Basic Clinl Pharmacol Monitoring of Selec - tive Serotonin Reuptake Inhibitors in doi: 10.1097/FTD.0000000000000169. Hoff A, S\u00f8gaard AJ, Syversen U, et al. Use of anti -oste oporotic drugs in central Norway after a forearm fracture. Archives of Osteoporosis. 2015;10:30. doi: 10.1007/s11657 -015-0235 -2. H\u00f8iseth G, Middelkoop H. Has Previous Abuse of Fluni - trazepam Been Replaced by Clonazepam? European Addiction Research. -21. Iversen Tell GS, Espehaug B, Midthjell K, Graue M, et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine -year follow -up of the Nord -Tr\u00f8ndelag Health Study, Norway. Journal of Psychosomatic Research. 2015;79(4):309 -15. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Vejrup K, et al. Hormonal contraceptive use before and after conception in re lation to preterm birth and small for gestational age: A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88 -91. doi:10.1016/j.seizure.2015.02.017 Kann IC, Lundqvist C, Lur\u00e5s H. Polypharmacy Among the Elderly in a List -Patient System. Drugs - Real World Outcomes. 2015;2(3):1 93-8. doi: 10.1007/s40801 -015 - 0036 -3 Kelly E, Lu CY, Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. Journal of Clinical Pharmacy and K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case- control study. BJOG -an International Skirbekk V. Fertility history and use of anti - depressant medication in late mid -life: a register - based analysis of Norwegian women and men. Aging & mental health. 2015:1 -10. doi: 10.1080/13607863.2015.1118010 Lund IO, Skurtveit S, Handal M. Commentary on Raitasalo et al: the great potential in nation -wide registers to study prescription drug use and abuse. Addiction (Abingdon, England). 2015;110(4):644 -5. DOI: 10.1111/add.12856 Lund Handal M, Nordfjaern T, Brunborg GS, Rossow I. A Cohort Study on Long -Term Adverse Effects of Parental Drinking: Background and Study Design. Subst Abuse. 2015 S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. Sep;19(8):1095 -100. SJ, Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Study. Thorax. mortality: causation The total sale of prescription drugs with an abuse potential pred icts the number of excessive users: a national LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study. BMC IF, Tanum L, Steen VM, Bramness JG. Incident Users of Antipsychotic Agents and Future Use of Cholesterol -Lowering Drugs: An Observatio nal, Pharmacoepidemiologic Study. 2015;76(1):E111 -E6. doi: 10.4088/JCP.14m08996. Suhrke P, Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register -based cohort study. Cancer Medicine. 2015;4(8):1303 -8. doi: 10.1002/cam4.474 Tvete IF, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiaz - epine use in a working age population: a nationwide 5 -year survey in Norway. Scand J Primary Health Prescription patterns of inhaled corticosteroids for preschool children - A Norwegian register study. Pediatric Allergy and Immunology. L, al. Use of SSRI and SNRI Antidepressants during Pregnancy: A Population -Based Study from Denmark, Iceland, Norway and Sweden. Plos One. 2015;10(12). Total drug treatment and comorbidity in myasthenia gravis: a population -based cohort study. Eur J Neurol 2014;21:948 - 955 Bakken AH, Hunskaar S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol -880 Berg -Hansen P, Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 2014;20:1780 -1782 Ferrer P, Rafaniello C, Sabate M, Ballarin E, Coma A, Zara C, et al. Cross - national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007 -2011. Health. 2014;11:e9405 -1. Fredheim M, Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemio - logical study from the Norwegian prescription databa se and the Nord -Tr\u00f8n - delag health B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self -poisoning: a multilevel approach. of b- Blockers and Prostate Cancer -Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High -Risk or Metastatic Disease. European Urology 2014;65:635 -641. Halvorsen T, M artinussen PE. The geography of chronic obstructive pulmonary disease: A population -based study of Norway. Soc Sci Med 2014;21:25 -34. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offsp ring overweight or obesity. Int J Obes. teinli V. Cross -country comparisons of health -care costs: The case of cancer treatment in the Nordic countries. Health Policy 2014:115;172 -179. Kann IC, Lundqvist C, Luras H. Prescription of addictive and non- addictive drugs to home -dwelling elderly. Drugs Aging. 2014 Jun;31(6):453 -9. Karlstad \u00d8, Furu K, Skurtveit S, Selmer R. Prescribing of Drugs for Attention - Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59 -65. Kieler H, K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case- control study. BJOG. 2014 Nov Amundsen EJ, Dalgard O. H CV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970 - 1984. Scand J Gastroenterol. 2014 Dec;49(12):1465 -72. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short - and Long -Term Mortality Risk Associated with the Use of Antipsy - chotics Among 26,940 Dementia Outpatients: A Population -Based Am Geriatr 2014;22:321 -331. Mahic M, Fredheim OM, Borchgrevink PC, S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ Co-morbidity in persistent opioid users with chronic non -malignant pain in Norway. Eur J Pain. 2014;18:1083 -1093 Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41 -80 year old Norwegians, 2005 -2010. Eur J Pain. 2014 Mar;18(3):438 - 46. Nordfj\u00e6rn T, Bjerkeset O, B ratberg G, Moylan S, Berk M, Grawe R. Socio - demographic, lifestyle and psychological predictors of benzodiazepine and z -hypnotic use patterns. Nord J 2014;68:107 Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children an d youths with attention - deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study. Glob J Health Sci. 2014 Jul;6(4):155 -62. Omland G, Ruths S, Diaz E. Use of hormonal contraceptives among immi - grants and native women in Norway: data from the Norwegian Prescription Database. BJOG 2014;121:1221 BS, Skurtveit of benzodi - azepines and benzod iazepine - related drugs to pregnant women: a popula - tion -based cohort study. Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0- 14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Child - hood Diabetes Registry. Diabetologia 2014;57:57 -62. Skurtveit S, Selmer R, Odsbu I, Handal M. Self -reported data on medicine use in the Norwegian mother and child 162 cohort s tudy compared to data from the Norwegian prescription database. Norsk Epidemiologi. 2014;24(1 -2). Str\u00f8m H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose - lowering drugs in Norway 2006 -2011: a nationw ide prescription database study. BMC Public Health. Svendsen K, Fredheim OM, Romundstad opioid use and socio -economic PA. High rate of per oral mecillinam treatment failure in community -acquired urinary tract S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013;42:5 14-20. Berge LI, Riise T, KJ, Midthjell K, et al. Does diabetes on migraine? Epid [Dispensing of benzodiazepines and Z drugs S, e t al. Antidepressants to cancer patients during the last year of life-- a population - based study. Psychooncology 2013;22:506 -14. Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti -osteoporosis drug use i n Norway. Osteoporos 2013;24:1225 S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population -based databases. British Journal of Clinical Pharmacology 2013;75:1134 KJ. Are children carrying the burden of broad -spectrum antibiotics in general practice? Prescription pattern for paediatric outpatient s with respiratory tract infec - tions in Norway. BMJ Open 2013;3:e002285. M, Skurtveit S. A pharmacoepi - demiological cohort study of subjects starting strong opioids for nonma - lignant pain: a study from the P Database. 201;154:2487 -93. Hold\u00f8 I, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013;98:732 -6. Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispe nsing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. Br J GenPract. 2013;63:e777 -86. Jonasson C, Tvete IF, pump inhibitor utilization in gastroesophageal reflux disea se and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Klovstad H, Systematic screening with infor - mation and home sampling for genital Chlamydi a trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:30. Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medici ne 2013;81:42 - 52. Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004 - 2008. J Vet Pharmacol Ther Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221 -32. Lillefjell M, Haugan T, Martinussen P, T. Treatmen t outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. Journal of Musculoskeletal Pain 2013;21:311 - 319. Log T, Skurtveit S, Selmer R, Tverdal A, Furu K , Hartz I. The association between prescribed opioid use for mothers and children: a record -linkage study. Eur J Clin Pharmacol 2013;69:111 Lund S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opio id Maintenance Treatment. Addic - tion 2013;108:367 -76. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from Multiple prescribers in older frequent opioid d uring pregnancy: a population study. J Nordeng H, Lupattelli A, Rom\u00f8ren Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and Gynecology 2013;121:306 -13. Nordfjaern Moylan Grawe RW. Clusters of person - ality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013;38:2575 -80. Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. Hum Psychopharmacol 2013;28:248 -57. for Prescription peer academic detaili ng to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Br J GenPract. 2013;63:e554 62. 163 O, Nilsson M, Tornhage CJ, Lokk J. National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc 2013;6:239 - tive prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67 -73. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug expo - sure: inclusion of dispensed drugs b efore pregnancy may lead to underesti - mation of risk associations. J Clin Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population -based cohort study. Journal of W omen's Health 2013;22:250 -8. Stephansson O, Kieler H, Haglund B, A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48 -54. Thelle Jugessur A, Graff -Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013;99:1755 -60. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3 -year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3:e003296. Westin AA, Bramness T, Slordal L. [Pregabalin s hould be Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti -diabetic agents. Diabet Med 2012;29:509 19 -\u00e5ringer i mai. [Increased use of antibiotics among nineteen -year - olds in May]. Tidsskr Nor Laegeforen 2012;132:1084 -8. Blix av legemidler 1975 -2010. [Patterns in of antihypertensive in Norway, 1975 - 2010] Tidsskr Nor -8. Bramness JG, Furu S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Pharmacol A. An increased risk of motor ve hicle accidents after prescription of methadone. Addiction 2012;107:967 -72. Devold Furu K, Skurtveit S, Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in inci - dent users in Norway. Pharmacoe Drug A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti -osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225 -33. Fasmer Opioid switching to methadone: A pharmacoepidemiological study from a national prescrip - tion Palliative 2012;26:804 S. Opoid switching to methadone: a pharmacoepidemiological study from national database. Gedde -Dahl A, Devold Statin in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21:881 -5. Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self -poisoning: a longitudinal study. J Clin Psychiatry. Handal M, Skurtveit S. Hypnotic drug use among 0-17 year old s during 2004 -2011: A nationwide prescription database study. Scandinavian Journal of Public Health 2012;40:704 -11. Hjellvik V, Mahic M, Tverdal A. Utdanning in an asthma population 8 -29 years old: A study from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2012;21:1045 -52. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson B. Selec - tive serotonin -reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries BMJ 2012;344:d8012. Kjome RL, Roraas T, Granas AG, Sandberg Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68:311 Holmen J. The HUNT study: Participation is associated with survival and depends on socioeco - nomic status, diseases and symptoms. BMC Medical Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non - malignant pain. Acta Anaesthesiologica Scandinavica 2012;56:1267 -76. Neutel CI, Skurtveit the point of guidelin es? Benzo - diazepine and z -hypnotic use by elderly population. Sleep Medicine 2012;13:893 -7. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medica - tion in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:1 99-206 164 Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z - hypnotic use in Norwe - gian elderly, aged 65 OM. Low -dose transdermal buprenorphine - long -term use and co -medication potentially addictive drugs. Acta Anaesthesiol Scand. 2012;56:88 -94. Nordfj\u00e6rn T. A population -based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z -hypnotic users. Addic J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical P harmacology 2012;68:1085 -94. Pedersen L, Hansen AB, Svendsen Fredheim Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population - based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053 -62. R\u00f8nning PA, Helseth E, Meling TR, Johannesen A population -based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use-- a 4- year follow -up of 78,453 incident users. Hartz I. Mental distress and subsequent use of psychotropic drugs among adolesce nts - a prospective register linkage study. J Adolescent Health 2012;50:578 -87 Steffenak AKM, Wilde- Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225 -31. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Ap r 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co - prescription of medi - cation for bipolar disorder and diabetes mellitus: A nationwide population - based study with focus on gender differences. BMC Medicine 2012;10:148. Svendsen K, Sku rtveit S, Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359 -69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196 -201. Von Soest T, Bramness W, Wichstr\u00f8m L. The relationship between socio -economic status and antidepressant prescription: A longi tudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87 -95. within the refer - ence range as a predictor of future hypothyroidism and hyperthyroidism: 11 -year follow -up of the HUNT Study in Norway. J Clin Endocrinol Metab. Tverdal A. Cigarette smoking and risk of s ubsequent use of antibacterials: a follow -up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159 -67. Bramness -42 Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years a go? A population based longitudinal observation study. BMC Public Health. 2011;11:144. Dalen DM, Furu K, Locatelli M, Str\u00f8m S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49 -59. Engeland A, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry - based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157 - 63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medic ation use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243 -8. Fasmer OB, Riise in opioid maintenance therapy: A - SJ, W. High validity of mother- reported use of antiasthmatics among children: a comparison with a population -based prescription database. J Clin Epidemiol 2011;64:878 -84. Furu ppf\u00f8lging. in South - and Tidsskr Nor Laegeforen 2011;131:461 Godman B, Sakshaug C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to redu ce reim - bursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121 -9. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba J, Dalen H, Lindb\u00e6k M. Do general practitioners' consultation rates influence 165 their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother Nafstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528 -36. Handal M, Engeland A, opioid anal gesics and co -medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953 -60 Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illici t drugs and their metabolites in wastewater, and subsequent year -long assessment of community drug usage. Environ Sci Technol. 2011;45:5676 Hartz I, Bramness Prescription of antidepressants to patients on opioid maintenance - A, Str\u00f8m H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011;22:418 -21. Hofvind S, Sakshaug S, Ursin G, Graff -Iversen S. Breast cancer incidence trends in Norway -explained by hormone therapy or mammographic s creening? International Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepide - miol , D, Initial prescription of anti - psychotics and antidepressants in general practice and specialist midler til SI. Prescription patterns of antiepileptic drugs in patients wi th epilepsy in a nation -wide population. Epilepsy Res. 2011;95:51 -9. Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti - dementia drugs with psychotropic drugs in Norway --a population -based study. Pharmacoepidemiol Drug Saf. 2011;20:131 9-26 Log Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population -based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90 -8. Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign - or Norwegian -born parents. Scand J Pain 2011;2:36 -44. Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005 -2009. Phar - macoepidemiol Drug Saf. 2011;20:457 -63. Neubert A, Hsia Y, de Jong -van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti -diabetic drug prescribing in hyphy children and adolescents in seven European countries. Br J Clin Pharmacol. 2011;72:969 P, Fredheim O. To what extent does a cohort of new users of weak opio ids develop persistent or probable problematic opioid use? JE.Use of ADHD in OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the migraine and antidepressant medica- tions: Complete one year data from the Norwegian population. J Affective Disorders 2011;1 29:198 -204. 2010: Amundsen MO, Engdahl B, Berg C, H. Cardiovascular co -medication among users of antiobesity drugs: a population -based study. Pharm World Sci. 2010;32:752 -8. Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs --a population based study. Pharmacoepidemiol Drug Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445 -50. Berg A, Furu for analgetika [Use of glucosamine does not reduce the need for pain -relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463 -6. Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Policy 2010;17:168 -80 Bramness P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gaba- pentin using the HE, Falch JA, S\u00f8gaard AJ. Prescription of anti -osteoporosis drugs during 2004- 2007 - a nationwide register study in Norway. Eur J Clin Pharmaco l 2010;66:299 -306. Fredheim OM, Borchgrevink P. Increasing use of opoids from 2004 to 2007 - Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14:289 - 294. Fredheim OM, Log T, Olsen W, Skurtveit Sagen \u00d8, Borchgrevink P. Prescrip - tion of opioids to children and adolescents; a study from a national prescrip - tion database in Norway. Pediatric Anesthesia 2010;20:537 - 544. 166 Furu K, Skurtveit S, Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as a cohort Clin Prescription persistence and safety of antipsychotic medication: a national registry - based 3 -year follow -up. Eur J Clin Pharmacol 2010;66:911 - 7. Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. Soc Sci Med 2010;70:921 -5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population -base d cohort study of 16 000 individuals. Scand J Public Health 2010;38:465 -73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235 -42. Hunskaar Bi\u00f8rn E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751 -64 Karl stad \u00d8, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti -asthma medication use in 2 - to 29 -year -olds: a nationwide prescription study. Eur J Clin Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population -based Eur Clin Kjome RL, Granas AG, Nerhus TH, Sandberg S. The prevalence of self -monitoring of blood glucose and costs of glucometer strips in a nation - wide cohort. Diabetes Technol Ther 2010;12:701 -5. Korn\u00f8r H, R, Tverdal A. Benzodiazepines predict use of opioids - a follow -up study of 17 074 men and women. Pai n Med 2010;11:805 -14. Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population -based cohort study. Ann Epidemiol 2010;20:890 -7. K, anti -inflammatory drugs: use and co -treatment with potentially interacting medications in the elderly. S. The risk of motor vehicle accidents involving drive rs with prescriptions for codeine i Sogn og Fjordane [Use of lithium in the Norwegian counties Fjordane]. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004 -2007 - a prescription database study. J Affect Disord 2009; 117:208 -11. Bramness JG, Skurtveit S, Neutel I, M\u00f8rland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharma - coepidemiol Drug Saf 2009;18:492 -6. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Diso rd 2009;118:224 -8. Devold H, Molden E, K. Co -medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234 Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Borchgrevink P. Prescription pattern of codeine for non - malignant pain in Norway - a pharmacoepidemio - logical study from The Norwegian Prescription Database. Scand 2009;53:627 -33. Gjerden P, Bramness and potential abuse of anticholin - ergic antiparkinson drugs in L, the use of anticho - linergic antiparkinson drugs and safety and receptor drug -binding profiles agents. antipsychotic and anticholin- ergic antiparkinson drugs in Norway after Clin Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320 -6. Hartz I, Tverdal A, Skurtveit S. A comparison of self - reported data on disability pension status with data from a nationwide ad ministrative register. Nor J Epidemiol 2009;19:169 -172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addic - tive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209 -218. Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007 -08. K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment : the use of benzodiazepines versus z -hypnotics. A prescription database study of predictors. J Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Databas e Pharmacoepidemiol Drug Saf 2009;18:572 -8. Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population -based study of prescriptions. Epilepsy Res 2009; 87: 31 -9. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol Introduction of low dose trans - dermal buprenorphine - did it influence use of potentially addictive drugs in chronic non -malignant pain patients? Eur J Pain 2009;13:949 T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose- lowering drugs. Prospective follow -up study. Med 2009; 26:404 -08. Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and durin g pregnancy - a population -based cohort study Pharmacoepidemiol Drug Saf 2009;18:737 -42. Norge S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185 -90. JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167 -72. Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074 -5. Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. J Clin Dalen I. Pharmacologically inappropriate prescriptions for elderly p atients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx -PAD) study. Scand J Prim Health S, Furu K. Prescription druguse among fat hers and mothers before and during preg - nancy. A population - based cohort study of 106,000 pregnancies in Norway 2004 -06. Br J Clin en registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry -based cohort study] Nor J Epidemiol 2008;18: 159 -66. Furu K. Establishment of the nationwide Norwegian Prescription Database (N orPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; 18:129 A, Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclo ne, zolpidem, flunitrazepam use of antipsychotic medication: linking population -based prescription data - base to the HUNT study. Pharmacoepid emiol Drug Saf 2008;17:372 -7. norske kreftpasi - enter [Variable prescription of opioids Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow -up study of 13 390 men and women aged 40 -42 years. Pharmacoepidemiol Drug Saf 2008;17:926 -933. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:71 4-17. Str\u00f8m H, Sakshaug S, Skurtveit of statins in patients receiving oral blood glucose- lowering drugs. Nor J Epidemiol 2008;18:191 -94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contributi on to national consumption. J Antimicrob HS, Engeland Age - and gender -specific anti - bacterial prescribing in Norway. f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2007;64: 210 -8. Bramness JG, Korn\u00f8r H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway . Drug Alcohol Depend 2007;90:203 -9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of road traffic acci - dents prescriptions of road traffic acciden ts associated with the prescription of medicinal drugs: a registry -based cohort study. Ann Epidemiol 2007;17:597 -602. Furu K, Skurtveit S, Langhammer Use of anti - asthmatic medica- tions as a proxy for prevalence of asthma in children and adol escents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol 2007;63:693 -8. 168 S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual -level prescription database N, Hausken T A large community outbreak of waterborne giardiasis -delayed detection in a non- endemic urban M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476 -81. Torkildsen O, Grytten N, Sakshaug S, R\u00f8nning M. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. Tidsskr Lindback M. Can antibi - otic prescriptions in respiratory tract infections be improved? A cluster - randomized educational intervention in general practice --the Prescription Peer A cademic Detailing M, Dalen I. A cluster - randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice --The Prescription Peer Academic Detailing (Rx Sakshaug S, R\u00f8nning M. [How many and who are receiving An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53 -56. 2001: Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor J Epidemiol 2001;11:55 -60. Utgitt av Folkehelseinstituttet Published by Norwegian Institute of Public Health September 202 2 Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no as PDF from "}